C40-, C28-and C-32 linked rapamycin analogs as mTOR inhibitors

By designing compounds that selectively inhibit mTORC1 or mTORC2, the problem of incomplete inhibition of existing mTOR inhibitors is solved, efficient inhibition of mTORC1 and mTORC2 is achieved, and the inhibition effect on mTORC1 downstream substrates is enhanced and the inhibition effect on mTORC1 is avoided. Akt activation interference.

CN118978535APending Publication Date: 2024-11-19REVOLUTION MEDICINES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410748492.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-04-18
Filing Date
2019-04-29
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The lack of selectivity between the existing mTOR inhibitors in inhibiting mTORC1 and mTORC2 leads to incomplete inhibition of mTORC1 downstream substrates, and the inhibition of mTORC2 may affect Akt activation, resulting in blockade of phosphorylation of Akt S473.

Method used

A novel compound is provided with selective inhibition of mTORC1 or mTORC2, and through specific chemical structure design, it ensures efficient inhibition of mTORC1 or mTORC2 without affecting other signaling paths.

Benefits of technology

Selective inhibition of mTORC1 and mTORC2 is achieved, which enhances the inhibitory effect of mTORC1 downstream substrates, while avoiding interference with Akt activation, providing more comprehensive signaling regulation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The present disclosure relates to inhibitors of mTOR. In particular, embodiments relate to compounds and compositions that inhibit mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of Chinese patent application No. 201980044255.9 (application date: April 29, 2019, invention name: C40-, C28- and C-32-linked rapamycin analogs as mTOR inhibitors).

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims the benefit of U.S. Provisional Application No. 62 / 665,435, filed May 1, 2018, U.S. Provisional Application No. 62 / 752,874, filed October 30, 2018, and U.S. Provisional Application No. 62 / 836,036, filed April 18, 2019, the contents of which are incorporated herein by reference in their entirety.

[0004] Sequence Listing

[0005] The sequence listing associated with this application is provided in text format in lieu of a paper copy and is hereby incorporated by reference into the specification. The name of the text file containing the sequence listing is REME_008_01WO_SeqList_ST25.txt. The text file is approximately 40 kilobytes, was created on April 26, 2019, and was submitted electronically via EFS-Web. Technical Field

[0006] The present invention relates to mTOR inhibitors. In particular, embodiments relate to compounds and compositions that inhibit mTOR, methods of treating mTOR-mediated diseases, and methods of synthesizing these compounds. Background Art

[0007] The mammalian target of rapamycin (mTOR) is a serine-threonine kinase related to the phosphoinositide 3-kinase (PI3K) family of lipid kinases. mTOR exists as two complexes (mTORC1 and mTORC2) that are differentially regulated, have different substrate specificities, and differ in sensitivity to rapamycin. mTORC1 integrates signals from growth factor receptors with cellular nutritional status and controls the level of cap-dependent mRNA translation by regulating the activity of key translational components such as cap-binding proteins and the oncogene eIF4E.

[0008] mTOR signaling has been deciphered in more and more detail. The different pharmacology of mTOR inhibitors is particularly rich. It should now be understood that the first reported mTOR inhibitor rapamycin is an incomplete inhibitor of mTORC1. Rapamycin is a selective mTORC1 inhibitor that binds to the FK506 rapamycin binding (FRB) domain of mTOR kinase with the help of FK506 binding protein 12 (FKBP12). The FRB domain of mTOR is accessible in the mTORC1 complex, but is less accessible in the mTORC2 complex. Interestingly, it is known that the efficacy of the inhibitory activity of downstream substrates of mTORC1 treated by rapamycin varies in mTORC1 substrates. For example, rapamycin strongly inhibits the phosphorylation of mTORC1 substrate S6K and indirectly inhibits the phosphorylation of downstream ribosomal protein S6 that controls ribosome biogenesis. On the other hand, rapamycin shows only partial inhibitory activity on the phosphorylation of 4E-BP1, which is the main regulator of eIF4E that controls the initiation of CAP-dependent translation. As a result, more complete inhibitors of mTORC1 signaling are of interest.

[0009] A second class of "ATP-site" inhibitors of mTOR kinase has been reported. Such mTOR inhibitors are referred to as TORi (ATP site TOR inhibitors). The molecules compete with ATP (the substrate of the kinase reaction) in the active site of mTOR kinase (and are therefore also mTOR active site inhibitors). As a result, these molecules inhibit downstream phosphorylation of a wider range of substrates.

[0010] While mTOR inhibition may have the effect of blocking 4E-BP1 phosphorylation, these agents may also inhibit mTORC2, which results in a blockade of Akt activation due to inhibition of phosphorylation of Akt S473.

[0011] mTOR inhibitors are particularly disclosed herein. In some embodiments, the compounds disclosed herein are inhibitors that are more selective for mTORC1 relative to mTORC2. In some embodiments, the compounds disclosed herein are inhibitors that are more selective for mTORC2 relative to mTORC1. In some embodiments, the compounds disclosed herein do not exhibit a selectivity difference between mTORC1 and mTORC2. Summary of the invention

[0012] The present invention relates to compounds that inhibit the activity of mTOR. The present invention further provides a process for preparing the compounds of the present invention, pharmaceutical formulations containing these compounds, and methods of using these compounds and compositions in the management of diseases or conditions mediated by mTOR.

[0013] The present invention provides a compound of formula Ic:

[0014]

[0015] or a pharmaceutically acceptable salt or tautomer thereof, wherein:

[0016] R 32 -H, =O, -OR 3 、-N 3 or -OC(=Z 1 )-R 32a ;

[0017] R 28 -H, (C 1 -C 6 )alkyl or -C(=Z 1 )-R 28a ;

[0018] R 40 is -H or -C(=Z 1 )-R 40a ;

[0019] When R 28 and R 40 When H, R 32 Not = O;

[0020] Z 1 Each independently is O or S;

[0021] R 28a , R 32a and R 40a Independently -A 1 -L 1 -A 2 -B, -A 1 -A 2 -B, -L 2 -A 1 -L 1 -A 2 -L 3 -B、-O-(C 1 -C 6 )alkyl, or -O-(C 6 -C 10 )aryl; wherein -O-(C 6 -C 10 ) the aryl group is unsubstituted or selected from -NO 2 and 1 to 5 substituents of halogen;

[0022] A 1 and A 2 is independently absent or independently selected from

[0023]

[0024]

[0025] As shown, A 1 The left bond is bound to -C(=Z 1 )- or L 2 ; and among them, as depicted, A 2 The right side of the key is connected to B or L 3 ;

[0026] Q is each independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0027] X is each independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0028] X 1 each independently is a heteroarylene or heterocyclylene ring;

[0029] W is each independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0030] W 1 each independently is a heteroarylene or heterocyclylene ring;

[0031] G is each independently absent or a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0032] G 1 and G 2 each independently is a heteroarylene or heterocyclylene ring;

[0033] L 1 Each independently selected from

[0034]

[0035] L 2 and L 3 is independently absent or independently selected from

[0036]

[0037] B are each independently selected from

[0038]

[0039] B 1 Each independently selected from NR 3 -(C(R 3 )2 ) n -、 NR 3 -(C(R 3 ) 2 ) n -(C 6 -C 10 )arylene-(C(R 3 ) 2 ) n -、 NR 3 -(C(R 3 ) 2 ) n -heteroarylene-, NR 3 -(C(R 3 ) 2 ) n -heteroarylene-(C(R 3 ) 2 ) n -、 (C 6 -C 10 ) arylene-, NR 3 -(C(R 3 ) 2 ) n -NR 3 C(O)-, NR 3 -(C(R 3 ) 2 ) n -heteroarylene-heterocyclylene-(C 6 -C 10 ) arylene-, Heteroarylene-heterocyclylene-(C 6 -C 10 ) arylene-,

[0040]

[0041] NR 3 -(C(R 3 ) 2 ) n -S(O) 2 -Arylene-C(O)- and NR 3 -(C(R 3 ) 2 ) n -S(O) 2 -arylene-(C(R 3 )2 ) n -, where as depicted, B 1 Left Bond to A 2 , L 3 or L 1 ; and wherein the heteroarylene, heterocyclylene and arylene are each independently optionally substituted with alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen or hydroxy;

[0042] R 3 Each independently is H or (C 1 -C 6 )alkyl;

[0043] R 4 Each independently is H, (C 1 -C 6 )alkyl, halogen, 5- to 12-membered heteroaryl, 5- to 12-membered heterocyclyl, (C 6 -C 10 ) aryl, wherein the heteroaryl, heterocyclyl and aryl are each independently optionally substituted by -N(R 3 ) 2 、-OR 3 , halogen, (C 1 -C 6 )alkyl, -(C 1 -C 6 )alkylene-heteroaryl, -(C 1 -C 6 )alkylene-CN, -C(O)NR 3 -heteroaryl or -C(O)NR 3 - Heterocyclyl substitution;

[0044] R 5 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 , where (C 1 -C 6 )alkyl, each of which is independently optionally substituted with -N(R 3 ) 2 OR 3 replace;

[0045] R 6 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 , where (C1 -C 6 )alkyl, each of which is independently optionally substituted with -N(R 3 ) 2 OR 3 replace;

[0046] R 7 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 , where (C 1 -C 6 )alkyl, each of which is independently optionally substituted with -N(R 3 ) 2 OR 3 replace;

[0047] R 8 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 , where (C 1 -C 6 )alkyl, each of which is independently optionally substituted with -N(R 3 ) 2 OR 3 replace;

[0048] Y is each independently C(R 3 ) 2 or key;

[0049] n is each independently an integer from 1 to 12;

[0050] o are each independently an integer from 0 to 30;

[0051] p is each independently an integer from 0 to 12;

[0052] q is each independently an integer from 0 to 30; and

[0053] r is an integer of 1 to 6 each independently.

[0054] The present invention provides a compound of formula Ia:

[0055]

[0056] or a pharmaceutically acceptable salt or tautomer thereof, wherein:

[0057] R 32-H, =O, -OR 3 、-N 3 or -OC(=Z 1 )-R 32a ;

[0058] R 28 -H, (C 1 -C 6 )alkyl or -C(=Z 1 )-R 28a ;

[0059] R 40 is -H or -C(=Z 1 )-R 40a ;

[0060] When R 28 and R 40 When H, R 32 Not = O;

[0061] Z 1 Each independently is O or S;

[0062] R 28a , R 32a and R 40a Independently -A 1 -L 1 -A 2 -B, -A 1 -A 2 -B, -L 2 -A 1 -L 1 -A 2 -L 3 -B、-O-(C 1 -C 6 )alkyl, or -O-(C 6 -C 10 )aryl; wherein -O-(C 6 -C 10 ) the aryl group is unsubstituted or selected from -NO 2 and 1 to 5 substituents of halogen;

[0063] A 1 and A 2 is independently absent or independently selected from

[0064]

[0065] As shown, A 1 The left bond is bound to -C(=Z 1 )- or L 2 ; and among them, as depicted, A2 The right side of the key is connected to B or L 3 ;

[0066] Q is each independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0067] X is each independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0068] X 1 each independently is a heteroarylene or heterocyclylene ring;

[0069] W is each independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0070] W 1 each independently is a heteroarylene or heterocyclylene ring;

[0071] G is each independently absent or a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0072] G 1 and G 2 each independently is a heteroarylene or heterocyclylene ring;

[0073] L 1 Each independently selected from

[0074]

[0075] L 2 and L 3 is independently absent or independently selected from

[0076]

[0077] B are each independently selected from

[0078]

[0079] B 1 Each independently selected from NR 3 -(C(R 3 ) 2 ) n -、 NR 3 -(C(R 3 ) 2 ) n -(C 6 -C 10 )arylene-(C(R 3 )2 ) n -、 NR 3 -(C(R 3 ) 2 ) n -heteroarylene-, (C 6 -C 10 ) arylene-, NR 3 -(C(R 3 ) 2 ) n -NR 3 C(O)-, NR 3 -(C(R 3 ) 2 ) n -heteroarylene-heterocyclylene-(C 6 -C 10 ) arylene-, Heteroarylene-heterocyclylene-(C 6 -C 10 ) arylene-, and NR 3 -(C(R 3 ) 2 ) n -S(O) 2 -arylene-C(O)-, wherein as shown, B 1 Left Bond to A 2 , L 3 or L 1 ; and wherein the heteroarylene, heterocyclylene and arylene are each independently optionally substituted with alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen or hydroxy;

[0081] R 3 Each independently is H or (C 1 -C 6 )alkyl;

[0082] R 4 Each independently is H, (C 1 -C 6 )alkyl, halogen, 5- to 12-membered heteroaryl, 5- to 12-membered heterocyclyl, (C 6 -C 10 ) aryl, wherein the heteroaryl, heterocyclyl and aryl are each independently optionally substituted by -N(R 3 ) 2 、-OR 3 , halogen, (C1 -C 6 )alkyl, -(C 1 -C 6 )alkylene-heteroaryl, -(C 1 -C 6 )alkylene-CN, -C(O)NR 3 -heteroaryl or -C(O)NR 3 - Heterocyclyl substitution;

[0083] R 5 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 , where (C 1 -C 6 )alkyl, each of which is independently optionally substituted with -N(R 3 ) 2 OR 3 replace;

[0084] R 6 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 , where (C 1 -C 6 )alkyl, each of which is independently optionally substituted with -N(R 3 ) 2 OR 3 replace;

[0085] R 7 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 , where (C 1 -C 6 )alkyl, each of which is independently optionally substituted with -N(R 3 ) 2 OR 3 replace;

[0086] R 8 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2, where (C 1 -C 6 )alkyl, each of which is independently optionally substituted with -N(R 3 ) 2 OR 3 replace;

[0087] Y is independently -C(R 3 ) 2 or key;

[0088] n is each independently an integer from 1 to 12;

[0089] o are each independently an integer from 0 to 30;

[0090] p is each independently an integer from 0 to 12;

[0091] q is each independently an integer from 0 to 30; and

[0092] r is an integer of 1 to 6 each independently.

[0093] The present invention provides a compound of formula I:

[0094]

[0095] or a pharmaceutically acceptable salt or tautomer thereof, wherein:

[0096] R 32 is -H, =O or -OR 3 ;

[0097] R 28 is -H or -C(=Z 1 )-R 28a ;

[0098] R 40 is -H or -C(=Z 1 )-R 40a ;

[0099] Where R 28 and R 40 At least one of is not H;

[0100] Z 1 independently O or S;

[0101] R 28a and R 40a Independently -A 1 -L 1 -A 2 -B, -A 1 -A 2 -B, -L 2 -A1 -L 1 -A 2 -L 3 -B、-O-(C 1 -C 6 )alkyl; or -O-(C 6 -C 10 )aryl; wherein -O-(C 6 -C 10 ) the aryl group is unsubstituted or selected from -NO 2 and 1 to 5 substituents of halogen;

[0102] A 1 and A 2 is independently absent or independently selected from

[0103]

[0104] As shown, A 1 The left bond is bound to -C(=Z 1 )- or L 2 ; and among them, as depicted, A 2 The right side of the key is connected to B or L 3 ;

[0105] Q is each independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0106] X is each independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0107] X 1 each independently is a heteroarylene or heterocyclylene ring;

[0108] W is each independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0109] W 1 each independently is a heteroarylene or heterocyclylene ring;

[0110] G is each independently absent or a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0111] G 1 and G 2 each independently is a heteroarylene or heterocyclylene ring;

[0112] L 1 Each independently selected from

[0113]

[0114] L 2 and L 3 is independently absent or independently selected from

[0115]

[0116] B are each independently selected from

[0117]

[0118] B 1 Each independently selected from NR 3 -(C(R 3 ) 2 ) n -、 NR 3 -(C(R 3 ) 2 ) n -(C 6 -C 10 )arylene-(C(R 3 ) 2 ) n -、 NR 3 -(C(R 3 ) 2 ) n -heteroarylene-, (C 6 -C 10 ) arylene-, NR 3 -(C(R 3 ) 2 ) n -NR 3 C(O)-, NR 3 -(C(R 3 ) 2 ) n -heteroarylene-heterocyclylene-(C 6 -C 10 ) arylene-, Heteroarylene-heterocyclylene-(C 6 -C 10 ) arylene-, and NR 3 -(C(R 3 ) 2 ) n -S(O) 2 -arylene-C(O)-, wherein as shown, B 1Left Bond to A 2 , L 3 or L 1 ; and wherein the heteroarylene, heterocyclylene and arylene are each independently optionally substituted with alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen or hydroxy;

[0119] R 3 Each independently is H or (C 1 -C 6 )alkyl;

[0120] R 4 Each independently is H, (C 1 -C 6 )alkyl, halogen, 5- to 12-membered heteroaryl, 5- to 12-membered heterocyclyl, (C 6 -C 10 ) aryl, wherein the heteroaryl, heterocyclyl and aryl are each independently optionally substituted by -N(R 3 ) 2 、-OR 3 , halogen, (C 1 -C 6 )alkyl, -(C 1 -C 6 )alkylene-heteroaryl, -(C 1 -C 6 )alkylene-CN, -C(O)NR 3 -heteroaryl or -C(O)NR 3 - Heterocyclyl substitution;

[0121] R 5 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 , where (C 1 -C 6 )alkyl, wherein the alkyl group is optionally substituted with -N(R 3 ) 2 OR 3 replace;

[0122] R 6 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 , where (C 1 -C 6 )alkyl, wherein the alkyl group is optionally substituted with -N(R 3) 2 OR 3 replace;

[0123] R 7 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 , where (C 1 -C 6 )alkyl, wherein the alkyl group is optionally substituted with -N(R 3 ) 2 OR 3 replace;

[0124] R 8 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 , where (C 1 -C 6 )alkyl, wherein the alkyl group is optionally substituted with -N(R 3 ) 2 OR 3 replace;

[0125] Y is independently -C(R 3 ) 2 or key;

[0126] n is each independently an integer from 1 to 12;

[0127] o are each independently an integer from 0 to 30;

[0128] p is each independently an integer from 0 to 12;

[0129] q is each independently an integer from 0 to 30; and

[0130] r is an integer of 1 to 6 each independently.

[0131] The present invention provides a compound of formula II:

[0132]

[0133] or a pharmaceutically acceptable salt or tautomer thereof, wherein:

[0134] R 32 is -H, =O or -OR 3 ;

[0135] R 28is -H or -C(=Z 1 )-R 28a ;

[0136] R 40 is -H or -C(=Z 1 )-R 40a ;

[0137] Where R 28 and R 40 At least one of is not H;

[0138] Z 1 independently O or S;

[0139] R 28a and R 40a Independently -A 1 -L 1 -A 2 -B, -A 1 -A 2 -B、-O-(C 1 -C 6 )alkyl; or -O-(C 6 -C 10 )aryl; wherein -O-(C 6 -C 10 ) the aryl group is unsubstituted or selected from -NO 2 and 1 to 5 substituents of halogen;

[0140] A 1 and A 2 is independently absent or independently selected from

[0141]

[0142]

[0143] As shown, A 1 The left bond is bound to -C(=Z 1 )-; and in which, as shown, A 2 The bond on the right side of the part is bound to B;

[0144] Q is each independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0145] X is each independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0146] X 1 each independently is a heteroarylene or heterocyclylene ring;

[0147] W is each independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0148] W 1 each independently is a heteroarylene or heterocyclylene ring;

[0149] G is each independently absent or a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0150] G 1 and G 2 each independently is a heteroarylene or heterocyclylene ring;

[0151] L 1 Each independently selected from

[0152]

[0153] B are each independently selected from

[0154]

[0155] B 1 Each independently selected from NR 3 -(C(R 3 ) 2 ) n -、 NR 3 -(C(R 3 ) 2 ) n -(C 6 -C 10 )arylene-(C(R 3 ) 2 ) n -、 NR 3 -(C(R 3 ) 2 ) n -heteroarylene-, (C 6 -C 10 ) arylene-, NR 3 -(C(R 3 ) 2 ) n -NR 3 C(O)-, NR 3 -(C(R 3 ) 2 ) n -heteroarylene-heterocyclylene-(C 6 -C10 ) arylene-, heteroarylene-heterocyclylene-(C 6 -C 10 ) arylene-, and NR 3 -(C(R 3 ) 2 ) n -S(O) 2 -arylene-C(O)-, wherein as shown, B 1 Left Bond to A 2 or L 1 ; and wherein the heteroarylene, heterocyclylene and arylene are each independently optionally substituted with alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen or hydroxy;

[0156] R 3 Each independently is H or (C 1 -C 6 )alkyl;

[0157] R 4 Each independently is H, (C 1 -C 6 )alkyl, halogen, 5- to 12-membered heteroaryl, 5- to 12-membered heterocyclyl, (C 6 -C 10 ) aryl, wherein the heteroaryl, heterocyclyl and aryl are each independently optionally substituted by -N(R 3 ) 2 、-OR 3 , halogen, (C 1 -C 6 )alkyl, -(C 1 -C 6 )alkylene-heteroaryl, -(C 1 -C 6 )alkylene-CN, -C(O)NR 3 -heteroaryl or -C(O)NR 3 - Heterocyclyl substitution;

[0158] R 5 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 , where (C 1 -C 6 )alkyl, wherein the alkyl group is optionally substituted with -N(R 3 ) 2 OR 3replace;

[0159] R 6 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 , where (C 1 -C 6 )alkyl, wherein the alkyl group is optionally substituted with -N(R 3 ) 2 OR 3 replace;

[0160] R 7 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 , where (C 1 -C 6 )alkyl, wherein the alkyl group is optionally substituted with -N(R 3 ) 2 OR 3 replace;

[0161] R 8 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 , where (C 1 -C 6 )alkyl, wherein the alkyl group is optionally substituted with -N(R 3 ) 2 OR 3 replace;

[0162] Y is each independently C(R 3 ) 2 or key;

[0163] n is each independently an integer from 1 to 12;

[0164] o are each independently an integer from 0 to 30;

[0165] p is each independently an integer from 0 to 12;

[0166] q is each independently an integer from 0 to 30; and

[0167] r is an integer of 1 to 6 each independently.

[0168] In some embodiments, the compound of Formula I or II is represented by the structure of Formula I-28:

[0169]

[0170] or a pharmaceutically acceptable salt or tautomer thereof.

[0171] In some embodiments, the compound of Formula Ia, Ic, I or II is represented by the structure of Formula I-28b:

[0172]

[0173] or a pharmaceutically acceptable salt or tautomer thereof.

[0174] In some embodiments, the compound of Formula I or II is represented by the structure of Formula I-40:

[0175]

[0176] or a pharmaceutically acceptable salt or tautomer thereof.

[0177] In some embodiments, the compound of Formula Ia, Ic, I or II is represented by the structure of Formula I-40b:

[0178]

[0179] or a pharmaceutically acceptable salt or tautomer thereof.

[0180] In some embodiments, the compound of Formula Ia, Ic, I or II is represented by the structure of Formula I-32b:

[0181]

[0182] or a pharmaceutically acceptable salt or tautomer thereof.

[0183] The present invention provides a method of treating a disease or condition mediated by mTOR, comprising administering to a subject suffering from or susceptible to a disease or condition mediated by mTOR a therapeutically effective amount of one or more disclosed compounds. The present invention provides a method of preventing a disease or condition mediated by mTOR, comprising administering to a subject suffering from or susceptible to a disease or condition mediated by mTOR a therapeutically effective amount of one or more disclosed compounds. The present invention provides a method of reducing the risk of a disease or condition mediated by mTOR, comprising administering to a subject suffering from or susceptible to a disease or condition mediated by mTOR a therapeutically effective amount of one or more disclosed compounds.

[0184] Another aspect of the present invention relates to a pharmaceutical composition comprising a compound of Formula I, Ia, Ib, Ic, II or IIb, or a pharmaceutically acceptable salt or tautomer of any of the above, and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may further include an excipient, a diluent or a surfactant. The pharmaceutical composition can be effectively used to treat, prevent or reduce the risk of a disease or condition mediated by mTOR in a subject in need thereof.

[0185] Another aspect of the invention relates to a compound of Formula I, Ia, Ib, Ic, II or IIb, or a pharmaceutically acceptable salt or tautomer of any of the foregoing, for use in treating, preventing or reducing the risk of a disease or condition mediated by mTOR in a subject in need thereof.

[0186] Another aspect of the present invention relates to the use of a compound of Formula I, Ia, Ib, Ic, II or IIb, or a pharmaceutically acceptable salt or tautomer of any of the foregoing, in the preparation of a medicament for treating, preventing or reducing the risk of a disease or condition mediated by mTOR in a subject in need thereof.

[0187] The present invention also provides compounds useful for inhibiting mTOR. DETAILED DESCRIPTION

[0188] The present invention relates to mTOR inhibitors. In particular, embodiments relate to compounds and compositions that inhibit mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.

[0189] The details of the present invention are described in the following accompanying description. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, illustrative methods and materials are now described. Other features, objects and advantages of the present invention will be apparent from the specification and from the claims. In this specification and the appended claims, unless otherwise clearly indicated in the context, the singular form may also include the plural form. Unless otherwise specified, all technical and scientific terms used herein have the same meaning as generally understood by those skilled in the art to which the present invention belongs. The full text of all patents and publications cited in this specification are incorporated herein by reference.

[0190] the term

[0191] The articles "a" and "an" are used herein and, unless otherwise specified, refer to one or more than one (ie, at least one) of the grammatical objects of the article. For example, "an element" may mean one element or more than one element unless otherwise specified.

[0192] Unless otherwise stated, the term "or" means "and / or". Unless otherwise stated, the term "and / or" means "and" or "or" or both.

[0193] Unless otherwise indicated, the term "optionally substituted" means that the group may be unsubstituted or substituted with one or more (e.g., 0, 1, 2, 3, 4, or 5 or more, or any range derivable therein) of the substituents listed for the group, wherein the substituents may be the same or different. In one embodiment, the optionally substituted group has 1 substituent. In another embodiment, the optionally substituted group has 2 substituents. In another embodiment, the optionally substituted group has 3 substituents. In another embodiment, the optionally substituted group has 4 substituents. In another embodiment, the optionally substituted group has 5 substituents.

[0194] Unless otherwise indicated, the term "alkyl" by itself or as part of another substituent means a linear (i.e., unbranched) or branched, non-cyclic carbon chain (or carbon), or combinations thereof, which may be fully saturated, monounsaturated, or polyunsaturated and may contain a number of carbon atoms (i.e., C 1 -C 10 alkyl, 2-propenyl, 2-butenyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and higher carbon number homologs and isomers.

[0195] Unless otherwise indicated, the term "alkylene" by itself or as part of another substituent means a divalent radical derived from an alkyl group. Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, such as those groups having 10 or fewer carbon atoms.

[0196] The term "alkenyl" means an aliphatic hydrocarbon group containing a carbon-carbon double bond and which may be straight or branched, having from about 2 to about 6 carbon atoms in the chain. Certain alkenyl groups have from 2 to about 4 carbon atoms in the chain. Branching may mean that one or more lower carbon number alkyl groups (such as methyl, ethyl or propyl) are attached to the straight alkenyl chain. Exemplary alkenyl groups include ethenyl, propenyl, n-butenyl and iso-butenyl. 2 -C 6 Alkenyl is an alkenyl group containing 2 to 6 carbon atoms.

[0197]

[0063] The term "alkenylene" by itself or as part of another substituent means, unless otherwise stated, a divalent radical derived from an alkenyl group.

[0198] The term "alkynyl" means an aliphatic hydrocarbon group containing a carbon-carbon triple bond and which may be straight or branched, having from about 2 to about 6 carbon atoms in the chain. Certain alkynyl groups have from 2 to about 4 carbon atoms in the chain. Branching may mean that one or more lower carbon number alkyl groups (such as methyl, ethyl or propyl) are attached to a straight alkynyl chain. Exemplary alkynyl groups include ethynyl, propynyl, n-butynyl, 2-butynyl, 3-methylbutynyl and n-pentynyl. 2 -C 6 Alkynyl is an alkynyl group containing 2 to 6 carbon atoms.

[0199]

[0063] The term "alkynylene" by itself or as part of another substituent means, unless otherwise stated, a divalent radical derived from an alkynyl group.

[0200] The term "cycloalkyl" means a monocyclic or polycyclic saturated or partially unsaturated carbon ring containing 3 to 18 carbon atoms. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, norbornyl, bicyclo[2.2.2]octyl or bicyclo[2.2.2]octenyl. 3 -C 8 Cycloalkyl is a cycloalkyl group containing 3 to 8 carbon atoms. Cycloalkyl groups can be fused (e.g., decahydronaphthalene) or bridged (e.g., norbornane).

[0201] "Cycloalkylene" by itself or as part of another substituent means a divalent radical derived from cycloalkyl.

[0202] The term "heterocyclyl" or "heterocycloalkyl" or "heterocycle" refers to a monocyclic or polycyclic 3 to 24 membered ring containing carbon and at least one heteroatom selected from oxygen, phosphorus, nitrogen and sulfur, and wherein there are no delocalized pi electrons (aromaticity) shared among the ring carbons or heteroatoms. Heterocyclyl rings include, but are not limited to, oxetane, azetidine, tetrahydrofuranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl, tetrahydropyranyl, dioxalinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, piperazinyl, aza Oxepinyl, diazepine The heterocyclyl or heterocycloalkyl rings may also be fused or bridged, for example, they may be bicyclic.

[0203] "Heterocyclylene" or "heterocycloalkylene" alone or as part of another substituent means a divalent radical derived from "heterocyclyl" or "heterocycloalkyl" or "heterocycle".

[0204] Unless otherwise indicated, the term "aryl" means a polyunsaturated aromatic hydrocarbon substituent which may be a single ring or multiple rings (preferably 1 to 3 rings) fused together (i.e., fused ring aryl) or covalently linked. A fused ring aryl may refer to multiple rings fused together, wherein at least one of the fused rings is an aryl ring.

[0205] "Arylene" by itself or as part of another substituent means a divalent radical derived from an aryl group.

[0206] The term "heteroaryl" refers to an aryl group (or ring) containing at least one heteroatom (such as N, O or S), wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom is optionally quaternized. Therefore, the term "heteroaryl" includes fused ring heteroaryls (i.e., multiple rings fused together, wherein at least one of the fused rings is a heteroaromatic ring). 5,6-fused ring heteroaryl substituents refer to two rings fused together, wherein one ring has 5 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. Similarly, 6,6-fused ring heteroaryl substituents refer to two rings fused together, wherein one ring has 6 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. And 6,5-fused ring heteroaryl substituents refer to two rings fused together, wherein one ring has 6 members and the other ring has 5 members, and wherein at least one ring is a heteroaryl ring. Heteroaryl can be connected to the rest of the molecule via carbon or heteroatoms. Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4 Substituents for each of the above aryl and heteroaryl ring systems are selected from the group consisting of acceptable substituents described herein.

[0207] The term "heteroaryl" may also include polycondensed ring systems having at least one such aromatic ring, which are further described below. The term may also include polycondensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings), wherein the heteroaryl as defined above may be fused to one or more rings selected from heteroaryl (to form, for example, naphthyridinyl, such as 1,8-naphthyridinyl), heterocycle (to form, for example, 1,2,3,4-tetrahydronaphthyridine, such as 1,2,3,4-tetrahydro-1,8-naphthyridinyl), carbocycle (to form, for example, 5,6,7,8-tetrahydroquinolinyl) and aryl (to form, for example, indazolyl) to form a polycondensed ring system. When valence requirements permit, the rings of the polycondensed ring system may be connected to each other via fusion, spiro and bridging bonds. It should be understood that the individual rings of the polycondensed ring system may be connected in any order relative to each other. It will also be understood that the points of attachment of the multi-fused ring system (as defined above for heteroaryl) may be at any position of the multi-fused ring system, including the heteroaryl, heterocyclic, aryl or carbocyclic portions of the multi-fused ring system, and at any suitable atom of the multi-fused ring system, including carbon atoms and heteroatoms (e.g., nitrogen).

[0208] "Heteroarylene" by itself or as part of another substituent means a divalent radical derived from heteroaryl.

[0209] Non-limiting examples of aryl and heteroaryl groups include pyridyl, pyrimidinyl, thiophenyl, thienyl, furanyl, indolyl, benzoxadiazolyl, benzodioxolyl, benzodioxanyl, thianaphthanyl, pyrrolopyridinyl, indazolyl, quinolinyl, quinoxalinyl, pyridopyrazinyl, quinazolinonyl, benzisoxazolyl, imidazopyridinyl, benzofuranyl, benzothiophene The heteroaryl groups may be substituted or unsubstituted, and the divalent radicals of the above heteroaryl examples are non-limiting examples of heteroarylene groups. The heteroaryl moiety may include one ring heteroatom (e.g., O, N, or S). The heteroaryl moiety may include two optionally different ring heteroatoms (e.g., O, N, or S). The heteroaryl moiety may contain three optionally different ring heteroatoms (e.g., O, N, or S). The heteroaryl moiety may contain four optionally different ring heteroatoms (e.g., O, N, or S). The heteroaryl moiety may contain five optionally different ring heteroatoms (e.g., O, N, or S). The aryl moiety may have a single ring. The aryl moiety may have two optionally different rings. The aryl moiety may have three optionally different rings. The aryl moiety may have four optionally different rings. The heteroaryl moiety may have one ring. The heteroaryl moiety may have two optionally different rings. The heteroaryl moiety may have three optionally different rings. The heteroaryl moiety may have four optionally different rings. The heteroaryl moiety may have five optionally different rings.

[0210] Unless otherwise indicated, the term "halo" or "halogen", by itself or as part of another substituent, means a fluorine, chlorine, bromine, or iodine atom. In addition, terms such as "haloalkyl" may include monohaloalkyl and polyhaloalkyl. For example, the term "halo(C 1 -C 4 The term "alkyl" may include, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, 1-fluoro-2-bromoethyl, and the like.

[0211] As used herein, the term "hydroxy" means -OH.

[0212] As used herein, the term "hydroxyalkyl" means that the alkyl moiety as defined herein is substituted with one or more (such as 1, 2 or 3) hydroxy groups. In some cases, the same carbon atom does not carry more than one hydroxyl group. Representative examples include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-(hydroxymethyl)-2-methylpropyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 2,3-dihydroxypropyl, 2-hydroxy-1-hydroxymethylethyl, 2,3-dihydroxybutyl, 3,4-dihydroxybutyl and 2-(hydroxymethyl)-3-hydroxypropyl.

[0213] As used herein, the term "oxo" means oxygen double bonded to a carbon atom.

[0214] As used herein, a substituent may be a group selected from the following moieties:

[0215] (A) Oxo, halogen, -CF 3 、-CN、-OH、-OCH 3 、-NH 2 , -COOH, -CONH 2 、-NO 2 、-SH、-SO 3 H, -SO 4 H, -SO 2 NH 2 、-NHNH 2 、-ONH 2 、-NHC=(O)NHNH 2 、-NHC=(O)NH 2 、-NHSO 2 H, -NHC=(O)H, -NHC(O)-OH, -NHOH, -OCF 3 、-OCHF 2 、-OCH 2 F, unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and

[0216] (B) an alkyl group, a cycloalkyl group, a heterocyclic group, an aryl group, a heteroaryl group substituted with at least one substituent selected from the following:

[0217] (i) Oxo, halogen, -CF 3 、-CN、-OH、-OCH 3 、-NH 2 , -COOH, -CONH 2 、-NO 2 、-SH、-SO 3 H, -SO 4 H, -SO2 NH 2 、-NHNH 2 、-ONH 2 、-NHC=(O)NHNH 2 、-NHC=(O)NH 2 、-NHSO 2 H, -NHC=(O)H, -NHC(O)-OH, -NHOH, -OCF 3 、-OCHF 2 、-OCH 2 F, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and

[0218] (ii) an alkyl group, a heteroalkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group substituted with at least one substituent selected from the following:

[0219] (a) Oxo, halogen, -CF 3 、-CN、-OH、-OCH 3 、-NH 2 , -COOH, -CONH 2 、-NO 2 、-SH、-SO 3 H, -SO 4 H, -SO 2 NH 2 、-NHNH 2 、-ONH 2 、-NHC=(O)NHNH 2 、-NHC=(O)NH 2 、-NHS O 2 H, -NHC=(O)H, -NHC(O)-OH, -NHOH, -OCF 3 、-OCHF 2 、-OCH 2 F, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and

[0220] (b) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl substituted with at least one substituent selected from the group consisting of oxo, halogen, -CF 3 、-CN、-OH、-OCH 3 、-NH 2 , -COOH, -CONH 2 、-NO 2 、-SH、-SO 3 H, -SO4 H, -SO 2 NH 2 、-NHNH 2 、-ONH 2 、-NHC=(O)NHNH 2 、-NHC=(O)NH 2 、-NHSO 2 H, -NHC=(O)H, -NHC(O)-OH, -NHOH, -OCF 3 、-OCHF 2 、-OCH 2 F. unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl.

[0221] When used in conjunction with a compound, an "effective amount" is an amount effective to treat or prevent a disease in a subject as described herein.

[0222] As used in the present invention, the term "carrier" encompasses carriers, excipients, and diluents and may mean a material, composition, or vehicle involved in carrying or delivering an agent from one organ or part of the body to another organ or part of the subject's body, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material.

[0223] The term "treating" with respect to a subject refers to ameliorating at least one symptom of a condition in the subject. Treatment may include curing, ameliorating, or at least partially ameliorating a condition.

[0224] The terms "prevent" or "preventing" with respect to a subject refer to avoiding a disease or condition from afflicting a subject. Prevention may include prophylactic treatment. For example, prevention may include administering a compound disclosed herein to a subject before the subject develops a disease and the administration will prevent the subject from developing the disease.

[0225] The term "disorder" is used herein and unless otherwise indicated, is intended to refer to and is used interchangeably with the terms disease, condition, or illness.

[0226] As used in the present invention, the term "administer / administering / administration" refers to directly administering a disclosed compound or a pharmaceutically acceptable salt or tautomer or composition of a disclosed compound to a subject, or administering a prodrug derivative or analog of a compound or a pharmaceutically acceptable salt or tautomer or composition of a compound to a subject, which can form an equivalent amount of an active compound in the body of the subject.

[0227] A "patient" or "subject" is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or a non-human primate such as a monkey, chimpanzee, baboon, or rhesus monkey.

[0228] Compound

[0229] The present invention provides a compound having a structure of formula Ic,

[0230]

[0231] or a pharmaceutically acceptable salt or tautomer thereof, wherein R 32 , R 28 and R 40 As mentioned above.

[0232] The present invention provides a compound having a structure of formula Ia,

[0233]

[0234] or a pharmaceutically acceptable salt or tautomer thereof, wherein R 32 , R 28 and R 40 As mentioned above.

[0235] The present invention provides a compound having a structure of formula I,

[0236]

[0237] or a pharmaceutically acceptable salt or tautomer thereof, wherein R 32 , R 28 and R 40 As mentioned above.

[0238] The present invention provides a compound having a structure of Formula Ib:

[0239]

[0240] or a pharmaceutically acceptable salt and / or tautomer thereof, wherein R 32 , R 28 and R 40 As described above for Formula I.

[0241] The present invention provides a compound having a structure of formula II,

[0242]

[0243] or a pharmaceutically acceptable salt or tautomer thereof, wherein R 32 , R 28 and R 40 As mentioned above.

[0244] The present invention provides a compound having a structure of Formula IIb:

[0245]

[0246] or a pharmaceutically acceptable salt or tautomer thereof, wherein R 32 , R 28 and R 40 As described above for Formula II.

[0247] In certain embodiments, the compound has the formula:

[0248]

[0249] or a pharmaceutically acceptable salt or tautomer thereof.

[0250] In certain embodiments, R 32 =0. In certain embodiments, R 32 For-OR 3 In certain embodiments, R 32 is H. In certain embodiments, R 32 -N 3 .

[0251] As mentioned above, R 3 Each independently is H or (C 1 -C 6 In certain embodiments, R 3 is H. In certain embodiments, R 3 For (C 1 -C 6 In certain embodiments, R 3 It is methyl.

[0252] In certain embodiments, R 28 is H. In certain embodiments, R 28 For (C 1 -C 6 In certain embodiments, R 40 For H.

[0253] In certain embodiments, the compound is represented by the structure of Formula I-40b:

[0254]

[0255] or a pharmaceutically acceptable salt or tautomer thereof, wherein R 32 and R 40 As described above for Formula Ia, Ic, I or II.

[0256] In certain embodiments, the compound is represented by the structure of Formula 1-40:

[0257]

[0258] or a pharmaceutically acceptable salt or tautomer thereof, wherein R 32 and R 40 As mentioned above.

[0259] In certain embodiments, R 40 =Z 1 )-R 40a In certain embodiments, Z 1 is O. In certain embodiments, Z 1 For S.

[0260] In certain embodiments, R 40a -O-(C 1 -C 6 )alkyl or -O-(C 6 -C 10 ) aryl; wherein the aryl is unsubstituted or selected from NO 2 and 1 to 5 substituents of halogen.

[0261] In certain embodiments, R 40a For-A 1 -L 1 -A 2 -B. In certain embodiments, R 40a For-A 1 -A 2 -B. In certain embodiments, R 40a For -L 2 -A 1 -L 1 -A 2 -L 3 -B.

[0262] In certain embodiments, R 40a For-A 1 -L 1 -A 2 -B, where A 1 and A 2 In certain embodiments, R 40a For-A 1 -L 1 -A 2 -B, where A 2 In certain embodiments, R 40a For-A 1 -L 1 -A2 -B, where A 1 In certain embodiments, R 40a For-A 1 -L 1 -A 2 -B. In certain embodiments, R 40a For-A 1 -A 2 -B. In certain embodiments, R 40a For -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2 and A 1 In certain embodiments, R 40a For -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2 In certain embodiments, R 40a For -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 3 Does not exist.

[0263] In certain embodiments, the compound is represented by the structure of Formula I-28b:

[0264]

[0265] or a pharmaceutically acceptable salt or tautomer thereof, wherein R 32 and R 28 As described above for Formula Ia, Ic, I or II.

[0266] In certain embodiments, the compound is represented by the structure of Formula 1-28:

[0267]

[0268] or a pharmaceutically acceptable salt or tautomer thereof, wherein R 32 and R 28 As mentioned above.

[0269] In certain embodiments, R 28 =Z 1 )-R 28a In certain embodiments, Z1 is O. In certain embodiments, Z 1 For S.

[0270] In certain embodiments, R 28a -O-(C 1 -C 6 )alkyl or -O-(C 6 -C 10 ) aryl; wherein the aryl is unsubstituted or selected from NO 2 and 1 to 5 substituents of halogen.

[0271] In certain embodiments, R 28a For-A 1 -L 1 -A 2 -B. In certain embodiments, R 28a For-A 1 -A 2 -B. In certain embodiments, R 28a For -L 2 -A 1 -L 1 -A 2 -L 3 -B.

[0272] In certain embodiments, R 28a For-A 1 -L 1 -A 2 -B, where A 1 and A 2 In certain embodiments, R 28a For-A 1 -L 1 -A 2 -B, where A 2 In certain embodiments, R 28a For-A 1 -L 1 -A 2 -B, where A 1 In certain embodiments, R 28a For-A 1 -L 1 -A 2 -B. In certain embodiments, R 28a For-A 1 -A 2 -B. In certain embodiments, R 28a For -L 2 -A 1 -L 1 -A 2 -L3 -B, where L 2 and A 1 In certain embodiments, R 28a For -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2 In certain embodiments, R 28a For -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 3 Does not exist.

[0273] In certain embodiments, the compound is represented by the structure of Formula I-32b:

[0274]

[0275] or a pharmaceutically acceptable salt or tautomer thereof, wherein R 32 As described above for Formula Ia, Ic, I or II.

[0276] In certain embodiments, R 32 =-OC(=Z 1 )-R 32a In certain embodiments, Z 1 is O. In certain embodiments, Z 1 For S.

[0277] In certain embodiments, R 32a -O-(C 1 -C 6 )alkyl or -O-(C 6 -C 10 ) aryl; wherein the aryl is unsubstituted or selected from NO 2 and 1 to 5 substituents of halogen.

[0278] In certain embodiments, R 32a For-A 1 -L 1 -A 2 -B. In certain embodiments, R 32a For-A 1 -A 2 -B. In certain embodiments, R 32a For -L 2 -A 1 -L 1 -A2 -L 3 -B.

[0279] In certain embodiments, R 32a For-A 1 -L 1 -A 2 -B, where A 1 and A 2 In certain embodiments, R 32a For-A 1 -L 1 -A 2 -B, where A 2 In certain embodiments, R 32a For-A 1 -L 1 -A 2 -B, where A 1 In certain embodiments, R 32a For-A 1 -L 1 -A 2 -B. In certain embodiments, R 32a For-A 1 -A 2 -B. In certain embodiments, R 32a For -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2 and A 1 In certain embodiments, R 32a For -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2 In certain embodiments, R 32a For -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 3 Does not exist.

[0280] As mentioned above, L 1 Each independently selected from

[0281]

[0282] As described above for Formula Ia, L 1Each independently selected from

[0283]

[0284] As described above for Formula Ic, L 1 Each independently selected from

[0285]

[0286] In certain embodiments, L 1 for

[0287] In certain embodiments, L 1 for

[0288] In certain embodiments, L 1 for

[0289] In certain embodiments, L 1 for In certain embodiments, L 1 for In certain embodiments, L 1 for In certain embodiments, L 1 for In certain embodiments, L 1 for In certain embodiments, L 1 for In certain embodiments, L 1 for

[0290] In certain embodiments, L 1 for In certain embodiments, L 1 for In certain embodiments, L 1 for In certain embodiments, L 1 for

[0291] As mentioned above, L 2 and L 3 is independently absent or independently selected from

[0292]

[0293] As described above for Formulas Ia and Ic, L 2 and L 3 is independently absent or independently selected from

[0294]

[0295] In certain embodiments, L 2 In certain embodiments, L 2 for In certain embodiments, L 2 for In certain embodiments, L 2 for In certain embodiments, L 2 for In certain embodiments, L 2 for In certain embodiments, L 2 for

[0296] In certain embodiments, L 2 for In certain embodiments, L 2 for In certain embodiments, L 2 for

[0297] In certain embodiments, L 2 for

[0298] In certain embodiments, L 2 for

[0299] In certain embodiments, L 2 for

[0300] In certain embodiments, L 3 In certain embodiments, L 3 for In certain embodiments, L 3 for In certain embodiments, L 3 for In certain embodiments, L 3 for In certain embodiments, L 3 for In certain embodiments, L 3 for

[0301] In certain embodiments, L 3 for In certain embodiments, L 3 for In certain embodiments, L 3 In certain embodiments, L 2 for In certain embodiments, L 2 for In certain embodiments, L 2 for

[0302] In certain embodiments, L 3 for

[0303] In certain embodiments, L 3 for

[0304] In certain embodiments, L 3 for

[0305] As mentioned above, A 1 and A 2 is independently absent or independently selected from

[0306]

[0307] Q is each independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0308] X is each independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0309] X 1 each independently is a heteroarylene or heterocyclylene ring;

[0310] W is each independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0311] W 1 each independently is a heteroarylene or heterocyclylene ring;

[0312] G is each independently absent or a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0313] G 1 and G 2 Each is independently a heteroarylene or heterocyclylene ring.

[0314] As described above for Formula Ia, A 1 and A 2 is independently absent or independently selected from

[0315]

[0316]

[0317] Q is each independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0318] X is each independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0319] X 1 each independently is a heteroarylene or heterocyclylene ring;

[0320] W is each independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0321] W 1 each independently is a heteroarylene or heterocyclylene ring;

[0322] G is each independently absent or a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0323] G 1 and G 2 Each is independently a heteroarylene or heterocyclylene ring.

[0324] As described above for Formula Ic, A 1 and A 2 is independently absent or independently selected from

[0325]

[0326]

[0327] Q is each independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0328] X is each independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0329] X 1 each independently is a heteroarylene or heterocyclylene ring;

[0330] W is each independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0331] W 1 each independently is a heteroarylene or heterocyclylene ring;

[0332] G is each independently absent or a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0333] G 1 and G 2 Each is independently a heteroarylene or heterocyclylene ring.

[0334] For formula I, as shown, A 1 The left bond is bound to -C(=Z 1 )- or L 2 ; and as depicted, A 2 The right side of the key is connected to B or L 3 For Formula II, as shown, A 1 The left bond is bound to -C(=Z 1 )-; and as shown, A 2 The bond on the right side of the portion is bound to B. For Formulas Ia and Ic, as shown, A 1 The left bond is bound to -C(=Z 1 )- or L 2 ; and among them, as depicted, A 2 The right side of the key is connected to B or L 3 .

[0335] In certain embodiments, A 1 In certain embodiments, A 1 for In certain embodiments, A 1 for In certain embodiments, A 1 for In certain embodiments, A 1 for

[0336] In certain embodiments, A 1 for wherein Q is each independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene.

[0337] In certain embodiments, A 1 for wherein Q is each independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene.

[0338] In certain embodiments, A 1 for wherein each X is independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene; and each X 1 is a heteroarylene or heterocyclylene ring.

[0339] In certain embodiments, A 1 for wherein each W is independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene; and each W 1 is a heteroarylene or heterocyclylene ring.

[0340] In certain embodiments, A 1 for wherein each W is independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene; and each W 1 is a heteroarylene or heterocyclylene ring.

[0341] In certain embodiments, A 1 for wherein each G is independently absent or is a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene.

[0342] In certain embodiments, A 1 for wherein each G is independently absent or is a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene; and G 1 and G 2 Each is independently a heteroarylene or heterocyclylene ring.

[0343] In certain embodiments, A 1 for

[0344] In certain embodiments, A 1 for In certain embodiments, A 1 for In certain embodiments, A 1 for In certain embodiments, A 1 for

[0345] In certain embodiments, A 2 In certain embodiments, A 2 for In certain embodiments, A 2 for In certain embodiments, A 2 for In certain embodiments, A 2 for

[0346] In certain embodiments, A 2 for wherein Q is each independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene.

[0347] In certain embodiments, A 2 for wherein Q is each independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene.

[0348] In certain embodiments, A 2 for wherein each X is independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene; and X 1 Each is independently a heteroarylene or heterocyclylene ring.

[0349] In certain embodiments, A 2 for wherein each W is independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene; and W 1 Each is independently a heteroarylene or heterocyclylene ring.

[0350] In certain embodiments, A 2 for wherein each W is independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene; and W 1 Each is independently a heteroarylene or heterocyclylene ring.

[0351] In certain embodiments, A 2 for wherein each G is independently absent or is a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene.

[0352] In certain embodiments, A 2 for wherein each G is independently absent or is a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene; and G 1 and G 2 Each is independently a heteroarylene or heterocyclylene ring.

[0353] In certain embodiments, A 2 for

[0354] In certain embodiments, A 2 for In certain embodiments, A 2 for In certain embodiments, A 2 for In certain embodiments, A 2 for

[0355] As mentioned above, B is each independently selected from

[0356]

[0357] In certain embodiments, B is

[0358] In certain embodiments, B is

[0359] In certain embodiments, B is

[0360] In certain embodiments, B is

[0361] As mentioned above, B 1 Each independently selected from NR 3 -(C(R 3 ) 2 ) n -、 NR 3 -(C(R 3 ) 2 ) n -(C 6 -C 10 )arylene-(C(R 3 ) 2 ) n -、 NR 3 -(C(R 3 ) 2 ) n -heteroarylene-, (C 6 -C 10 ) arylene-, NR 3 -(C(R 3 ) 2 ) n -NR 3 C(O)-, NR 3 -(C(R 3 ) 2 ) n -heteroarylene-heterocyclylene-(C 6 -C 10 ) arylene-, Heteroarylene-heterocyclylene-(C 6 -C 10 ) arylene-, and NR 3 -(C(R 3 ) 2 ) n -S(O) 2 -arylene-C(O)-, wherein as shown, B 1 Left Bond to A 2 or L 1 ; and wherein the heteroarylene, heterocyclylene and arylene are each independently optionally substituted by alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen or hydroxy.

[0362] As described above for Formula Ic, B 1 Each independently selected from NR 3 -(C(R 3 ) 2 ) n -、 NR 3 -(C(R 3 ) 2 ) n -(C 6 -C 10 )arylene-(C(R 3 ) 2 ) n -、 NR 3 -(C(R 3 ) 2 ) n -heteroarylene-, NR 3 -(C(R 3 ) 2 ) n -heteroarylene-(C(R 3 ) 2 ) n -、 (C 6 -C 10 ) arylene-, NR 3 -(C(R 3 ) 2 ) n -NR 3 C(O)-, NR 3 -(C(R 3 ) 2 ) n -heteroarylene-heterocyclylene-(C 6 -C 10 ) arylene-, Heteroarylene-heterocyclylene-(C 6 -C 10 ) arylene-, NR 3 -(C(R 3 ) 2 ) n -S(O) 2 -Arylene-C(O)- and NR 3 -(C(R 3 ) 2 ) n -S(O) 2 -arylene-(C(R 3 ) 2 ) n -; where as depicted, B 1 Left Bond to A 2 , L 3 or L 1 ; and wherein the heteroarylene, heterocyclylene and arylene are each independently optionally substituted by alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen or hydroxy.

[0363] In certain embodiments, B 1 for NR 3 -(C(R 3 ) 2 ) n -.

[0364] In certain embodiments, B 1 for In certain embodiments, B 1 for wherein the arylene group is optionally substituted with a haloalkyl group.

[0365] In certain embodiments, B 1 for NR 3 -(C(R 3 ) 2 ) n -、 NR 3 -(C(R 3 ) 2 ) n -(C 6 -C 10 )arylene-(C(R 3 ) 2 ) n -、 NR 3 -(C(R 3 ) 2 ) n -heteroarylene-, (C 6 -C 10 ) arylene-, NR 3 -(C(R 3 ) 2 ) n -NR 3 C(O)-, NR 3 -(C(R 3 ) 2 ) n -heteroarylene-heterocyclylene-(C 6 -C 10 )arylene- or Heteroarylene-heterocyclylene-(C 6 -C 10 )arylene-. In certain embodiments, B 1 for

[0366] In certain embodiments, B 1 for In certain embodiments, B 1 for In certain embodiments, B 1 for NR 3 -(C(R 3 ) 2 ) n -S(O) 2 -arylene-C(O)-.

[0367] In certain embodiments, B 1 for NR 3 -(C(R 3 ) 2 ) n -heteroarylene-(C(R 3 ) 2 ) n -. In certain embodiments, B 1 for In certain embodiments, B 1 for In certain embodiments, B 1 for NR 3 -(C(R 3 )2 ) n -S(O) 2 -arylene-(C(R 3 ) 2 ) n -.

[0368] In certain embodiments, in B 1 In the above, the heteroaryl, heterocyclyl and arylene groups are optionally substituted by alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen or hydroxy.

[0369] In certain embodiments, R 3 is H. In certain embodiments, R 3 For (C 1 -C 6 )alkyl.

[0370] In certain embodiments, R 4 is H. In certain embodiments, R 4 For (C 1 -C 6 In certain embodiments, R 4 In certain embodiments, R 4 is a 5- to 12-membered heteroaryl, a 5- to 12-membered heterocyclic group or (C 6 -C 10 ) aryl, wherein the heteroaryl, heterocyclyl and aryl are optionally substituted by -N(R 3 ) 2 、-OR 3 , halogen, (C 1 -C 6 )alkyl, -(C 1 -C 6 )alkylene-heteroaryl, -(C 1 -C 6 )alkylene-CN or -C(O)NR 3 -heteroaryl substitution. In certain embodiments, R 4 -C(O)NR 3 -heterocyclyl. In certain embodiments, R 4 is optionally replaced by -N(R 3 ) 2 OR 3 Substituted 5- to 12-membered heteroaryl.

[0371] As mentioned above, R 5 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2, where (C 1 -C 6 )alkyl, wherein the alkyl group is optionally substituted with -N(R 3 ) 2 OR 3 In certain embodiments, R 5 is H. In certain embodiments, R 5 For (C 1 -C 6 )alkyl, wherein the alkyl is optionally substituted with -N(R 3 ) 2 OR 3 In certain embodiments, R 5 -C(O)OR 3 In certain embodiments, R 5 -N(R 3 ) 2 .

[0372] As mentioned above, R 6 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 , where (C 1 -C 6 )alkyl, wherein the alkyl group is optionally substituted with -N(R 3 ) 2 OR 3 In certain embodiments, R 6 is H. In certain embodiments, R 6 For (C 1 -C 6 )alkyl, wherein the alkyl is optionally substituted with -N(R 3 ) 2 OR 3 In certain embodiments, R 6 -C(O)OR 3 In certain embodiments, R 6 -N(R 3 ) 2 .

[0373] As mentioned above, R 7 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 , where (C 1 -C 6)alkyl, wherein the alkyl group is optionally substituted with -N(R 3 ) 2 OR 3 In certain embodiments, R 7 is H. In certain embodiments, R 7 For (C 1 -C 6 )alkyl, wherein the alkyl is optionally substituted with -N(R 3 ) 2 OR 3 In certain embodiments, R 7 -C(O)OR 3 In certain embodiments, R 7 -N(R 3 ) 2 .

[0374] As mentioned above, R 8 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 , where (C 1 -C 6 )alkyl, wherein the alkyl group is optionally substituted with -N(R 3 ) 2 OR 3 In certain embodiments, R 8 is H. In certain embodiments, R 8 For (C 1 -C 6 )alkyl, wherein the alkyl is optionally substituted with -N(R 3 ) 2 OR 3 In certain embodiments, R 8 -C(O)OR 3 In certain embodiments, R 8 -N(R 3 ) 2 .

[0375] As described above, Y is each independently C(R 3 ) 2 In certain embodiments, Y is C(R 3 ) 2 In certain embodiments, Y is CH 2 In certain embodiments, Y is a bond.

[0376] In certain embodiments, n is 1, 2, 3, 4, 5, 6, 7, or 8, or any range derivable therein. In certain embodiments, n is 1, 2, 3, or 4. In certain embodiments, n is 5, 6, 7, or 8. In certain embodiments, n is 9, 10, 11, or 12.

[0377] In certain embodiments, o is an integer from 0 to 10, or any range derivable therein. In certain embodiments, o is 0, 1, 2, 3, 4, or 5. In certain embodiments, o is 6, 7, 8, 9, or 10. In certain embodiments, o is 1 to 7. In certain embodiments, o is 1 to 8. In certain embodiments, o is 1 to 9. In certain embodiments, o is 3 to 8.

[0378] In certain embodiments, o is an integer from 0 to 30, or any range derivable therein. In certain embodiments, o is an integer from 0 to 30, 29, 28, 27, or 26. In certain embodiments, o is an integer from 0 to 25, 24, 23, 22, or 21. In certain embodiments, o is an integer from 0 to 20, 19, 18, 17, or 16. In certain embodiments, o is an integer from 0 to 15, 14, 13, 12, or 11.

[0379] In certain embodiments, p is 0, 1, 2, 3, 4, 5, or 6, or any range derivable therein. In certain embodiments, p is 7, 8, 9, 10, 11, or 12. In certain embodiments, p is 0, 1, 2, or 3. In certain embodiments, p is 4, 5, or 6.

[0380] In certain embodiments, q is an integer from 0 to 10, or any range derivable therein. In certain embodiments, q is 0, 1, 2, 3, 4, or 5. In certain embodiments, q is 6, 7, 8, 9, or 10. In certain embodiments, q is from 1 to 7. In certain embodiments, q is from 1 to 8. In certain embodiments, q is from 1 to 9. In certain embodiments, q is from 3 to 8.

[0381] In certain embodiments, q is an integer from 0 to 30, or any range derivable therein. In certain embodiments, q is an integer from 0 to 30, 29, 28, 27, or 26. In certain embodiments, q is an integer from 0 to 25, 24, 23, 22, or 21. In certain embodiments, q is an integer from 0 to 20, 19, 18, 17, or 16. In certain embodiments, q is an integer from 0 to 15, 14, 13, 12, or 11.

[0382] As described above, r is an integer from 1 to 6. In certain embodiments, r is 1. In certain embodiments, r is 2. In certain embodiments, r is 3. In certain embodiments, r is 4. In certain embodiments, r is 5. In certain embodiments, r is 6.

[0383] As mentioned above, when R 28 and R 40 When H, R 32 Is not =0. In certain embodiments, the compound is not rapamycin, as shown below:

[0384]

[0385] In certain embodiments, in Formula Ia or Ic, R 32 =-OC(=Z 1 )-R 32a In certain embodiments, R 32 =-OC(=Z 1 )-R 32a ; where R 32a For-A 1 -L 1 -A 2 -B; -A 1 -A 2 -B; or -L 2 -A 1 -L 1 -A 2 -L 3 -B. In certain embodiments, in Formula Ia or Ic, R 28 =Z 1 )-R 28a In certain embodiments, R 28 =Z 1 )-R 28a ; where R 28a For-A 1 -L 1 -A 2 -B; -A 1 -A 2 -B; or -L 2 -A 1 -L 1 -A 2 -L 3 -B. In certain embodiments, in Formula Ia or Ic, R 40 =Z 1 )-R 40a In certain embodiments, R 40 =Z 1 )-R40a , where R 40a For-A 1 -L 1 -A 2 -B; -A 1 -A 2 -B; or -L 2 -A 1 -L 1 -A 2 -L 3 -B.

[0386] The present invention provides a compound of formula Ia or Ic, or a pharmaceutically acceptable salt or tautomer thereof, which has one, two or three of the following characteristics:

[0387] a) R 32 =-OC(=Z 1 )-R 32a ;

[0388] b) R 28 =Z 1 )-R 28a ;

[0389] c) R 40 =Z 1 )-R 40a .

[0390] The present invention provides a compound of formula Ia or Ic, or a pharmaceutically acceptable salt or tautomer thereof, which has one, two or three of the following characteristics:

[0391] a) R 32 =-OC(=Z 1 )-R 32a ; where R 32a For-A 1 -L 1 -A 2 -B; -A 1 -A 2 -B; or -L 2 -A 1 -L 1 -A 2 -L 3 -B;

[0392] b) R 28 =Z 1 )-R 28a ; where R 28a For-A 1 -L 1 -A 2 -B; -A 1 -A2 -B; or -L 2 -A 1 -L 1 -A 2 -L 3 -B;

[0393] c) R 40 =Z 1 )-R 40a , where R 40a For-A 1 -L 1 -A 2 -B; -A 1 -A 2 -B; or -L 2 -A 1 -L 1 -A 2 -L 3 -B.

[0394] The present invention provides a compound of formula Ia or Ic, or a pharmaceutically acceptable salt or tautomer thereof, which has one, two or three of the following characteristics:

[0395] a) R 40 =Z 1 )-R 40a ;

[0396] b) R 40a For-A 1 -L 1 -A 2 -B; -A 1 -A 2 -B; -L 2 -A 1 -L 1 -A 2 -L 3 -B;

[0397] c) R 32 For-OR 3 , such as -OH.

[0398] The present invention provides a compound of formula Ia or Ic, or a pharmaceutically acceptable salt or tautomer thereof, which has one, two, three or four of the following characteristics:

[0399] a) R 28a , R 32a and R 40a One of them is -A 1 -L 1 -A 2 -B;

[0400] b)A 1 for not existing;

[0401] c)A 2 for not existing;

[0402] d) L 1 for

[0403] e) B is

[0404] f)B 1 for NR 3 -(C(R 3 ) 2 ) n -or

[0405] g)R 4 is optionally replaced by -N(R 3 ) 2 OR 3 Substituted 5- to 12-membered heteroaryl.

[0406] The present invention provides a compound of the following formula:

[0407]

[0408] or a pharmaceutically acceptable salt or tautomer thereof, which has one, two, three or four of the following characteristics:

[0409] a) Z 1 is O;

[0410] b)A 1 for not existing;

[0411] c)L 1 for

[0412] d) B is

[0413] e)B 1 for NR 3 -(C(R 3 ) 2 ) n -or

[0414] f)R 4 is optionally replaced by -N(R 3 ) 2 OR 3 substituted 5- to 12-membered heteroaryl; and

[0415] g)R 32 is =O.

[0416] In the above, R 40a Can be -A 1 -L 1 -A 2 -B; -A 1 -A 2 -B; or -L 2 -A 1 -L 1 -A 2 -L 3 -B.

[0417] The present invention provides a compound of the following formula:

[0418]

[0419] or a pharmaceutically acceptable salt or tautomer thereof, which has one, two, three or four of the following characteristics:

[0420] a) Z 1 is O;

[0421] b)A 1 for not existing;

[0422] c)L 1 for

[0423] d) B is

[0424] e)B 1 for NR 3 -(C(R 3 ) 2 ) n -or

[0425] f)R 4 is optionally replaced by -N(R 3 ) 2 OR 3 substituted 5- to 12-membered heteroaryl; and

[0426] g)R 32 It is -OH.

[0427] In the above, R 40a Can be -A 1 -L 1 -A 2 -B; -A 1 -A 2 -B; or -L2 -A 1 -L 1 -A 2 -L 3 -B.

[0428] The present invention provides a compound of the following formula:

[0429]

[0430] or a pharmaceutically acceptable salt or tautomer thereof, which has one, two, three or four of the following characteristics:

[0431] a) Z 1 is O;

[0432] b)A 1 for

[0433] c)L 1 for

[0434] d) B is

[0435] e)B 1 for NR 3 -(C(R 3 ) 2 ) n -or

[0436] f)R 4 is optionally replaced by -N(R 3 ) 2 OR 3 substituted 5- to 12-membered heteroaryl; and

[0437] g)R 32 is =O.

[0438] In the above, R 40a Can be -A 1 -L 1 -A 2 -B; -A 1 -A 2 -B; or -L 2 -A 1 -L 1 -A 2 -L 3 -B.

[0439] The present invention provides a compound of the following formula:

[0440]

[0441] or a pharmaceutically acceptable salt or tautomer thereof, which has one, two, three or four of the following characteristics:

[0442] a) Z 1 is O;

[0443] b)A 1 for not existing;

[0444] c)L 1 for

[0445] d) B is

[0446] e)B 1 for NR 3 -(C(R 3 ) 2 ) n -、 NR 3 -(C(R 3 ) 2 ) n -S(O) 2 -arylene-C(O)-, wherein the arylene is optionally substituted with alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen or hydroxy;

[0447] f)R 4 is optionally replaced by -N(R 3 ) 2 OR 3 substituted 5- to 12-membered heteroaryl; and

[0448] g)R 32 It is -OH.

[0449] In the above, R 40a Can be -A 1 -L 1 -A 2 -B; -A 1 -A 2 -B; or -L 2 -A 1 -L 1 -A 2 -L 3 -B.

[0450] The present invention provides a compound of the following formula:

[0451]

[0452] or a pharmaceutically acceptable salt or tautomer thereof, which has one, two, three or four of the following characteristics:

[0453] a) Z 1 is O;

[0454] b)A 1 for

[0455] c)A 2 for

[0456] d) L 1 for

[0457] e) B is

[0458] f)B 1 for NR 3 -(C(R 3 ) 2 ) n -、 NR 3 -(C(R 3 ) 2 ) n -S(O) 2 -arylene-C(O)-, wherein the arylene is optionally substituted with alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen or hydroxy;

[0459] g)R 4 is optionally replaced by -N(R 3 ) 2 OR 3 substituted 5- to 12-membered heteroaryl; and

[0460] h)R 32 It is -OH.

[0461] In the above, R 40a Can be -A 1 -L 1 -A 2 -B, -A 1 -A 2 -B or -L 2 -A 1 -L 1 -A 2 -L 3 -B.

[0462] In certain embodiments, in Formula Ia or Ic, R 40ais any organic moiety, which can have a molecular weight (e.g., the sum of the atomic weights of the atoms of the substituents) of less than 15, 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 g / mol.

[0463] In certain embodiments, the present invention provides a compound selected from the following, or a pharmaceutically acceptable salt or tautomer thereof,

[0464]

[0465]

[0466]

[0467]

[0468]

[0469]

[0470]

[0471]

[0472]

[0473]

[0474]

[0475]

[0476]

[0477]

[0478]

[0479] In certain embodiments, the present invention provides a compound selected from the following, or a pharmaceutically acceptable salt or tautomer thereof,

[0480]

[0481]

[0482]

[0483]

[0484]

[0485]

[0486]

[0487]

[0488]

[0489]

[0490]

[0491]

[0492]

[0493]

[0494] In certain embodiments, the present invention provides a compound selected from the following, or a pharmaceutically acceptable salt or tautomer thereof,

[0495]

[0496]

[0497]

[0498]

[0499]

[0500] The compounds of the present invention may include pharmaceutically acceptable salts of the compounds disclosed herein. Representative "pharmaceutically acceptable salts" may include, for example, water-soluble salts and water-insoluble salts, such as acetate, stilbenesulfonate (4,4-diaminostilbene-2,2-disulfonate), benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromate, butyrate, calcium salt, calcium ethylenediaminetetraacetate, right-rotating camphorsulfonic acid, carbonate, hydrochloride, citrate, clavulariate, dihydrochloride, ethylenediaminetetraacetate, edisylate, propionate lauryl sulfate (estolate), ethanesulfonate, fumarate, gluconate, gluconate, glutamate, glycolyl p-aminophenylarsonic acid salt (glycollylarsanilate), hexafluorophosphate, hexylresorcinol salt, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, Iodide, isethionate, lactate, lactobionate, laurate, magnesium salt, malate, maleate, mandelate, methanesulfonate, methyl bromide, methyl nitrate, methyl sulfate, mucate, naphthenate, nitrate, N-methylglucamine ammonium salt, 3-hydroxy-2-naphthoate, oleate, oxalate, palmitate, pamoate, 1,1-methylene-bis-2-hydroxy-3-naphthoate, einbonate, pantothenate, phosphate / hydrogen phosphate, picrate, polygalacturonate, propionate, p-toluenesulfonic acid, salicylate, stearate, subacetate, succinate, sulfate, sulfosalicylate, suramate, tannate, tartrate, teoclate, toluenesulfonate, triethyl iodide and valerate.

[0501] "Pharmaceutically acceptable salts" may also include both acid and base addition salts. "Pharmaceutically acceptable acid addition salts" may refer to those salts that retain the biological effectiveness and properties of the free bases which are not biologically or otherwise undesirable and may be formed using inorganic acids such as, but not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid , formic acid, fumaric acid, galactonic acid, gentisic acid, glucoheptanoic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid, glycerophosphate, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid, undecylenic acid, etc.

[0502] "Pharmaceutically acceptable base addition salts" may refer to those salts that retain the biological effectiveness and properties of the free acids which are not biologically or otherwise undesirable. These salts may be prepared from the addition of inorganic or organic bases to the free acids. Salts derived from inorganic bases may include, but are not limited to, sodium salts, potassium salts, lithium salts, ammonium salts, calcium salts, magnesium salts, iron salts, zinc salts, copper salts, manganese salts, aluminum salts, and the like. For example, inorganic salts may include, but are not limited to, ammonium salts, sodium salts, potassium salts, calcium salts, and magnesium salts. Salts derived from organic bases may include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, denanol, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, phenethamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like.

[0503] Unless otherwise indicated, structures depicted herein may also include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having a present structure differ in that a hydrogen atom is replaced by deuterium or tritium, or a carbon atom is replaced by 13 C or 14 C replacement, or nitrogen atom15 N replacement, or oxygen atoms 17 O or 18 O-substituted compounds are within the scope of the present invention. Such isotopically labeled compounds are useful as research or diagnostic tools.

[0504] In some embodiments, one or more deuterium atoms may be introduced into the PEG portion of any of the compounds of the invention. Starting from commercially available starting materials such as isotopically enriched hydroxylamine building blocks, the mechanisms of such modifications are known in the art. In some embodiments, tritium or deuterium may be introduced at the C32 position of the compounds of the invention using, for example, commercially available isotopically pure reducing agents and methods known to those skilled in the art. In some embodiments, commercially available materials and methods known to those skilled in the art may be used to introduce tritium or deuterium into the PEG portion of any of the compounds of the invention. 14 C introduces the C40 carbamate moiety of the compound of the invention. In some embodiments, isotopes (such as deuterium or tritium) can be introduced into the R of the compound of Formula Ia, Ic, I or II using commercially available starting materials and methods known to those skilled in the art. 40a Substituent.

[0505] Methods of synthesizing the disclosed compounds

[0506] The compounds of the present invention can be prepared by a variety of methods including standard chemistry. Suitable synthetic routes are depicted in the reaction schemes provided below.

[0507] Any of the compounds of the formula described herein can be prepared by methods known in organic synthesis techniques such as partially by the following synthesis schemes and examples. In the following reaction schemes, it should be fully understood that the protective groups of sensitive or reactive groups are used according to general principles or chemistry where necessary. Protective groups are operated according to standard methods of organic synthesis (TW Greene and PGM Wuts, "Protective Groups in Organic Synthesis", 3rd edition, Wiley, New York 1999). These groups are removed at a convenient stage of compound synthesis using methods obvious to those skilled in the art. The selection method and reaction conditions and their execution order should be consistent with the preparation of pharmaceutically acceptable salts or tautomers of Formula I, Ia, Ib, II or IIb compounds or any of the above.

[0508] Compounds of any of the formulae described herein can be prepared by methods that avoid the use of metal-mediated cycloaddition reactions that require the use of azide-containing compounds. Azide-containing compounds present potential safety hazards associated with their preparation and storage (e.g., explosion due to high-energy decomposition). The reaction schemes herein can also avoid the use of copper or ruthenium metal in the penultimate or final synthesis step, which can be advantageous. Avoiding the use of copper or ruthenium metal in the penultimate or final synthesis step reduces the likelihood of contamination of the final compound with undesirable metal impurities.

[0509] Because rapamycin can be an expensive starting material, good reaction yields are advantageous. The reaction scheme herein provides better yields than other reaction schemes. In the reaction scheme herein, alkylation at the C40-hydroxyl of rapamycin is not necessary, which advantageously provides up to a 5-fold increase in overall yield in the preparation of divalent compounds from rapamycin compared to other reaction schemes.

[0510] There are additional synthetic improvements associated with better yields. Avoiding the need for alkylation at the C40-hydroxy group results in up to 5-fold improved overall yields in the preparation of divalent compounds from rapamycin.

[0511] Those skilled in the art will know whether the stereocenter is present in any one of the compounds of the present invention. Therefore, the present invention may include possible stereoisomers (unless specified in the synthesis) and may include not only racemic compounds, but also individual enantiomers and / or diastereomers. When the desired compound is a single enantiomer or diastereomer, it can be obtained by stereospecific synthesis or by the splitting of the final product or any convenient intermediate. The splitting of the final product, intermediate or starting material can be achieved by any suitable method known in the art. See, for example, "Stereochemistry of Organic Compounds" (Wiley-Interscience, 1994) by ELEiel, SH Wilen and LN Mander.

[0512] Preparation of compounds

[0513] The compounds described herein can be prepared from commercially available starting materials or synthesized using known organic, inorganic and / or enzymatic methods.

[0514] The compounds of the present invention can be prepared by many methods well known to those skilled in the art of organic synthesis. For example, the compounds of the present invention can be synthesized using the following methods, together with synthetic methods known in the field of synthetic organic chemistry, or variations thereof as understood by those skilled in the art. These methods may include, but are not limited to, those described below.

[0515] The term "tautomer" may refer to a group of compounds having the same number and type of atoms, but with different bond connections and in equilibrium with each other. A "tautomer" is a single member of the group of compounds. Typically a single tautomer is drawn, but it is understood that this single structure may represent all possible tautomers that may exist. Examples may include enol-keto tautomerism. When a ketone is drawn, it is understood that both the enol and keto forms are part of the present invention.

[0516] In addition to the tautomers that may exist at all amide, carbonyl, and oxime groups within compounds of Formula I, Ia, Ib, Ic, II, or lib, the compounds in this family readily interconvert via ring-opening species between two major isomeric forms, referred to as pyran and oxepane isomers (shown below). This interconversion can be facilitated by magnesium ions, mildly acidic conditions, or alkylamine salts as described in the following references: i) Hughes, PF, Musser, J.; Conklin, M., Russo, R. 1992. Tetrahedron Lett. 33(33): 4739-32. ii) Zhu, T. 2007. U.S. Patent 7,241,771; Wyeth. iii) Hughes, PF 1994. U.S. Patent 5,344,833; American Home Products Corp. The following schemes show the interconversion between pyran and oxepane isomers in compounds of Formula I, Ia, Ib, Ic, II or lib.

[0517]

[0518] Because this interconversion occurs under mild conditions and the position of thermodynamic equilibrium can vary between different members of the compounds of Formula I, Ia, Ib, Ic, II or lib, the compounds of Formula I, Ia, Ib, Ic, II or lib encompass both isomers. For the sake of brevity, all intermediates and pyranomeric isomeric forms of the compounds of Formula I, Ia, Ib, Ic, II or lib are shown.

[0519] General assembly method for bifunctional rapalogs

[0520] For the following regimens, rapamycin is of the formula RAP,

[0521]

[0522] Where R 16 OCH 3 ; R 26 =O; R 28 is -OH; R 32 =O; and R 40is -OH. "Rapalog" refers to an analog or derivative of rapamycin. For example, with respect to the following schemes, a rapamycin analog may be present at any position (such as R 16 , R 26 , R 28 , R 32 or R 40 ) is a rapamycin substituted at ). Active site inhibitors (AS inhibitors) are active site mTOR inhibitors. In certain embodiments, the AS inhibitor is described by B in Formula I, Ia, Ib, Ic, II or IIb.

[0523] Series 1 Bifunctional Rapaxoids

[0524] The general structure of the series 1 bifunctional rapalogs is shown in Scheme 1 below. For these types of bifunctional rapalogs, the linker may include variations where q = 0 to 30, such as q = 1 to 7, and r = 1 to 6. The linker amine may include substituents such as R = H and C1-C6 alkyl groups. The carbamate moiety (where Z 1 =O or S) can be in R 40 or R 28 The mTOR active site inhibitor may be linked to the linker via a primary or secondary amine, and may include the variations found in Table 2 of the Examples section.

[0525] Scheme 1. Series 1 bifunctional rapamycin analogs.

[0526]

[0527] Series 2 Bifunctional Rapa Analogs

[0528] The general structure of a series 2 bifunctional rapalog is shown in Scheme 2 below. For these types of bifunctional rapalogs, the linker may include variations where q = 0 to 30, such as q = 1 to 7. The linker amine may include substituents such as R = H and C1-C6 alkyl. The pre-linker amine may include substituents such as R 2 =H, C1-C6 alkyl and cycloalkyl containing 4 to 8 ring members. Carbamate moiety (wherein Z 1 =O or S) can be in R 40 or R 28 The mTOR active site inhibitor may be linked to the linker via a primary or secondary amine and may include the variations found in Table 2 of the Examples section.

[0529] Scheme 2. Series 2 bifunctional rapamycin analogs.

[0530]

[0531] Series 3 Bifunctional Rapa Analogs

[0532] The general structure of a series 3 bifunctional rapalog is shown in Scheme 3 below. For these types of bifunctional rapalogs, the linker may include variations where q = 0 to 30, such as q = 1 to 7. The linker amine may include substituents such as R = H and C1-C6 alkyl. The rear linker amine may include substituents such as R 2 =H, C1-C6 alkyl and cycloalkyl containing 4 to 8 ring members. Carbamate moiety (wherein Z 1 =O or S) can be in R 40 or R 28 The mTOR active site inhibitor may be linked to the linker via a primary or secondary amine and may include the variations found in Table 2 of the Examples section.

[0533] Scheme 3. Series 3 Bifunctional Rapaxoids

[0534]

[0535] Series 4 Bifunctional Rapa Analogs

[0536] The general structure of a series 4 bifunctional rapalog is shown in Scheme 4 below. For these types of bifunctional rapalogs, the linker may include variations where q = 0 to 30, such as q = 1 to 7. The linker amine may include substituents such as R = H and C1-C6 alkyl. The front linker amine and the rear linker amine may each include substituents such as R 2 =H, C1-C6 alkyl and cycloalkyl containing 4 to 8 ring members. Carbamate moiety (wherein Z 1 =O or S) can be in R 40 or R 28 The mTOR active site inhibitor may be linked to the linker via a primary or secondary amine and may include the variations found in Table 2 of the Examples section.

[0537] Scheme 4. Series 4 Bifunctional Rapaxone Analogs

[0538]

[0539] Series 5 Bifunctional Rapa Analogues

[0540] The general structure of a series 5 bifunctional rapalog is shown below in Scheme 5. For these types of bifunctional rapalogs, the front linker amine may contain a substituent such as R 2 =H, C1-C6 alkyl and cycloalkyl containing 4 to 8 ring members. Carbamate moiety (wherein Z 1 =O or S) can be in R 40 or R 28 The mTOR active site inhibitor may be linked to the linker via a primary or secondary amine and may include the variations found in Table 2 of the Examples section.

[0541] Scheme 5. Series 5 Bifunctional Rapaxone Analogs

[0542]

[0543] Series 6 Bifunctional Rapa Analogs

[0544] The general structure of a series 6 bifunctional rapalog is shown in Scheme 6 below. For these types of bifunctional rapalogs, the linker may include variations where q = 0 to 30, such as q = 1 to 7. The linker amine may include substituents such as R = H and C1-C6 alkyl. The rear linker amine may include substituents such as R 2 =H, C1-C6 alkyl and cycloalkyl containing 4 to 8 ring members. Carbamate moiety (wherein Z 1 =O or S) can be in R 40 or R 28 The mTOR active site inhibitor may be linked to the linker via a primary or secondary amine and may include the variations found in Table 2 of the Examples section.

[0545] Scheme 6. Series 6 Bifunctional Rapa Analogs

[0546]

[0547] Series 7 Bifunctional Rapa Analogs

[0548] The general structure of a series 7 bifunctional rapalog is shown in Scheme 7 below. For these types of bifunctional rapalogs, the linker may include variations where q = 0 to 30, such as q = 1 to 7. The linker amine may include substituents such as R = H and C1-C6 alkyl. The front linker amine and the rear linker amine may each include substituents such as R 2 =H, C1-C6 alkyl and cycloalkyl containing 4 to 8 ring members. Carbamate moiety (wherein Z 1=O or S) can be in R 40 or R 28 The mTOR active site inhibitor may be linked to the linker via a primary or secondary amine and may include the variations found in Table 2 of the Examples section.

[0549] Scheme 7. Series 7 Bifunctional Rapaxone Analogs

[0550]

[0551] Series 8 Bifunctional Rapa Analogs

[0552] The structure of a series 8 bifunctional rapalog is shown below in Scheme 8. For these types of bifunctional rapalogs, the linker may include variations where q = 0 to 30, such as q = 1 to 7. The linker amine may include substituents such as R = H and C1-C6 alkyl. The rear linker amine may include substituents such as R 2 =H, C1-C6 alkyl and cycloalkyl containing 4 to 8 ring members. Carbamate moiety (wherein Z 1 =O or S) can be in R 40 or R 28 The mTOR active site inhibitor may be linked to the linker via a primary or secondary amine and may include the variations found in Table 2 of the Examples section.

[0553] Scheme 8. Series 8 Bifunctional Rapaxone Analogs

[0554]

[0555] Pharmaceutical composition

[0556] Another aspect provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the present invention or a pharmaceutically acceptable salt or tautomer thereof.

[0557] In embodiments of pharmaceutical compositions, the compounds of the present invention or pharmaceutically acceptable salts or tautomers thereof may be included in a therapeutically effective amount.

[0558] Administration of the disclosed compounds or compositions can be achieved via any mode of administration of the therapeutic agent. These modes can include systemic or local administration, such as oral, nasal, parenteral, transdermal, subcutaneous, vaginal, buccal, rectal, topical, intrathecal or intracranial modes of administration.

[0559] In certain embodiments, administration may include oral administration, administration as a suppository, topical contact, intravenous, parenteral, intraperitoneal, intramuscular, intralesional, intrathecal, intracranial, intranasal or subcutaneous administration, or implantation of a slow release device (e.g., a mini-osmotic pump) into an individual. Administration may be by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal or transdermal). Parenteral administration includes, for example, intravenous, intramuscular, intraarterial, intradermal, subcutaneous, intraperitoneal, intraventricular and intracranial. Other modes of delivery include, but are not limited to, the use of liposome formulations, intravenous infusions, transdermal patches, etc. The compositions of the present invention may be delivered transdermally, by topical routes, formulated into applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jelly, pigments, powders and aerosols. Oral formulations include tablets, pills, powders, dragees, capsules, liquids, lozenges, cachets, gels, syrups, slurries, suspensions, etc. suitable for patient ingestion. Solid form formulations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. Liquid form formulations include solutions, suspensions, and emulsions, for example, water or water / propylene glycol solutions. The compositions of the present invention may additionally include components that provide sustained release and / or comfort. Such components include high molecular weight anionic simulated mucus polymers, gelatin polysaccharides, and subdivided drug carrier substrates. These components are discussed in more detail in U.S. Patents Nos. 4,911,920, 5,403,841, 5,212,162, and 4,861,760. For all purposes, the entire contents of these patents are incorporated herein by reference. The compositions of the present invention may also be delivered in microspheres for slow release in vivo. For example, the microspheres can be administered via intradermal injection of drug-containing microspheres that are slowly released subcutaneously (see Rao, J. Biomater Set Polym. ed. 7: 623-645, 1995); as biodegradable and injectable gel formulations (see, e.g., Gao Pharm. Res. 12: 857-863, 1995); or as microspheres for oral administration (see, e.g., Eyles, J. Pharm. Pharmacol. 49: 669-674, 1997). In another embodiment, formulations of the compositions of the invention can be delivered by using liposomes that fuse with cell membranes, or by endocytosis, i.e., by employing receptor ligands attached to the liposomes that bind to surface membrane protein receptors of the cells leading to endocytosis. By using liposomes, particularly where receptor ligands specific for target cells are carried on the surface of the liposomes or are otherwise preferentially directed to specific organs, one can focus delivery of the compositions of the invention to target cells in vivo.(See, e.g., Al-Muhammed, J. Microencapsul. 13:293-306, 1996; Chonn, Curr. Opin. Biotechnol. 6:698-708, 1995; Ostro, Am. J. Hosp. Pharm. 46:1576-1587, 1989.) The compositions of the present invention may also be delivered as nanoparticles.

[0560] Depending on the intended mode of administration, the disclosed compounds or pharmaceutical compositions may be in solid, semisolid or liquid dosage forms, such as, for example, injectables, tablets, suppositories, pills, time-release capsules, elixirs, tinctures, emulsions, syrups, powders, liquids, suspensions or the like, sometimes in unit doses and consistent with conventional pharmaceutical practices. Likewise, they may also be administered in intravenous (both pills and infusions), intraperitoneal, intrathecal, subcutaneous or intramuscular forms and all forms of use well known to those skilled in the art of medicine.

[0561] Illustrative pharmaceutical compositions are tablets and gelatin capsules comprising a compound of the invention and a pharmaceutically acceptable carrier, such as a) a diluent, for example, purified water, triglycerides (such as hydrogenated or partially hydrogenated vegetable oils or mixtures thereof), corn oil, olive oil, sunflower oil, safflower oil, fish oil (such as EPA or DHA) or esters or triglycerides or mixtures thereof, omega-3 fatty acids or derivatives thereof, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, sodium, saccharin, glucose and / or glycine; b) a lubricant, for example, silica, talc, stearic acid, its magnesium or calcium salts, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and / or polyethylene glycol; also used for tablets; c) if necessary, binders, for example, magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, magnesium carbonate, natural sugars (such as glucose or β-lactose), corn sweeteners, natural and synthetic gums (such as acacia, tragacanth or sodium alginate), waxes and / or polyvinylpyrrolidone; d) disintegrants, for example, starch, agar, methylcellulose, bentonite, xanthan gum, alginic acid or its sodium salt, or effervescent mixtures; e) adsorbents, colorants, flavorings and sweeteners; f) emulsifiers or dispersants, such as Tween 80, Labrasol, HPMC, DOSS, caproyl 909, labrafac, labrafil, peceol, transcutol, capmul MCM, capmul PG-12, captex 355, gelucire, vitamin E TGPS or other acceptable emulsifiers; and / or g) agents that enhance the absorption of the compound, such as cyclodextrin, hydroxypropyl-cyclodextrin, PEG400, PEG200.

[0562] Liquid (especially injectable) compositions can be prepared, for example, by dissolution, dispersion, etc. For example, the disclosed compounds are dissolved in a pharmaceutically acceptable solvent (such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, etc.) or mixed with to form an injectable isotonic solution or suspension. Proteins (such as albumin, chylomicrons or serum proteins) can be used to dissolve the disclosed compounds.

[0563] The disclosed compounds may also be formulated as suppositories prepared from fatty emulsions or suspensions using a polyalkylene glycol such as propylene glycol as a carrier.

[0564] The disclosed compounds can also be administered in the form of liposome delivery systems such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from various phospholipids including cholesterol, stearylamine, or phosphatidylcholine. In some embodiments, the membrane of the lipid component is hydrated with an aqueous solution of the drug to form a lipid layer encapsulating the drug, as described, for example, in U.S. Pat. No. 5,262,564, the contents of which are incorporated herein by reference.

[0565] The disclosed compounds can also be delivered by using monoclonal antibodies as individual carriers, and the disclosed compounds are coupled to such carriers. The disclosed compounds can also be coupled with water-soluble polymers as targetable drug carriers. Such polymers may include polyvinyl pyrrolidone, pyran copolymers, polyhydroxypropyl methacrylamide-phenol, polyhydroxyethyl asparagine phenol, or polyethylene oxide polylysine substituted with palmitoyl residues. In addition, the disclosed compounds can be coupled with a class of biodegradable polymers (e.g., crosslinking or amphiphilic block copolymers of polylactic acid, polycaprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates, and hydrogels) that can be used to achieve controlled release of drugs. In one embodiment, the disclosed compounds are non-covalently bound to a polymer (e.g., a polycarboxylic acid polymer or a polyacrylate).

[0566] Parenteral injectable administration is generally for subcutaneous, intramuscular or intravenous injection and infusion. Injectables can be prepared in conventional forms as liquid solutions or suspensions or solid forms suitable for dissolution in liquid prior to injection.

[0567] Another aspect of the present invention relates to a pharmaceutical composition comprising a compound of the present invention, or a pharmaceutically acceptable salt or tautomer thereof, and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may further include an excipient, a diluent or a surfactant.

[0568] The compositions can each be prepared according to conventional mixing, granulating or coating methods, and the pharmaceutical compositions of the present invention can contain about 0.1% to about 99%, about 5% to about 90%, or about 1% to about 20% of the disclosed compound by weight or volume.

[0569] The compounds described herein can be used in combination with other active agents known to be useful for treating cancer, autoimmune diseases, inflammatory diseases, metabolic diseases, neurodegenerative diseases, fungal infections or transplant rejection, or with adjuvants that may not be effective alone but can promote the efficacy of the active agents. The compounds described herein can be used in combination with other active agents known to be longevity agents or anti-aging agents.

[0570] In embodiments of the pharmaceutical composition, the pharmaceutical composition may include a second agent (e.g., a therapeutic agent). In embodiments of the pharmaceutical composition, the pharmaceutical composition may include a therapeutically effective amount of a second agent (e.g., a therapeutic agent). In certain embodiments, the second agent is an anticancer agent. In certain embodiments, the second agent is an immunotherapeutic agent. In certain embodiments, the second agent is an immuno-oncology agent. In certain embodiments, the second agent is an anti-autoimmune disease agent. In embodiments, the second agent is an anti-inflammatory disease agent. In certain embodiments, the second agent is an anti-neurodegenerative disease agent. In certain embodiments, the second agent is an anti-metabolic disease agent. In certain embodiments, the second agent is an anti-cardiovascular disease agent. In certain embodiments, the second agent is an anti-aging agent. In certain embodiments, the second agent is a longevity agent. In certain embodiments, the second agent is an agent for treating or preventing transplant rejection. In certain embodiments, the second agent is an agent for treating or preventing fungal infection. In certain embodiments, the second agent is an immune system inhibitor. In certain embodiments, the second agent is an mTOR regulator. In certain embodiments, the second agent is an mTOR inhibitor. In certain embodiments, the second agent is an active site mTOR inhibitor. In certain embodiments, the second agent is rapamycin. In certain embodiments, the second agent is a rapamycin analog. In certain embodiments, the second agent is an mTOR pathway inhibitor. In certain embodiments, the second agent is a CDK4 / 6 inhibitor; an anti-PD1 / PD-L1, PI3K inhibitor; or a Ras inhibitor.

[0571] "Anticancer" or "anticancer drug" is used according to its ordinary meaning and refers to a composition (e.g., compound, drug, antagonist, inhibitor, modulator) that has anti-tumor properties or the ability to inhibit cell growth or proliferation. In some embodiments, the anticancer agent is a chemotherapeutic agent. In some embodiments, the anticancer agent is an agent approved by the FDA or similar regulatory agencies in countries other than the USA for the treatment of cancer. Examples of anticancer agents include, but are not limited to, rapamycin, rapamycin analogs, bevacizumab, PP242, ΓN 128, MLN0128, anti-androgen (e.g., Casodex, Flutamide, MDV3100 or ARN-509), MEK (e.g., MEK1, MEK2 or MEK1 and MEK2) inhibitors (e.g., XL518, CI-1040, PD035901, selumetinib / AZD6244, GSK1120212 / trametinib, GDC-0973, ARRY-162, ARRY-300, AZD8330, PD0325901, U0126, PD98059, TAK-733, PD318088, AS703026, BAY 869766), alkylating agents (e.g., cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan, mechlorethamine, uramustine, thiotepa, nitrosoureas, nitrogen mustards (e.g., mechlorethamine, cyclophosphamide, chlorambucil, melphalan), ethyleneimine and methylmelamines (e.g., hexamethylmelamine, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomustine, semustine, streptozocin), reptozocin), triazenes (decarbazine), antimetabolites (e.g., 5-azathioprine, leucovorin, capecitabine, fludarabine, gemcitabine, pemetrexed, raltitrexed, folic acid analogs (e.g., methotrexate), pyrimidine analogs (e.g., fluorouracil, floxuridine, cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin), etc.),Plant alkaloids (e.g., vincristine, vinblastine, vinorelbine, vindesine, podophyllotoxin, paclitaxel, docetaxel, etc.), topoisomerase inhibitors (e.g., irinotecan, topotecan, amsacrine, etoposide (VP 16), etoposide phosphate, teniposide, etc.), antitumor antibiotics (e.g., doxorubicin, adriamicin, daunorubicin, epirubicin, actinomycin, bleomycin, mitomycin, mitoxantrone, plicamycin, etc.), platinum-based compounds (e.g., cisplatin, oxaloplatin, carboplatin )), anthracenediones (e.g., mitoxantrone), substituted ureas (e.g., hydroxyurea), methylhydrazine derivatives (e.g., procarbazine), adrenocortical hormone inhibitors (e.g., mitotane, aminoglutethimide), epipodophyllotoxins (e.g., etoposide), antibiotics (e.g., daunomycin, doxorubicin, bleomycin), enzymes (e.g., L-asparaginase), mitogen-activated protein kinase signaling inhibitors (e.g., U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin or LY294002), mTOR inhibitors, antibodies (e.g., rituxan), 5-aza-2′-deoxycytidine, doxorubicin, vincristine, etoposide, gemcitabine, imatinib (Gleevec.RTM.), geldanamycin, 17-N-allylamino-17-demethoxygeldanamycin (17-AAG), bortezomib, trastuzumab, anastrozole; angiogenesis inhibitors; antiandrogens,antiestrogens; antisense oligonucleotides; apoptosis gene modulators; apoptosis modulators; arginine deaminase; BCR / ABL antagonists; beta-lactam derivatives; bFGF inhibitors; bicalutamide; camptothecin derivatives; casein kinase inhibitors (ICOS); clomifene analogs; cytarabine dacliximab; dexamethasone; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; non finasteride; fludarabine; fluorodaunorubicin hydrochloride; texaphyrin; gallium nitrate; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; immunostimulatory peptides; insulin-like growth factor-1 receptor inhibitors; interferon agonists; interferons; interleukins; letrozole; leukemia inhibitory factor; leukocyte interferon alpha; leuprolide + estrogen + progesterone; leuprorelin; matrixlysin inhibitors; matrix metalloproteinase inhibitors; MIF inhibitors; mifepristone tone; mismatched double-stranded RNA; monoclonal antibody; mycobacterial cell wall extract; nitric oxide modulators; oxaliplatin; panomifene; pentrozole; phosphatase inhibitors; plasminogen activator inhibitors; platinum complexes; platinum compounds; prednisone; proteasome inhibitors; protein A-based immunomodulators; protein kinase C inhibitors; protein tyrosine phosphatase inhibitors; purine nucleotide phosphatase inhibitors; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitors; ribozymes; signal transduction inhibitors; signal transduction modulators; single-chain antigen binding proteins; stem cell inhibitors; stem cell division inhibitors antagonists; stromelysin inhibitors; synthetic mucopolysaccharides; tamoxifen methyl iodide; telomerase inhibitors; thyroid stimulating hormone; translation inhibitors; tyrosine kinase inhibitors; urokinase receptor antagonists; steroids (e.g., dexamethasone), finasteride, aromatase inhibitors, gonadotropin-releasing hormone agonists (GnRH) (such as goserelin or leuprolide), adrenocortical steroids (e.g., prednisolone), progestins (e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate), estrogens (e.g., diethylstilbestrol, ethinyl estradiol), antiestrogens (e.g., tamoxifen), androgens (e.g., testosterone propionate,Fluorine methyl testosterone), anti-androgens (e.g., flutamide), immunostimulants (e.g., Calmette-Guerin bacillus (BCG), levamisole, interleukin-2, α-interferon, etc.), monoclonal antibodies (e.g., anti-CD20, anti-HER2, anti-CD52, anti-HLA-DR and anti-VEGF monoclonal antibodies), immunotoxins (e.g., anti-CD33 monoclonal antibody-calicheamicin conjugate, anti-CD22 monoclonal antibody-Pseudomonas exotoxin conjugate, etc.), radioimmunotherapy (e.g., conjugated to, U1 ln, 90 Y or 131 I anti-CD20 monoclonal antibody, etc.), triptolide, homoharringtonine, dactinomycin, doxorubicin, epirubicin, topotecan, itraconazole, vindesine, cerivastatin, vincristine, deoxyadenosine, sertraline, pitavastatin, irinotecan, clofazimine, 5-nonyloxytryptamine, vemurafenib, dabrafenib, erlotinib, gefitinib, EGFR inhibitors, epidermal growth factor receptor (EGFR)-targeted therapy or treatment (e.g., gefitinib, TM ), erlotinib (Tarceva TM ), cetuximab (Erbitux TM ), lapatinib (1apatinib) (TykerbT M ), panitumumab (Vectibix TM ), vandetanib (Caprelsa TM)、afatinib / BIBW2992、CI-1033 / canertinib、neratinib / HKI-272、CP-724714、TAK-285、AST-1306、ARRY334543、ARRY-380、AG-1478、dacomitinib / PF299804、OSI-420 / desmethyl erlotinib、 AZD8931, AEE788, pelitinib / EKB-569, CUDC-101, WZ8040, WZ4002, WZ3146, AG-490, XL647, PD153035, BMS-599626), sorafenib, imatinib, sunitinib, dasatinib, pyrrolobenzodiazepines (e.g., tomaymycin), carboplatin, CC-1065 and CC-1065 analogs (including amino-CBI), nitrogen mustards (such as chlorambucil and melphalan), dolastatin and dolastatin analogs (including auristatin: for example, monomethyl auristatin E), anthracyclines (such as doxorubicin, daunomycin, etc.), duocarmycin and duocarmycin analogs, enediynes (such as neocarzinostatin and calicheamicin), leptostomycin, and styraxone. omycin derivatives, maytansinoids and maytansinoid analogs (e.g., mertansine), methotrexate, mitomycin C, taxoids, vinca alkaloids (such as vinblastine and vincristine), epothilones (e.g., epothilone B), camptothecins and their clinical analogs topotecan and irinotecan, ΓNK128, PP242, PP121, MLN0128, AZD8055, AZD2014, VP-BEZ235, BGT226, SF1 126, Torin 1, Torin 2, WYE687, WYE 687 salt (e.g., hydrochloride), PF04691502, PI-103, CC-223, OSI-027, XL388, KU-0063794, GDC-0349, PKI-587, rapamycin, deforolimus (AP23573, MK-8669, ridaforolimus), temsirolimus (CCI-779), ABT478, everolimus (RAD001), and the like.

[0572] mTOR and treatment methods

[0573] The term "mTOR" refers to the protein "mechanistic target of rapamycin (serine / threonine kinase)" or "mammalian target of rapamycin". The term "mTOR" may refer to the nucleotide sequence or protein sequence of human mTOR (e.g., Entrez2475, Uniprot P42345, RefSeq NM_004958, or RefSeq NP_004949) (SEQ ID NO: 1). The term "mTOR" may include both the wild-type form of the nucleotide sequence or protein and any mutations thereof. In some embodiments, "mTOR" is wild-type mTOR. In some embodiments, "mTOR" is one or more mutant forms. The term "mTOR" XYZ may refer to the nucleotide sequence or protein of a mutant mTOR, wherein the Y-numbered amino acid of the mTOR that normally has the X amino acid in the wild type instead has the Z amino acid in the mutant. In embodiments, the mTOR is human mTOR. In embodiments, the mTOR has a nucleotide sequence corresponding to reference number GL206725550 (SEQ ID NO: 2). In embodiments, the mTOR has a nucleotide sequence corresponding to RefSeq In embodiments, the mTOR has a nucleotide sequence of NM_004958.3 (SEQ ID NO: 2). In embodiments, the mTOR has a protein sequence corresponding to reference number GL4826730 (SEQ ID NO: 1). In embodiments, the mTOR has a protein sequence corresponding to RefSeq NP_004949.1 (SEQ ID NO: 1). In embodiments, the mTOR has the following amino acid sequence:

[0574]

[0575] In embodiments, the mTOR is a mutant mTOR. In embodiments, the mutant mTOR is associated with a disease that is not associated with wild-type mTOR. In embodiments, the mTOR may comprise at least one amino acid mutation compared to the above sequence (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 mutations, or any range derivable therein).

[0576] The term "mTORC1" refers to a protein complex comprising mTOR and Raptor (mTOR regulatory-associated protein). mTORC1 may also comprise MLST8 (mammalian lethal factor containing SEC 13 protein 8), PRAS40 and / or DEPTOR. mTORC1 may serve as a nutrient / energy / redox sensor and regulator of protein synthesis. The term "mTORC1 pathway" or "mTORC1 signal transduction pathway" may refer to a cellular pathway comprising mTORC1. The mTORC1 pathway includes pathway components upstream and downstream from mTORC1. The mTORC1 pathway is a signal transduction pathway regulated by regulating mTORC1 activity. In an embodiment, the mTORC1 pathway is a signal transduction pathway regulated by regulating mTORC1 activity but not by regulating mTORC2 activity. In an embodiment, the mTORC1 pathway is a signal transduction pathway that is regulated to a greater extent by regulating mTORC1 activity than by regulating mTORC2 activity.

[0577] The term "mTORC2" refers to a protein complex comprising mTOR and RICTOR (rapamycin-insensitive partner of mTOR). mTORC2 may also include GβL, mSIN1 (mammalian stress-activated protein kinase interacting protein 1), Protor1 / 2, DEPTOR, TTI1 and / or TEL2. mTORC2 can regulate cell metabolism and cytoskeleton. The term "mTORC2 pathway" or "mTORC2 signal transduction pathway" may refer to a cell pathway comprising mTORC2. The mTORC2 pathway includes pathway components upstream and downstream from mTORC2. The mTORC2 pathway is a signal transduction pathway regulated by regulating mTORC2 activity. In an embodiment, the mTORC2 pathway is a signal transduction pathway regulated by regulating mTORC2 activity but not by regulating mTORC1 activity. In an embodiment, the mTORC2 pathway is a signal transduction pathway that is regulated to a greater extent by regulating mTORC2 activity than by regulating mTORC1 activity.

[0578] The term "rapamycin" or "sirolimus" refers to a macrolide produced by the bacterium Streptomyces hygroscopicus. Rapamycin prevents activation of T cells and B cells. Rapamycin has the IUPAC name (3S, 6R, 7E, 9R, 10R, 12R, 14S, 15E, 17E, 19E, 21S, 23S, 26R, 27R, 34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexahydro-9,27-dihydroxy-3-[( 1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]-oxazacyclotriacontane-1,5,11,28,29(4H,6H,31H)-pentanone. Rapamycin has CAS number 53123-88-9. Rapamycin can be synthesized (e.g., by chemical synthesis) or produced by using a preparation method that does not include the use of Streptomyces hygroscopicus.

[0579] "Analog" is used according to its ordinary meaning in chemistry and biology and refers to a chemical compound that is structurally similar to another compound (i.e., the so-called "reference" compound) but differs in composition, for example, in the replacement of one atom by an atom of a different element, or in the presence of a particular functional group, or replacement of one functional group by another functional group, or in the absolute stereochemistry of one or more chiral centers of the reference compound (including isomers thereof).

[0580] The term "rapamycin analog" or "rapalog" refers to an analog or derivative (eg, a prodrug) of rapamycin.

[0581] The terms "active site mTOR inhibitor" and "ATP mimetic" refer to compounds that inhibit the activity of mTOR (e.g., kinase activity) and bind to the active site of mTOR (e.g., ATP binding site, overlaps with the ATP binding site, blocks ATP from accessing the ATP binding site of mTOR). Examples of active site mTOR inhibitors include, but are not limited to, FNK128, PP242, PP121, MLN0128, AZD8055, AZD2014, NVP-BEZ235, BGT226, SF1126, Torin 1, Torin 2, WYE687, WYE 687 salt (e.g., hydrochloride), PF04691502, PI-103, CC-223, OSI-027, XL388, KU-0063794, GDC-0349, and PKI-587. In an embodiment, the active site mTOR inhibitor is asTORi. In some embodiments, an "active site inhibitor" may refer to an "active site mTOR inhibitor."

[0582] The term "FKBP" refers to the protein peptidyl-prolyl cis-trans isomerase. For non-limiting examples of FKBP, see Cell Mol Life Sci. 2013 Sep; 70(18): 3243-75. In embodiments, "FKBP" may refer to "FKBP-12" or "FKBP 12" or "FKBP 1A". In embodiments, "FKBP" may refer to a human protein. Included in the term "FKBP" are wild-type and mutant forms of the protein. In embodiments, "FKBP" may refer to a wild-type human protein. In embodiments, "FKBP" may refer to a wild-type human nucleic acid. In embodiments, the FKBP is a mutant FKBP. In embodiments, the mutant FKBP is associated with a disease that is not associated with wild-type FKBP. In embodiments, the FKBP comprises at least one amino acid mutation compared to wild-type FKBP (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 mutations, or any range derivable therein).

[0583] The term "FKBP-12" or "FKBP 12" or "FKBP1A" may refer to the protein "peptidyl-prolyl cis-trans isomerase FKBP 1A". In embodiments, "FKBP-12" or "FKBP 12" or "FKBP 1A" may refer to the human protein. Included in the term "FKBP-12" or "FKBP 12" or "FKBP 1A" are wild-type and mutant forms of the protein. In embodiments, "FKBP-12" or "FKBP 12" or "FKBP 1A" may refer to a protein related to Entrez Gene 2280, OMIM 186945, UniProtP62942, and / or RefSeq (protein) NP_000792 (SEQ ID NO: 3). In embodiments, the reference numbers directly above may refer to proteins and related nucleic acids known as of the filing date of this application. In embodiments, "FKBP-12" or "FKBP 12" or "FKBP1A" may refer to a wild-type human protein. In embodiments, "FKBP-12" or "FKBP 12" or "FKBP1A" may refer to a wild-type human nucleic acid. In embodiments, the FKBP-12 is a mutant FKBP-12. In embodiments, the mutant FKBP-12 is associated with a disease that is not associated with wild-type FKBP-12. In embodiments, the FKBP-12 may comprise at least one amino acid mutation (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 mutations, or any range derivable therein) compared to wild-type FKBP-12. In embodiments, the FKBP-12 has a protein sequence corresponding to Reference Number GI: 206725550. In embodiments, the FKBP-12 has a protein sequence corresponding to RefSeq NP_000792.1 (SEQ ID NO: 3).

[0584] The term "4E-BP1" or "4EBP1" or "EIF4EBP1" refers to the protein "eukaryotic translation initiation factor 4E-binding protein 1". In embodiments, "4E-BP1" or "4EBP1" or "EIF4EBP 1" may refer to the human protein. Included in the term "4E-BP 1" or "4EBP 1" or "EIF4EBP1" are wild-type and mutant forms of the protein. In embodiments, "4E-BP1" or "4EBP1" or "EIF4EBP1" may refer to a protein related to Entrez Gene 1978, OMIM 602223, UniProt Q13541, and / or RefSeq (protein) NP_004086 (SEQ ID NO: 4). In embodiments, the reference numbers directly above may refer to proteins and related nucleic acids known as of the filing date of this application. In embodiments, "4E-BP 1" or "4EBP1" or "EIF4EBP1" may refer to a wild-type human protein. In embodiments, "4E-BP1" or "4EBP1" or "EIF4EBP1" may refer to a wild-type human nucleic acid. In embodiments, the 4EBP1 is a mutant 4EBP1. In embodiments, the mutant 4EBP1 is associated with a disease that is not associated with wild-type 4EBP1. In embodiments, the 4EBP1 may comprise at least one amino acid mutation (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 mutations compared to wild-type 4EBP1, or any range derivable therein). In embodiments, the 4EBP1 has a protein sequence corresponding to reference number GL4758258. In embodiments, the 4EBP1 has a protein sequence corresponding to RefSeq NP_004086.1 (SEQ ID NO: 4).

[0585] The term "Akt" refers to a serine / threonine-specific protein kinase involved in cellular processes such as glucose metabolism, apoptosis, proliferation, and other functions, also known as "protein kinase B" (PKB) or "Akt1". In embodiments, "Akt" or "AM" or "PKB" may refer to a human protein. Included in the term "Akt" or "Akt1" or "PKB" are wild-type and mutant forms of the protein. In embodiments, "Akt" or "Akt1" or "PKB" may refer to a protein related to Entrez Gene 207, OMIM164730, UniProt P31749, and / or RefSeq (protein) NP_005154 (SEQ ID NO: 5). In embodiments, the reference numbers immediately above may refer to proteins and related nucleic acids known as of the filing date of this application. In embodiments, "Akt" or "Akt1" or "PKB" may refer to a wild-type human protein. In embodiments, "Akt" or "Aktl" or "PKB" may refer to a wild-type human nucleic acid. In embodiments, the Akt is a mutant Akt. In embodiments, the mutant Akt is associated with a disease that is not associated with wild-type Akt. In embodiments, the Akt may comprise at least one amino acid mutation compared to wild-type Akt (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 mutations, or any range derivable therein). In embodiments, the Akt has a protein sequence corresponding to reference number GI:62241011. In embodiments, the Akt has a protein sequence corresponding to RefSeqNP_005154.2 (SEQ ID NO:5).

[0586] The present invention provides a method of treating a disease or condition mediated by mTOR, comprising administering to a subject suffering from or susceptible to a disease or condition mediated by mTOR a therapeutically effective amount of one or more disclosed compositions or compounds. The present invention provides a method of preventing a disease or condition mediated by mTOR, comprising administering to a subject suffering from or susceptible to a disease or condition mediated by mTOR a therapeutically effective amount of one or more disclosed compositions or compounds. The present invention provides a method of reducing the risk of a disease or condition mediated by mTOR, comprising administering to a subject suffering from or susceptible to a disease or condition mediated by mTOR a therapeutically effective amount of one or more disclosed compositions or compounds.

[0587] In some embodiments, the disease is cancer or an immune-mediated disease. In some embodiments, the cancer is selected from brain and neurovascular tumors, head and neck cancer, breast cancer, lung cancer, mesothelioma, lymphoma, stomach cancer, kidney cancer, renal cancer, liver cancer, ovarian cancer, ovarian endometriosis, testicular cancer, gastrointestinal cancer, prostate cancer, glioblastoma, skin cancer, melanoma, neural cancer, spleen cancer, pancreatic cancer, blood proliferative disorders, lymphoma, leukemia, endometrial cancer, cervical cancer, vulvar cancer, prostate cancer, penis cancer, bone cancer, muscle cancer, soft tissue cancer, intestinal or rectal cancer, anal cancer, bladder cancer, bile duct cancer, eye cancer, gastrointestinal stromal tumors and neuro-endocrine tumors. In some embodiments, the disease is cirrhosis. In some embodiments, the immune-mediated disease is selected from resistance to transplantation of heart, kidney, liver, bone marrow, skin, cornea, lung, pancreas, small intestine, limbs, muscle, nerve, duodenum, small intestine or pancreatic islet cells; Graft-versus-host disease brought by bone marrow transplantation; Rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, allergic encephalomyelitis and glomerulonephritis. In certain embodiments, the disease is tuberous sclerosis complex (TSC). In certain embodiments, the disease is pancreatic neuroendocrine tumor (PNET), mantle cell lymphoma (MCL), colorectal cancer or intestinal cancer (CRC), uterine cancer, ovarian cancer, bladder cancer, genitourinary tract cancer or renal cell carcinoma (RCC).

[0588] The present invention provides a method for treating cancer, comprising administering to a subject a therapeutically effective amount of one or more disclosed compositions or compounds. In some embodiments, the cancer is selected from brain and neurovascular tumors, head and neck cancer, breast cancer, lung cancer, mesothelioma, lymphoma, gastric cancer, kidney cancer, renal cancer, liver cancer, ovarian cancer, ovarian endometriosis, testicular cancer, gastrointestinal cancer, prostate cancer, glioblastoma, skin cancer, melanoma, neural cancer, spleen cancer, pancreatic cancer, hematopoietic proliferative disorders, lymphoma, leukemia, endometrial cancer, cervical cancer, vulvar cancer, prostate cancer, penile cancer, bone cancer, muscle cancer, soft tissue cancer, intestinal or rectal cancer, anal cancer, bladder cancer, bile duct cancer, eye cancer, gastrointestinal stromal tumors and neuro-endocrine tumors. In some embodiments, the disease is cirrhosis. In certain embodiments, the disease is tuberous sclerosis complex (TSC). In certain embodiments, the disease is pancreatic neuroendocrine tumor (PNET), mantle cell lymphoma (MCL), colorectal or intestinal cancer (CRC), uterine cancer, ovarian cancer, bladder cancer, genitourinary tract cancer, or renal cell carcinoma (RCC).

[0589] In certain embodiments, cancers include human cancers and carcinomas, sarcomas, adenocarcinomas, lymphomas, leukemias, and the like, including solid and lymphoid carcinomas, renal cancer, breast cancer, lung cancer, bladder cancer, colon cancer, ovarian cancer, prostate cancer, pancreatic cancer, stomach cancer, brain cancer, head and neck cancer, skin cancer, uterine cancer, testicular cancer, gliomas, esophageal cancer, and liver cancer (including hepatocarcinoma), lymphomas (including B-acute lymphoblastic lymphoma, non-Hodgkin's lymphoma (e.g., Burkitt's lymphoma, small cell lymphoma, and large cell lymphoma), Hodgkin's lymphoma), leukemias (including AML, ALL, and CML), or multiple myeloma. In certain embodiments, the disease is multiple myeloma. In certain embodiments, the disease is breast cancer. In certain embodiments, the disease is triple negative breast cancer.

[0590] In certain embodiments, cancer includes cancers, neoplasms or malignancies found in mammals (e.g., humans), including leukemias, carcinomas and sarcomas. Exemplary cancers that can be treated with the compounds or methods provided herein include prostate cancer, thyroid cancer, endocrine system cancer, brain cancer, breast cancer, cervical cancer, colon cancer, head and neck cancer, liver cancer, kidney cancer, lung cancer, non-small cell lung cancer, melanoma, mesothelioma, ovarian cancer, sarcoma, gastric cancer, uterine cancer, medulloblastoma, colorectal cancer, pancreatic cancer. Other examples may include Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, essential thrombocythemia, essential macroglobulinemia, primary brain tumor, malignant pancreatic insulinoma, malignant carcinoid, bladder cancer, premalignant skin lesions, testicular cancer, lymphoma, thyroid cancer, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenocortical carcinoma, neoplasms of the endocrine or exocrine pancreas, medullary thyroid cancer / medullary thyroid carcinoma, melanoma, colorectal cancer, papillary thyroid cancer, hepatocellular carcinoma, or prostate cancer.

[0591] In certain embodiments, the disease is a leukemia. The term "leukemia" refers broadly to progressive, malignant diseases of blood-forming organs and is generally characterized by abnormal proliferation and development of white blood cells and their precursors in the blood and bone marrow. Leukemias are generally clinically classified based on: (1) the duration and characteristics of the disease, whether acute or chronic; (2) the type of cells involved; myeloid (myeloid), lymphoid (lymphogenic), or monocytic; and (3) an increase or absence of an increase in the number of abnormal cells in the blood leukemia or leukopenia (subleukemia). Exemplary leukemias that can be treated with the compounds or methods provided herein include, for example, acute non-lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, acute promyelocytic leukemia, adult T-cell leukemia, leukopenic leukemia, leukocytic leukemia, basophilic leukemia, blast cell leukemia, bovine leukemia, chronic myelogenous leukemia, leukemia cutis, embryonic leukemia, eosinophilic leukemia, Gross' leukemia, hairy cell leukemia, hemoblastic leukemia, histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, leukopenia, Leukemia, lymphoid leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphogenic leukemia, lymphoid leukemia, lymphosarcoma cell leukemia, mast cell leukemia, megakaryocytic leukemia, micromyeloblastic leukemia, monocytic leukemia, myeloblastic leukemia, myelocytic leukemia, myelogranulocytic leukemia, myelomonocytic leukemia, Naegeli leukemia, plasma cell leukemia, multiple myeloma, plasma cell leukemia, promyelocytic leukemia, Rieder cell leukemia, Schilling's leukemia, stem cell leukemia, subleukemic leukemia or undifferentiated cell leukemia.

[0592] In certain embodiments, the disease is a sarcoma. The term "sarcoma" generally refers to a tumor composed of a substance such as embryonic connective tissue and generally composed of tightly packed cells embedded in a fibrous or homogeneous substance. Sarcomas that can be treated with the compounds or methods provided herein include chondrosarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abemethy's sarcoma, liposarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastic sarcoma, botryoid sarcoma, chloroma sarcoma, choriocarcinoma, embryonal sarcoma, Wilms' tumor sarcoma, endometrial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial sarcoma, fibroblastic sarcoma, giant sarcoma, granulocytic sarcoma, Hodgkin's sarcoma, idiopathic multiple pigmented hemorrhagic sarcoma, immunoblastic sarcoma of B cells, lymphoma, immunoblastic sarcoma of T cells, Jensen's sarcoma, Kaposi's sarcoma, Kupffer cell sarcoma, angiosarcoma, white sarcoma, malignant mesenchymal sarcoma, parosteal sarcoma, reticular cell sarcoma, Rous sarcoma, serous cystic sarcoma, synovial sarcoma, or telangiectatic sarcoma.

[0593] In certain embodiments, the disease is melanoma. The term "melanoma" means a tumor produced by the melanocyte system of the skin and other organs. Melanomas that can be treated with the compounds or methods provided herein include, for example, acral-lentiginous melanoma, non-melanotic melanoma, benign juvenile melanoma, Cloudman's melanoma, S91 melanoma, Harding-Passey melanoma, juvenile melanoma, lentigo maligna melanoma, malignant melanoma, nodular melanoma, subungual melanoma, or superficial spreading melanoma.

[0594] In certain embodiments, the disease is cancer.The term "cancer" refers to a malignant new growth composed of epithelial cells that tends to infiltrate surrounding tissues and give rise to metastases.Exemplary cancers that can be treated with the compounds or methods provided herein include, for example, medullary thyroid carcinoma, familial medullary thyroid carcinoma, acinar carcinoma, acinar carcinoma, adenoid carcinoma, adenoid cystic carcinoma, adenocarcinoma, adrenal cortical carcinoma, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma (basal cell carcinoma / carcinoma basocellulare), basaloid carcinoma, basosquamous cell carcinoma, bronchoalveolar carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, brain-shaped carcinoma, cholangiocellular carcinoma, choriocarcinoma, colloid carcinoma, comedo carcinoma, uterine body carcinoma, cribriform carcinoma, armor carcinoma, skin carcinoma, cylindrical carcinoma, cylindrical cell carcinoma, ductal carcinoma, carcinoma durum, embryonal carcinoma, brain carcinoma, epidermoid carcinoma, epithelial adenoid carcinoma, exophytic carcinoma, exo-ulcerative carcinoma, fibrocarcinoma, gelatin sponge carcinoma, colloid carcinoma, giant cell carcinoma (giant cell carcinoma / carcinoma gigantocellulare), adenocarcinoma, granular cell carcinoma, hair-stromal carcinoma, hematogenous carcinoma, hepatocellular carcinoma, Hurthle cell carcinoma, clear carcinoma, renal cell carcinoma, immature embryonal carcinoma, carcinoma in situ, intraepidermal carcinoma, intraepithelial carcinoma, Krompecher's carcinoma, Kulchitzky cell carcinoma, large cell carcinoma, lenticular carcinoma (carcinoma lenticulare), lipomatous carcinoma, lymphoepithelial carcinoma, medullary carcinoma (carcinoma medullare / medullary carcinoma), melanoma, soft carcinoma, mucinous carcinoma (mucinous carcinoma / carcinoma muciparum), mucous cell carcinoma, mucoepidermoid carcinoma, carcinomamucosum / mucous carcinoma, myxoma, nasopharyngeal carcinoma, oat cell carcinoma, ossifying carcinoma, osteoid carcinoma, papillary carcinoma, periportal carcinoma, preinvasive carcinoma, prickle cell carcinoma, medullary carcinoma (pultaceous carcinoma), renal cell renal carcinoma, reserve cell carcinoma, sarcomatoid carcinoma, schneiderian carcinoma, scirrhous carcinoma, scrotal carcinoma, signet ring cell carcinoma, simple carcinoma, small cell carcinoma, potato carcinoma, spherical cell carcinoma, spindle cell carcinoma, cavernous carcinoma, squamous carcinoma, squamous cell carcinoma, rope-shaped carcinoma, carcinoma telangiectaticum / carcinoma telangiectodes, transitional cell carcinoma, carcinoma tuberosum / tuberous carcinoma, verrucous carcinoma, or villous carcinoma.

[0595] The present invention provides a method for treating an immune-mediated disease, comprising administering to a subject a therapeutically effective amount of one or more disclosed compositions or compounds. In some embodiments, the immune-mediated disease is selected from resistance to transplantation of heart, kidney, liver, bone marrow, skin, cornea, lung, pancreas, small intestine, limbs, muscle, nerve, duodenum, small intestine or pancreatic islet cells; graft-versus-host disease caused by bone marrow transplantation; rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, allergic encephalomyelitis and glomerulonephritis.

[0596] In certain embodiments, the disease is an autoimmune disease. As used herein, the term "autoimmune disease" refers to a disease or condition in which the subject's immune system has an abnormal immune response to a substance that normally does not cause an immune response in a healthy subject. Examples of autoimmune diseases that can be treated with the compounds, pharmaceutical compositions, or methods described herein include acute disseminated encephalomyelitis (ADEM), acute necrotizing hemorrhagic leukoencephalitis, Addison's disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti-GBM / anti-TBM nephritis, antiphospholipid syndrome (APS), autoimmune angioedema, autoimmune aplastic anemia, autoimmune autonomic dysfunction, autoimmune hepatitis, autoimmune hyperlipidemia, autoimmune immunodeficiency, autoimmune inner ear disease (AIED), autoimmune myocarditis, autoimmune ovarian inflammation, autoimmune pancreatitis, autoimmune retinopathy, autoimmune thrombocytopenic purpura (ATP), autoimmune thyroid disease, autoimmune urticaria, axonal or neuronal neuropathy, Balo's disease, Behcet's disease, bullous pemphigoid, cardiomyopathy, Castleman's disease, diarrheal disease, Chagas disease, chronic fatigue syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic recurrent multifocal osteomyelitis (CRMO), Churg-Strauss syndrome, cicatricial pemphigoid / benign mucosal neuropathy Pemphigoid, Crohn's disease, Cogans syndrome, cold agglutinin disease, congenital heart block, Coxsackie myocarditis, CREST disease, essential mixed cryoglobulinemia, demyelinating neuropathy, dermatitis herpetiformis, dermatomyositis, Devic's disease (neuromyelitis optica), discoid lupus, Dressier's syndrome, endometrial translocation, eosinophilic esophagitis, eosinophilic fasciitis, erythema nodosum, experimental allergic encephalomyelitis, Evans syndrome, fibromyalgia, fibrosing alveolitis, giant cell arteritis (temporal arteritis), giant cell myocarditis, glomerulonephritis, Goodpasture's syndrome, granulomatosis with polyangiitis (GPA) (formerly Wegener's granulomatosis), Graves' disease, Guillain-Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, hemolytic anemia, Henoch-Schonlein purpura, herpes gestationis, hypogammaglobulinemia, idiopathic thrombocytopenic purpura (ITP), IgA nephropathy, IgG4-related sclerosis, immunomodulatory lipoproteins,Included are myositis, interstitial cystitis, juvenile arthritis, juvenile diabetes mellitus (type 1 diabetes), juvenile myositis, Kawasaki syndrome, Lambert-Eaton syndrome, leukocytic vasculitis, lichen planus, lichen sclerosus, woody conjunctivitis, linear IgA disease (LAD), systemic lupus erythematosus (SLE), Lyme disease, chronic Meniere's disease, microscopic polyangiitis, mixed connective tissue disease (MCD), and leukocytic leukemia. CTD), Mooren's ulcer, Mucha-Habermann disease, multiple sclerosis, myasthenia gravis, myositis, narcolepsy, neuromyelitis optica (Devic's), neutropenia, ocular cicatricial pemphigoid, optic neuritis, relapsing rheumatic disease, PANDAS (pediatric autoimmune neuropsychiatric disorders associated with streptococci), paraneoplastic cerebellar degeneration, paroxysmal nocturnal hemoglobinuria (PNH), Parry Roberge's Romberg syndrome, Parsonnage-Tumer syndrome, pars plana (peripheral uveitis), pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia, POEMS syndrome, polyarteritis nodosa, autoimmune polyglandular syndromes type I, II, and III, polymyalgia rheumatica, polymyositis, post-myocardial infarction syndrome, postpericardiotomy syndrome, progesterone dermatitis, primary biliary cirrhosis, primary sclerosing cholangitis, psoriasis, psoriatic arthritis Arthritis, idiopathic pulmonary fibrosis, pyoderma gangrenosum, pure red cell aplasia, Raynaud's phenomenon, reactive arthritis, reflex sympathetic dystrophy, Reiter's syndrome, relapsing polychondritis, restless legs syndrome, retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis, sarcoidosis, Schmidt's syndrome, scleritis, scleroderma, Sjogren's syndrome, sperm and testicular autoimmunity, stiff man syndrome person syndrome), subacute bacterial endocarditis (SBE), Susac's syndrome, sympathetic ophthalmia, Takayasu's arteritis, temporal arteritis / giant cell arteritis, thrombocytopenic purpura (TTP), Tolosa-Hunt syndrome, transverse myelitis, type 1 diabetes mellitus, ulcerative colitis, undifferentiated connective tissue disease (UCTD), uveitis, vasculitis, cystic dermatosis, vitiligo, or Wegener's granulomatosis (ie, granulomatosis with polyangiitis (GPA)).

[0597] The present invention provides a method for treating an age-related condition, comprising administering to a subject a therapeutically effective amount of one or more disclosed compositions or compounds. In certain embodiments, the age-related condition is selected from sarcopenia, skin atrophy, muscle wasting, brain atrophy, atherosclerosis, arteriosclerosis, emphysema, osteoporosis, osteoarthritis, hypertension, erectile dysfunction, dementia, Huntington's disease, Alzheimer's disease, cataracts, age-related macular degeneration, prostate cancer, stroke, shortened life expectancy, impaired kidney function, and age-related hearing loss, age-related disability (e.g., frailty), cognitive decline, age-related dementia, memory impairment, tendon stiffness, cardiac dysfunction (such as cardiac hypertrophy and systolic and diastolic dysfunction), immunosenescence, cancer, obesity, and diabetes.

[0598] In certain embodiments, the disclosed compositions or compounds can be used for immunosenescence. Immunosenience may refer to a decline in immune function, resulting in, for example, an impaired immune response, especially to cancer, vaccines, infectious pathogens. It involves both the host's ability to respond to infection and the development of long-term immune memory (especially through vaccines). This immunodeficiency is ubiquitous and is found in both long-lived and short-lived species as a function of their age relative to life expectancy rather than chronological time. This is considered to be the main contributing factor to the increased incidence and mortality rates in the elderly. Immunosenience is not a random deterioration phenomenon, on the contrary, it seems to be a reverse repeating evolutionary pattern, and most parameters affected by immunosenescence seem to be under genetic control. Sometimes immunosenescence can also be envisioned as the result of unavoidable exposure to continuous challenges of various antigens (such as viruses and bacteria). Immunosenience is a multifactorial condition that leads to many pathologically significant health problems (for example, in the elderly population). Age-dependent biological changes (such as hematopoietic stem cell exhaustion, an increase in PD1+ lymphocytes, a decrease in the total number of phagocytes and NK cells, and a decrease in humoral immunity) contribute to the onset of immunosenescence. In one aspect, immunosenescence can be measured in an individual by measuring the telomere length of immune cells (see, e.g., U.S. Pat. No. 5,741,677). Immunosenescence can also be determined by documenting a lower than normal number of naive CD4 and / or CD8 T cells, a T cell pool, a number of T cells expressing PD1 (e.g., lower than the normal number of PD-1 negative T cells) or a response to a vaccine in an individual aged 65 years or older. In certain embodiments, selective modulation of mTOR in certain T-cell populations can improve vaccine efficacy in elderly populations and enhance the effectiveness of cancer immunotherapy. The present invention provides a method for treating immunosenescence comprising administering to a subject a therapeutically effective amount of one or more disclosed compositions or compounds.

[0599] In certain embodiments, the disease that can be treated with the compounds, pharmaceutical compositions, or methods described herein is organ or tissue transplant rejection (e.g., heart, lung, combined heart-lung, liver, kidney, pancreas, skin, or corneal transplant; graft-versus-host disease), restenosis, hamartoma syndromes (e.g., tuberous sclerosis or Cowden's disease), lymphangioleiomyomatosis, retinitis pigmentosa, encephalomyelitis, insulin-dependent diabetes mellitus, lupus, dermatomyositis, arthritis, rheumatic diseases, steroid-resistant acute lymphoblastic leukemia, fibrosis, scleroderma, pulmonary fibrosis, renal fibrosis, cystic fibrosis, pulmonary hypertension, multiple sclerosis, VHL syndrome, Carney syndrome, familial adenomatous polyposis, juvenile polyposis syndrome, Birt-Hogg-Duke syndrome, familial hypertrophic cardiomyopathy, Wolf-Parkinson-White syndrome, Parkinson's disease, Parkinson's disease, Huntington's disease, Alzheimer's disease, dementia caused by tau mutations, spinocerebellar ataxia type 3, motor neuron disease caused by SOD1 mutations, neuronal lipid fucose / Batten disease (pediatric neurodegeneration), wet macular degeneration, dry macular degeneration, muscle wasting (atrophy, cachexia), myopathy (e.g., Danon's disease), bacterial infection, viral infection, M. tuberculosis, group A streptococcus, HSVI, HIV infection, neurofibromatosis (e.g., neurofibromatosis type 1), or Peutz-Jeghers syndrome.

[0600] In certain embodiments, the disease is a neurodegenerative disease. As used herein, the term "neurodegenerative disease" refers to a disease or condition in which the function of the nervous system of an individual is impaired. Examples of neurodegenerative diseases that can be treated with the compounds, pharmaceutical compositions, or methods described herein include Alexander's disease, Alper's disease, Alzheimer's disease, amyotrophic lateral sclerosis, ataxia telangiectasia, Batten's disease (also known as Spielmeyer-Vogt-Sjogren-Batten disease), bovine spongiform encephalopathy (BSE), Canavan's disease, Cockayne syndrome, corticobasal degeneration, Creutzfeldt-Jakob disease, frontotemporal dementia, Gerstmann-Straussler-Scheinker syndrome, Huntington's disease, H1V-related dementia, Kennedy's disease, Krabbe's disease, s disease, kuru, dementia with Lewy bodies, Machado-Joseph disease (spinocerebellar ataxia type 3), multiple sclerosis, multiple system atrophy, narcolepsy, neuroborreliosis, Parkinson's disease, Pelizaeus-Merzbacher disease, Pick's disease, primary lateral sclerosis, prion disease, Refsum's disease, Sandhoff's disease, Schilder's disease, subacute mixed degeneration of the spinal cord secondary to pernicious anemia, schizophrenia, spinocerebellar ataxia (various types with varying features), spinal muscular atrophy, Steele-Richardson-Olszewski disease, or Tabes dorsalis.

[0601] In certain embodiments, the disease is a metabolic disease. As used herein, the term "metabolic disease" refers to a disease or condition in which the metabolism or metabolic system (e.g., the function of storing or utilizing energy) of an individual is impaired. Examples of metabolic diseases that can be treated with the compounds, pharmaceutical compositions, or methods described herein include diabetes (e.g., type I or type II), obesity, metabolic syndrome, or mitochondrial disease (e.g., mitochondrial dysfunction or abnormal mitochondrial function).

[0602] In certain embodiments, the disease is a fungal disease. As used herein, the term "fungal disease" refers to a disease or condition associated with a fungal infection in an individual. Examples of fungal diseases that can be treated with the compounds, pharmaceutical compositions, or methods described herein include infections with Mucor circinelloide, zygomycetes, Cryptococcus neoformans, Candida albican, yeast, and Saccharomyces cerevisiae.

[0603] In certain embodiments, the disease is an inflammatory disease. As used herein, the term "inflammatory disease" refers to a disease or condition characterized by abnormal inflammation, such as increased levels of inflammation compared to a control, such as a healthy individual not suffering from the disease. Examples of inflammatory diseases include traumatic brain injury, arthritis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, multiple sclerosis, systemic lupus erythematosus (SLE), myasthenia gravis, juvenile-onset diabetes, type 1 diabetes, Guillain-Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, ankylosing spondylitis, psoriasis, Sjogren's syndrome, vasculitis, glomerulonephritis, autoimmune thyroiditis, Behcet's disease, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, ichthyosis, Graves' ophthalmopathy, inflammatory bowel disease, Addison's disease, vitiligo, asthma, allergic asthma, acne vulgaris, diarrheal diseases, chronic prostatitis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, transplant rejection, interstitial cystitis, atherosclerosis, and atopic dermatitis.

[0604] In certain embodiments, the disease is a cardiovascular disease. As used herein, the term "cardiovascular disease" refers to a disease or condition in which the function of the cardiovascular system of a subject is impaired. Examples of cardiovascular diseases that can be treated with the compounds, pharmaceutical compositions, or methods described herein include congestive heart failure, arrhythmic syndromes (e.g., paroxysmal tachycardia, delayed after depolarization, ventricular tachycardia, sudden tachycardia, exercise-induced arrhythmias, long QT syndrome, or bidirectional tachycardia), thromboembolic disease (e.g., arterial cardiovascular thromboembolic disease, venous cardiovascular thromboembolic disease, or ventricular thromboembolic disease), atherosclerosis, restenosis, peripheral arterial disease, coronary artery bypass graft surgery, carotid artery disease, arteritis, myocarditis, cardiovascular inflammation, vascular inflammation, coronary heart disease (CHD), unstable angina (UA), unstable refractory angina, stable angina (SA), chronic stable angina, acute coronary syndrome (ACS), myocardial infarction (first or recurrence), acute myocardial infarction (AMI), myocardial infarction, non-Q wave myocardial infarction, non-STE myocardial infarction, coronary artery disease, ischemic heart disease, myocardial ischemia, ischemia, ischemic sudden death, transient ischemic attack, stroke, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary thrombosis, cerebral artery thrombosis, cerebral embolism, renal embolism, pulmonary embolism, thrombosis (e.g., associated with prosthetic valves or other grafts, indwelling catheters, stents, cardiopulmonary bypass, hemodialysis), thrombosis (e.g., associated with atherosclerosis, surgery, prolonged immobility, arterial fibrillation, congenital thrombophilia, cancer, diabetes, hormones, or pregnancy), or arrhythmia (e.g., supraventricular arrhythmia, atrial arrhythmia, atrial flutter, or atrial fibrillation).

[0605] In one aspect, a method of treating a disease associated with abnormal levels of mTOR activity in a subject in need of such treatment is provided. The disease may be caused by upregulation of mTOR. The method may include administering to the subject one or more compositions or compounds described herein. The method may include administering to the subject a therapeutically effective amount of one or more compositions or compounds described herein (e.g., an mTOR modulator (e.g., inhibitor) as described above).

[0606] In one aspect, one or more compositions or compounds as described herein are provided for use as a medicament. In embodiments, the medicament can be used to treat a disease caused by upregulation of mTOR. The use may include administering to the subject one or more compositions or compounds as described herein. The use may include administering to the subject a therapeutically effective amount of one or more compositions or compounds as described herein (e.g., an mTOR modulator (e.g., inhibitor) as described above).

[0607] In one aspect, one or more compositions or compounds as described herein are provided for use in treating a disease caused by an abnormal level of mTORC1 activity in a subject in need of such treatment. The disease may be caused by upregulation of mTORC1. The use may include administering to the subject one or more compositions or compounds as described herein. The use may include administering to the subject a therapeutically effective amount of one or more compositions or compounds as described herein (e.g., an mTOR modulator (e.g., inhibitor) as described above).

[0608] Upregulation of mTOR can result in an increased amount of mTOR activity compared to the normal level of mTOR activity in a particular subject or a population of healthy subjects. An increased amount of mTOR activity can result in, for example, excessive cell proliferation, thereby causing a disease state.

[0609] The subject for treatment of the disease is typically a mammal. The mammal treated with a compound (eg, a compound described herein, an mTOR modulator (eg, inhibitor)) can be a human, a non-human primate, and / or a non-human mammal (eg, a carnivore, a canine).

[0610] In another aspect, provided is a method of treating a disease associated with mTOR activity in a subject in need of such treatment, the method comprising administering to the subject one or more compositions or compounds as described herein (including embodiments (e.g., claims, embodiments, examples, tables or claims)).

[0611] In another aspect, one or more compositions or compounds as described herein are provided for use as a medicament. In an embodiment, the medicament can be used to treat a disease associated with mTORC1 activity in a subject in need of such treatment. In an embodiment, the use can include administering to the subject one or more compositions or compounds as described herein (including embodiments (e.g., aspects, embodiments, examples, tables or claims)).

[0612] In another aspect, one or more compositions or compounds are provided for use in treating a disease associated with mTOR activity in a subject in need of such treatment. In embodiments, the use may include administering to the subject one or more compositions or compounds as described herein (including embodiments (e.g., aspects, embodiments, examples, tables or claims)).

[0613] In an embodiment, an mTOR activity-related disease or a disease associated with an abnormal level of mTOR activity is cancer. In an embodiment, an mTOR activity-related disease or a disease associated with an abnormal level of mTOR activity is an autoimmune disease. In an embodiment, an mTOR activity-related disease or a disease associated with an abnormal level of mTOR activity is an inflammatory disease. In an embodiment, an mTOR activity-related disease or a disease associated with an abnormal level of mTOR activity is a neurodegenerative disease. In an embodiment, an mTOR activity-related disease or a disease associated with an abnormal level of mTOR activity is a metabolic disease. In an embodiment, an mTOR activity-related disease or a disease associated with an abnormal level of mTOR activity is transplant rejection. In an embodiment, an mTOR activity-related disease or a disease associated with an abnormal level of mTOR activity is a fungal infection. In an embodiment, an mTOR activity-related disease or a disease associated with an abnormal level of mTOR activity is a cardiovascular disease.

[0614] In embodiments, mTOR activity-related diseases or diseases associated with abnormal levels of mTOR activity are aging. In embodiments, mTOR activity-related diseases or diseases associated with abnormal levels of mTOR activity are death due to age-related diseases. In embodiments, mTOR activity-related diseases or diseases associated with abnormal levels of mTOR activity are age-related conditions. In certain embodiments, the age-related conditions are selected from: sarcopenia, skin atrophy, muscle wasting, brain atrophy, atherosclerosis, arteriosclerosis, emphysema, osteoporosis, osteoarthritis, hypertension, erectile dysfunction, dementia, Huntington's disease, Alzheimer's disease, cataracts, age-related macular degeneration, prostate cancer, stroke, shortened life expectancy, impaired renal function, and age-related hearing loss, age-related disability (e.g., weakness), cognitive decline, age-related dementia, memory impairment, tendon stiffness, cardiac dysfunction (such as cardiac hypertrophy and cardiac systolic and diastolic dysfunction), immunosenescence, cancer, obesity and diabetes. In certain embodiments, selective modulation of mTOR in certain T-cell populations can improve vaccine efficacy in elderly populations and enhance the effectiveness of cancer immunotherapy. The present invention provides a method of treating immunosenescence comprising administering to the subject a therapeutically effective amount of one or more disclosed compounds.

[0615] In an embodiment, the mTOR activity-related disease or the disease associated with abnormal levels of mTOR activity is cancer (e.g., carcinoma, sarcoma, adenocarcinoma, lymphoma, leukemia, solid cancer, lymphoid carcinoma, kidney cancer, breast cancer, lung cancer, bladder cancer, colon cancer, gastrointestinal cancer, ovarian cancer, prostate cancer, pancreatic cancer, stomach cancer, brain cancer, head and neck cancer, skin cancer, uterine cancer, esophageal cancer, liver cancer, testicular cancer, glioma, hepatocellular carcinoma, lymphoma (including B-acute lymphoblastic lymphoma, non-Hodgkin's lymphoma (e.g., Burkitt's, small cell and large cell lymphoma), Hodgkin's lymphoma), leukemia (including AML, ALL and CML), multiple myeloma and breast cancer (e.g., triple-negative breast cancer)).

[0616] In the embodiment, the mTOR activity-related disease or the disease associated with abnormal levels of mTOR activity is acute disseminated encephalomyelitis (ADEM), acute necrotizing hemorrhagic leukoencephalitis, Addison's disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti-GBM / anti-TBM nephritis, antiphospholipid syndrome (APS), autoimmune angioedema, autoimmune aplastic anemia, autoimmune autonomic dysfunction, autoimmune hepatitis, autoimmune hyperlipidemia, autoimmune immunodeficiency, autoimmune inner ear disease (AIED), autoimmune Myocarditis, autoimmune oophoritis, autoimmune pancreatitis, autoimmune retinopathy, autoimmune thrombocytopenic purpura (ATP), autoimmune thyroid disease, autoimmune urticaria, axonal or neuronal neuropathy, Barlow's disease, Behcet's disease, bullous pemphigoid, cardiomyopathy, Castleman's disease, diarrheal disease, Chagas' disease, chronic fatigue syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic recurrent multifocal osteomyelitis (CRMO), Church-Strauss syndrome, cicatricial pemphigoid / benign mucous membrane pemphigoid, Crohn's disease, C. ogans syndrome, cold agglutinin disease, congenital heart block, coxsackie myocarditis, CREST disease, idiopathic mixed cryoglobulinemia, demyelinating neuropathy, dermatitis herpetiformis, dermatomyositis, Devic's disease (neuromyelitis optica), discoid lupus, De Lacy's syndrome, endometrial translocation, eosinophilic esophagitis, eosinophilic fasciitis, erythema nodosum, experimental allergic encephalomyelitis, Evans syndrome, fibromyalgia, fibrosing alveolitis, giant cell arteritis (temporal arteritis), giant cell myocarditis, glomerulonephritis, Goodpasture's syndrome, granulomatosis with polyangiitis (GPA) (formerly Wegener's granulomatosis), Graves' disease, Guillain-Barré syndrome, Hashimoto's encephalitis , Hashimoto's thyroiditis, hemolytic anemia, Henoch-Schwann purpura, herpes gestationis, hypogammaglobulinemia, idiopathic thrombocytopenic purpura (ITP), IgA nephropathy, IgG4-related sclerosis, immunomodulatory lipoproteins, incorporation of myositis, interstitial cystitis, juvenile arthritis, juvenile diabetes mellitus (type 1 diabetes), juvenile myositis, Kawasaki syndrome, Lambert-Eaton syndrome, leukocytic vasculitis, lichen planus, lichen sclerosus, woody conjunctivitis, linear IgA disease (LAD), systemic lupus erythematosus (SLE), Lyme's disease, chronic Meniere's disease, microscopic polyangiitis, mixed connective tissue disease (MCTD), Moren's ulcer, Muhlenberg's disease, multiple sclerosis, myasthenia gravis, myositis, exacerbation Narcolepsy, neuromyelitis optica (Devic's), neutropenia, ocular cicatricial pemphigoid, optic neuritis, relapsing rheumatic disease, PANDAS (pediatric autoimmune neuropsychiatric disorder associated with streptococci), paraneoplastic cerebellar degeneration, paroxysmal nocturnal hemoglobinuria (PNH), Parilloberg's syndrome, Parker's syndrome, pars plana cyclitis (peripheral uveitis), pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia, POEMS syndrome, polyarteritis nodosa, autoimmune polyglandular syndromes type I, II, and III, polymyalgia rheumatica, polymyositis, post-myocardial infarction syndrome, postpericardiotomy syndrome, progesterone dermatitis, primary biliary cirrhosis, primary Sclerosing cholangitis, psoriasis, psoriatic arthritis, idiopathic pulmonary fibrosis, pyoderma gangrenosum, pure red cell agenesis, Raynaud's phenomenon, reactive arthritis, reflex sympathetic dystrophy, Reiter's syndrome, relapsing polychondritis, restless legs syndrome, retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis, sarcoidosis, Schmidt's syndrome, scleritis, scleroderma, Shoegraan's syndrome, sperm and testicular autoimmunity, stiff-man syndrome, subacute bacterial endocarditis (SBE), Susac's syndrome, sympathetic ophthalmia, Takayasu's arteritis, temporal arteritis / giant cell arteritis, thrombocytopenic purpura (TTP), Tolosa-Hunter syndrome, transverse myelitis, type 1 diabetes, ulcerative colitis,Undifferentiated connective tissue disease (UCTD), uveitis, vasculitis, cystic dermatosis, vitiligo, Wegener's granulomatosis (i.e., granulomatosis with polyangiitis (GPA)), traumatic brain injury, arthritis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, multiple sclerosis, systemic lupus erythematosus (SLE), myasthenia gravis, juvenile-onset diabetes mellitus, type 1 diabetes mellitus, Guillain-Barré syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, ankylosing spondylitis, psoriasis, Shoemaker-Graham syndrome, vasculitis, glomerulonephritis, autoimmune thyroiditis, Behcet's disease, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, ichthyosis, Graves' ophthalmopathy, inflammatory bowel disease , Addison's disease, vitiligo, asthma, allergic asthma, acne vulgaris, diarrheal diseases, chronic prostatitis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, transplant rejection, interstitial cystitis, atherosclerosis, atopic dermatitis, Alexander's disease, Alper's disease, Alzheimer's disease, amyotrophic lateral sclerosis, ataxia-telangiectasia, Batten's disease (also known as Spielmeyer-Vogt-Sjogren-Batten disease), bovine spongiform encephalopathy (BSE), Canavan's disease, Cockayne's syndrome, corticobasal degeneration, Creutzfeldt-Jakob disease, frontotemporal dementia, Gerstmann-Straussler-Scheinker syndrome, Huntington's disease, H1V-associated dementia, Kennedy's disease, Krabbe's disease, Kulu's disease, dementia with Lewy bodies, Machado-Joseph disease (spinocerebellar ataxia type 3), multiple sclerosis, multiple system atrophy, narcolepsy, neuroborreliosis, Parkinson's disease, Perelman-Merzbacher disease, Pick's disease, primary lateral sclerosis, prion diseases, Refsum's disease, Sandhoff's disease, Sidley's disease, subacute mixed degeneration of the spinal cord secondary to pernicious anemia, schizophrenia, spinocerebellar ataxia (various types with varying features), spinal muscular atrophy, Steele-Richardson-Olszewski disease, tabes dorsalis, diabetes mellitus (e.g., type I or type II), obesity, metabolic syndrome, mitochondrial diseases (e.g., mitochondrial dysfunction or abnormal mitochondrial function), fungal infection, transplant rejection, or cardiovascular disease (e.g., congestive heart failure, arrhythmic syndromes (e.g., paroxysmal tachycardia, delayed after depolarization, ventricular tachycardia, sudden tachycardia, exercise-induced arrhythmia, long QT syndrome, or bidirectional tachycardia), thromboembolic disease (e.g., arterial cardiovascular thromboembolism, venous cardiovascular thromboembolism, or ventricular thromboembolism), atherosclerosis, restenosis, peripheral arterial disease, coronary artery bypass graft surgery, carotid artery disease, arteritis, myocarditis, cardiovascular inflammation, vascular inflammation, coronary heart disease (CHD), unstable angina (UA), unstable refractory angina, stable angina (SA),Chronic stable angina, acute coronary syndrome (ACS), myocardial infarction (first or recurrent), acute myocardial infarction (AMI), myocardial infarction, non-Q wave myocardial infarction, non-STE myocardial infarction, coronary artery disease, ischemic heart disease, myocardial ischemia, ischemia, ischemic sudden death, transient ischemic attack, stroke, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary artery thrombosis, cerebral artery thrombosis, cerebral embolism, renal embolism, pulmonary embolism, thrombosis (e.g., associated with prosthetic valves or other implants, indwelling catheters, stents, cardiopulmonary bypass, hemodialysis), thrombosis (e.g., associated with atherosclerosis, surgery, prolonged immobility, arterial fibrillation, congenital thrombophilia, cancer, diabetes, hormones, or pregnancy), or arrhythmia (e.g., supraventricular arrhythmia, atrial arrhythmia, atrial flutter, or atrial fibrillation).

[0617] In one aspect, a method for treating a disease is provided, comprising administering an effective amount of one or more compositions or compounds as described herein. In one aspect, one or more compositions or compounds as described herein are provided for use as a medicine (e.g., for treating a disease). In one aspect, one or more compositions or compounds as described herein are provided for treating a disease (e.g., comprising administering an effective amount of one or more compositions or compounds as described herein). In embodiments, the disease is cancer. In embodiments, the disease is an autoimmune disease. In embodiments, the disease is an inflammatory disease. In embodiments, the disease is a neurodegenerative disease. In embodiments, the disease is a metabolic disease. In embodiments, the disease is a fungal infection. In embodiments, the disease is transplant rejection. In embodiments, the disease is a cardiovascular disease.

[0618] In embodiments, the disease is cancer (e.g., carcinoma, sarcoma, adenocarcinoma, lymphoma, leukemia, solid cancer, lymphoid carcinoma, kidney cancer, breast cancer, lung cancer, bladder cancer, colon cancer, ovarian cancer, prostate cancer, pancreatic cancer, stomach cancer, brain cancer, head and neck cancer, skin cancer, uterine cancer, esophageal cancer, liver cancer, testicular cancer, glioma, hepatocellular carcinoma, lymphoma (including B-acute lymphoblastic lymphoma, non-Hodgkin's lymphoma (e.g., Burkitt's, small cell and large cell lymphoma), Hodgkin's lymphoma), leukemia (including AML, ALL and CML), multiple myeloma and breast cancer (e.g., triple negative breast cancer)).

[0619] In the embodiment, the disease is acute disseminated encephalomyelitis (ADEM), acute necrotizing hemorrhagic leukoencephalitis, Addison's disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti-GBM / anti-TBM nephritis, antiphospholipid syndrome (APS), autoimmune angioedema, autoimmune aplastic anemia, autoimmune autonomic dysfunction, autoimmune hepatitis, autoimmune hyperlipidemia, autoimmune immunodeficiency, autoimmune inner ear disease (AIED), autoimmune myocarditis, autoimmune oophoritis, autoimmune pancreatitis, autoimmune retinopathy, autoimmune thrombocytopenic purpura (ATP), autoimmune thyroid disease, autoimmune Urticaria, axonal or neuronal neuropathy, Barlow's disease, Behcet's disease, bullous pemphigoid, cardiomyopathy, Castleman's disease, diarrheal disease, Chagas' disease, chronic fatigue syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic recurrent multifocal osteomyelitis (CRMO), Church-Strauss syndrome, cicatricial pemphigoid / benign mucous membrane pemphigoid, Crohn's disease, Kogan's syndrome, cold agglutinin disease, congenital heart block, coxsackie's myocarditis, CREST disease, essential mixed cryoglobulinemia, demyelinating neuropathy, dermatitis herpetiformis, dermatomyositis, Devic's disease (neuromyelitis optica), discoid lupus, De Lacy's syndrome, endometrial translocation, eosinophilic esophagitis, eosinophilic fasciitis, erythema nodosum, experimental allergic encephalomyelitis, Evans syndrome, fibromyalgia, fibrosing alveolitis, giant cell arteritis (temporal arteritis), giant cell myocarditis, glomerulonephritis, Goodpasture's syndrome, granulomatosis with polyangiitis (GPA) (formerly Wegener's granulomatosis), Graves' disease, Guillain-Barré syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, hemolytic anemia, Henoch-Schwann purpura, herpes gestationis, hypogammaglobulinemia, idiopathic thrombocytopenic purpura (ITP), IgA nephropathy, IgG4-related sclerosis, immunomodulatory lipoproteins, incorporation of myositis, interstitial cystitis, juvenile arthritis, juvenile diabetes mellitus (type 1 diabetes), juvenile myositis , Kawasaki syndrome, Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, woody conjunctivitis, linear IgA disease (LAD), systemic lupus erythematosus (SLE), Lyme's disease, chronic Meniere's disease, microscopic polyangiitis, mixed connective tissue disease (MCTD), Moren's ulcer, Mu-Ha's disease, multiple sclerosis, myasthenia gravis, myositis, narcolepsy, neuromyelitis optica (Devic's), neutropenia, ocular cicatricial pemphigoid, optic neuritis, relapsing rheumatic disease, PANDAS (pediatric autoimmune neuropsychiatric disorder associated with streptococci), paraneoplastic cerebellar degeneration, paroxysmal nocturnal hemoglobinuria (PNH), Parry-Roberg's syndrome, Parker-Turner's syndrome,Pars plana ciliitis (peripheral uveitis), pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia, POEMS syndrome, polyarteritis nodosa, autoimmune polyglandular syndromes type I, II, and III, polymyalgia rheumatica, polymyositis, post-myocardial infarction syndrome, postpericardiotomy syndrome, progesterone dermatitis, primary biliary cirrhosis, primary sclerosing cholangitis, psoriasis, psoriatic arthritis, idiopathic pulmonary fibrosis, pyoderma gangrenosum, pure red cell agenesis, Raynaud's phenomenon, reactive arthritis, reflex sympathetic dystrophy, Reiter's syndrome, relapsing polychondritis, restless legs syndrome, retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis, sarcoidosis, Schmidt's syndrome , scleritis, scleroderma, Shew-Graham syndrome, sperm and testicular autoimmunity, stiff-man syndrome, subacute bacterial endocarditis (SBE), Susac's syndrome, sympathetic ophthalmia, Takayasu's arteritis, temporal arteritis / giant cell arteritis, thrombocytopenic purpura (TTP), Tolosa-Hunt syndrome, transverse myelitis, type 1 diabetes, ulcerative colitis, undifferentiated connective tissue disease (UCTD), uveitis, vasculitis, cystic dermatosis, vitiligo, Wegener's granulomatosis (i.e., granulomatosis with polyangiitis (GPA)), traumatic brain injury, arthritis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, multiple sclerosis, systemic lupus erythematosus (SLE), myasthenia gravis force, juvenile onset diabetes, type 1 diabetes, Guillain-Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, ankylosing spondylitis, psoriasis, vasculitis, glomerulonephritis, autoimmune thyroiditis, Behcet's disease, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, ichthyosis, Graves' ophthalmopathy, inflammatory bowel disease, Addison's disease, vitiligo, asthma, allergic asthma, acne vulgaris, diarrheal disease, chronic prostatitis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, transplant rejection, interstitial cystitis, atherosclerosis, atopic dermatitis, Alexander's disease, Alper's disease, Alzheimer's disease, amyotrophic lateral sclerosis, ataxia-telangiectasia, Batten's disease (also Spielmeyer-Vogt-Sjogren-Batten disease), bovine spongiform encephalopathy (BSE), Canavan disease, Cockayne syndrome, corticobasal degeneration, Creutzfeldt-Jakob disease, frontotemporal dementia, Gerstmann-Straussler-Scheinker syndrome, Huntington disease, HTV-related dementia, Kennedy disease, Krabbe disease, Kulu disease, dementia with Lewy bodies, Machado-Joseph disease (spinocerebellar ataxia type 3), multiple sclerosis, multiple system atrophy, narcolepsy, neuroborreliosis, Parkinson's disease, Perelman-Merzbacher disease, Pick's disease, primary lateral sclerosis, prion diseases, Refsum's disease, Sandhoff's disease, Sidley's disease,Subacute mixed degeneration of the spinal cord secondary to pernicious anemia, schizophrenia, spinocerebellar ataxia (multiple types with varying features), spinal muscular atrophy, Steele-Richardson-Olszewski disease, tabes dorsalis, diabetes mellitus (e.g., type I or type II), obesity, metabolic syndrome, mitochondrial disease (e.g., mitochondrial dysfunction or abnormal mitochondrial function), fungal infection, transplant rejection, or cardiovascular disease (e.g., congestive heart failure, arrhythmia syndromes (e.g., paroxysmal tachycardia, delayed afterdepolarization, ventricular tachycardia, sudden tachycardia, exercise-induced arrhythmia, long QT syndrome, or bidirectional tachycardia), thromboembolism (e.g., arterial cardiovascular thromboembolism, venous cardiovascular thromboembolism, or ventricular thromboembolism), atherosclerosis, restenosis, peripheral arterial disease, coronary artery bypass graft surgery, carotid artery disease, arteritis, myocarditis, cardiovascular inflammation, vascular inflammation, coronary heart disease (CHD), unstable angina (UA), unstable refractory angina, stable angina (SA), chronic stable angina, acute coronary syndrome (ACS), CS), myocardial infarction (first or recurrent), acute myocardial infarction (AMI), myocardial infarction, non-Q wave myocardial infarction, non-STE myocardial infarction, coronary artery disease, ischemic heart disease, myocardial ischemia, ischemia, ischemic sudden death, transient ischemic attack, stroke, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary artery thrombosis, cerebral artery thrombosis, cerebral embolism, renal embolism, pulmonary embolism, thrombosis (e.g., with prosthetic valves or other grafts, indwelling catheters, stents, cardiopulmonary bypass, hemodialysis In embodiments, the disease is polycystic disease. In embodiments, the disease is polycystic kidney disease. In embodiments, the disease is stenosis. In embodiments, the disease is restenosis. In embodiments, the disease is neointimal hyperplasia. In embodiments, the disease is neointimal hyperplasia. ,

[0620] In another aspect, a method of treating aging in a subject in need of such treatment is provided, the method comprising administering to the subject one or more compositions or compounds as described herein (including embodiments (e.g., claims, embodiments, examples, tables or claims)). The present invention provides a method of treating immunosenescence, comprising administering to the subject a therapeutically effective amount of one or more disclosed compounds or compositions.

[0621] In another aspect, one or more compositions or compounds as described herein are provided for use as medicines. In embodiments, the medicine can be used to treat the aging of a subject in need of such treatment. In embodiments, the purposes may include administering to the subject one or more compositions or compounds as described herein (including embodiments (e.g., aspects, embodiments, examples, tables or claims)).

[0622] In another aspect, one or more compositions or compounds disclosed herein are provided for use in treating aging in a subject in need of such treatment. In embodiments, the use may include administering to the subject one or more compositions or compounds as described herein (including embodiments (e.g., aspects, embodiments, examples, tables, or claims)).

[0623] In another aspect, a method of extending lifespan or inducing longevity in a subject in need of such treatment is provided, the method comprising administering to the subject one or more compositions or compounds as described herein (including embodiments (e.g., claims, embodiments, examples, tables or claims)).

[0624] In another aspect, one or more compositions or compounds as described herein are provided for use as medicines. In embodiments, the medicine can be used to prolong life or induce longevity in a subject in need of such treatment. In embodiments, the purposes may include administering to the subject one or more compositions or compounds as described herein (including embodiments (e.g., aspects, embodiments, examples, tables or claims)).

[0625] In another aspect, one or more compositions or compounds are provided for extending life span or inducing longevity in a subject in need of such treatment. In embodiments, the purposes may include administering to the subject one or more compositions or compounds as described herein (including embodiments (e.g., aspects, embodiments, examples, tables or claims)).

[0626] In one aspect, a method of treating a polycystic disease in a subject in need of such treatment is provided. The polycystic disease may be polycystic kidney disease. The method may include administering to the subject one or more compositions or compounds described herein. The method may include administering to the subject a therapeutically effective amount of one or more compositions or compounds described herein (e.g., an mTOR modulator (e.g., inhibitor) as described above).

[0627] In one aspect, one or more compositions or compounds as described herein are provided for use as a medicament. In embodiments, the medicament can be used to treat polycystic disease. The polycystic disease can be polycystic kidney disease. The use may include administering to the subject one or more compositions or compounds as described herein. The use may include administering to the subject a therapeutically effective amount of one or more compositions or compounds as described herein (e.g., an mTOR modulator (e.g., inhibitor) as described above).

[0628] In one aspect, one or more compositions or compounds as described herein are provided for use in treating a polycystic disease in a subject in need of such treatment. The polycystic disease may be polycystic kidney disease. The use may include administering to the subject one or more compositions or compounds as described herein. The use may include administering to the subject a therapeutically effective amount of one or more compositions or compounds as described herein (e.g., an mTOR modulator (e.g., inhibitor) as described above).

[0629] In one aspect, a method of treating stenosis in a subject in need of such treatment is provided. The stenosis may be restenosis. The method may include administering to the subject one or more compositions or compounds described herein. In an embodiment, the one or more compositions or compounds are administered as a drug eluting stent. The method may include administering to the subject a therapeutically effective amount of one or more compositions or compounds described herein (e.g., an mTOR modulator (e.g., inhibitor) as described above).

[0630] In one aspect, one or more compositions or compounds as described herein are provided for use as a medicament. In embodiments, the medicament can be used to treat stenosis. The stenosis can be restenosis. The use may include administering to the subject one or more compositions or compounds as described herein. In embodiments, the compound is administered as a drug eluting stent. The use may include administering to the subject a therapeutically effective amount of one or more compositions or compounds as described herein (e.g., an mTOR modulator (e.g., inhibitor) as described above).

[0631] In one aspect, one or more compositions or compounds as described herein are provided for use in treating stenosis in a subject in need of such treatment. The stenosis may be restenosis. The use may include administering to the subject one or more compositions or compounds as described herein. In an embodiment, the one or more compositions or compounds are administered in the form of a drug eluting stent. The use may include administering to the subject a therapeutically effective amount of one or more compositions or compounds as described herein (e.g., an mTOR modulator (e.g., inhibitor) as described above).

[0632] In embodiments, the disease is a disease described herein, and the compound is a compound described herein, and the composition is a composition described herein.

[0633] Methods of regulating mTOR

[0634] In some embodiments, the compounds disclosed herein are more selective inhibitors of mTORC1 relative to mTORC2. In some embodiments, the compounds disclosed herein are more selective inhibitors of mTORC2 relative to mTORC1. In some embodiments, the compounds disclosed herein exhibit no selectivity difference between mTORC1 and mTORC2.

[0635] In another aspect, a method of regulating mTORCl activity in a subject in need thereof is provided, comprising administering to the subject an effective amount of a compound as described herein or a pharmaceutically acceptable salt thereof. In embodiments, the method comprises inhibiting mTORCl activity. In embodiments, the method comprises inhibiting mTORCl activity and not inhibiting mTORC2 activity.

[0636] In embodiments, the method comprises inhibiting mTORC1 activity more than inhibiting mTORC2 activity. In embodiments, the method comprises inhibiting mTORC1 activity by at least 1.1 times (e.g., at least 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2 000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200000, 300000, 400000, 500000, 600000, 700000, 800000, 900000, or 1000000 times).

[0637] In another aspect, a method of modulating mTORC2 activity in a subject in need thereof is provided, comprising administering to the subject an effective amount of a compound as described herein or a pharmaceutically acceptable salt thereof. In embodiments, the method comprises inhibiting mTORC2 activity. In embodiments, the method comprises inhibiting mTORC2 activity and not inhibiting mTORC1 activity.

[0638] In embodiments, the method comprises inhibiting mTORC2 activity more than inhibiting mTORC1 activity. In embodiments, the method comprises inhibiting mTORC2 activity by at least 1.1 times (e.g., at least 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2 000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200000, 300000, 400000, 500000, 600000, 700000, 800000, 900000, or 1000000 times).

[0639] In some embodiments, the mTOR is located in a cell. In some embodiments, the cell is a mammalian cell, such as a human cell. The cell can be isolated in vitro, form part of an in vitro tissue, or can form part of an organism.

[0640] Exemplary embodiments

[0641] Some embodiments of the present invention are the following Embodiment I:

[0642] Embodiment I-1. A compound of formula I:

[0643]

[0644] or a pharmaceutically acceptable salt or tautomer thereof, wherein:

[0645] R 32 is -H, =O or -OR 3 ;

[0646] R 28 is -H or -C(=Z 1 )-R 28a ;

[0647] R 40 is -H or -C(=Z 1 )-R 40a ;

[0648] Where R 28 and R 40 At least one of is not H;

[0649] Z1 O or S;

[0650] R 28a and R 40a Independently -A 1 -L 1 -A 2 -B, -A 1 -A 2 -B, -L 2 -A 1 -L 1 -A 2 -L 3 -B、-O-(C 1 -C 6 )alkyl, or -O-(C 6 -C 10 ) aryl; wherein the aryl is unsubstituted or selected from -NO 2 and 1 to 5 substituents of halogen;

[0651] A 1 and A 2 is independently absent or independently selected from

[0652]

[0653]

[0654] As shown, A 1 The left bond is bound to -C(=Z 1 )- or L 2 ; and among them, as depicted, A 2 The right side of the key is connected to B or L 3 ;

[0655] Q is each independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0656] X is each independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0657] Each X 1 is a heteroarylene or heterocyclylene ring;

[0658] W is each independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0659] Each W 1 is a heteroarylene or heterocyclylene ring;

[0660] G is each independently absent or a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0661] G 1 and G 2 each independently is a heteroarylene or heterocyclylene ring;

[0662] L 1 Selected from

[0663] L 2 and L 3 is independently absent or independently selected from

[0664]

[0665] B is selected from

[0666]

[0667] B 1 Selected from NR 3 -(C(R 3 ) 2 ) n -、 NR 3 -(C(R 3 ) 2 ) n -(C 6 -C 10 )arylene-(C(R 3 ) 2 ) n -、 NR 3 -(C(R 3 ) 2 ) n -heteroarylene-, (C 6 -C 10 ) arylene-, NR 3 -(C(R 3 ) 2 ) n -NR 3 C(O)-, NR 3 -(C(R 3 ) 2 ) n -heteroarylene-heterocyclylene-(C 6 -C 10 ) arylene-, Heteroarylene-heterocyclylene-(C 6 -C 10) arylene-, and NR 3 -(C(R 3 ) 2 ) n -S(O) 2 -arylene-C(O)-, wherein as shown, B 1 Left Bond to A 2 , L 3 or L 1 ; and wherein the heteroarylene, heterocyclylene and arylene are optionally substituted with alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen or hydroxy;

[0670] R 3 Each independently is H or (C 1 -C 6 )alkyl;

[0671] R 4 Each independently is H, (C 1 -C 6 )alkyl, halogen, 5- to 12-membered heteroaryl, 5- to 12-membered heterocyclyl, (C 6 -C 10 ) aryl, wherein the heteroaryl, heterocyclyl and aryl are optionally substituted by -N(R 3 ) 2 、-OR 3 , halogen, (C 1 -C 6 )alkyl, -(C 1 -C 6 )alkylene-heteroaryl, -(C 1 -C 6 )alkylene-CN, -C(O)NR 3 -heteroaryl or -C(O)NR 3 - Heterocyclyl substitution;

[0672] R 5 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 wherein the alkyl group is optionally replaced by -N(R 3 ) 2 OR 3 replace;

[0673] R 6 Each independently is H, (C 1 -C6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 wherein the alkyl group is optionally replaced by -N(R 3 ) 2 OR 3 replace;

[0674] R 7 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 wherein the alkyl group is optionally replaced by -N(R 3 ) 2 OR 3 replace;

[0675] R 8 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 wherein the alkyl group is optionally replaced by -N(R 3 ) 2 OR 3 replace;

[0676] Y is each independently C(R 3 ) 2 or key;

[0677] n is each independently a number from 1 to 12;

[0678] o are each independently a number from 0 to 30;

[0679] p is each independently a number from 0 to 12;

[0680] q is each independently a number from 0 to 30; and

[0681] r is a number from 1 to 6 each independently.

[0682] Embodiment I-2. A compound of formula II:

[0683]

[0684] or a pharmaceutically acceptable salt or tautomer thereof, wherein:

[0685] R 32 is -H, =O or -OR 3 ;

[0686] R 28 is -H or -C(=Z 1 )-R 28a ;

[0687] R 40 is -H or -C(=Z 1 )-R 40a ;

[0688] Where R 28 and R 40 At least one of is not H;

[0689] Z 1 O or S;

[0690] R 28a and R 40a Independently -A 1 -L 1 -A 2 -B, -A 1 -A 2 -B、-O-(C 1 -C 6 )alkyl, or -O-(C 6 -C 10 ) aryl; wherein the aryl is unsubstituted or selected from -NO 2 and 1 to 5 substituents of halogen;

[0691] A 1 and A 2 is independently absent or independently selected from

[0692]

[0693]

[0694] As shown, A 1 The left bond is bound to -C(=Z 1 )-; and in which, as shown, A 2 The bond on the right side of the part is bound to B;

[0695] Q is each independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0696] X is each independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0697] Each X 1 is a heteroarylene or heterocyclylene ring;

[0698] W is each independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0699] Each W 1 is a heteroarylene or heterocyclylene ring;

[0700] G is each independently absent or a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0701] G 1 and G 2 each independently is a heteroarylene or heterocyclylene ring;

[0702] L 1 Selected from

[0703] B is selected from

[0704]

[0705] B 1 Selected from NR 3 -(C(R 3 ) 2 ) n -、 NR 3 -(C(R 3 ) 2 ) n -(C 6 -C 10 )arylene-(C(R 3 ) 2 ) n -、 NR 3 -(C(R 3 ) 2 ) n -heteroarylene-, (C 6 -C 10 ) arylene-, NR 3 -(C(R 3 ) 2 ) n -NR 3 C(O)-, NR 3 -(C(R 3 ) 2 ) n -heteroarylene-heterocyclylene-(C 6 -C 10 ) arylene-, Heteroarylene-heterocyclylene-(C 6 -C 10 ) arylene-, and NR 3 -(C(R 3 ) 2 ) n -S(O) 2 -arylene-C(O)-, wherein as shown, B 1 Left Bond to A 2 or L 1 ; and wherein the heteroarylene, heterocyclylene and arylene are optionally substituted with alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen or hydroxy;

[0708] R 3 Each independently is H or (C 1 -C 6 )alkyl;

[0709] R 4 Each independently is H, (C 1 -C 6 )alkyl, halogen, 5- to 12-membered heteroaryl, 5- to 12-membered heterocyclyl, (C 6 -C 10 ) aryl, wherein the heteroaryl, heterocyclyl and aryl are optionally substituted by -N(R 3 ) 2 、-OR 3 , halogen, (C 1 -C 6 )alkyl, -(C 1 -C 6 )alkylene-heteroaryl, -(C 1 -C 6 )alkylene-CN, -C(O)NR 3 -heteroaryl or -C(O)NR 3 - Heterocyclyl substitution;

[0710] R 5 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 wherein the alkyl group is optionally replaced by -N(R 3 ) 2 OR 3 replace;

[0711] R6 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 wherein the alkyl group is optionally replaced by -N(R 3 ) 2 OR 3 replace;

[0712] R 7 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 wherein the alkyl group is optionally replaced by -N(R 3 ) 2 OR 3 replace;

[0713] R 8 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 wherein the alkyl group is optionally replaced by -N(R 3 ) 2 OR 3 replace;

[0714] Y is each independently C(R 3 ) 2 or key;

[0715] n is each independently a number from 1 to 12;

[0716] o are each independently a number from 0 to 30;

[0717] p is each independently a number from 0 to 12;

[0718] q is each independently a number from 0 to 30; and

[0719] r is a number from 1 to 6 each independently.

[0720] Embodiment I-3. A compound according to Embodiment I-1 or I-2, wherein R 32 is =O.

[0721] Embodiment I-4. A compound according to Embodiment I-1 or I-2, wherein R 32 For-OR 3 .

[0722] Embodiment I-5. A compound according to any one of Embodiments I-1 to I-4, wherein the compound is represented by the structure of Formula I-40:

[0723]

[0724] or a pharmaceutically acceptable salt thereof.

[0725] Embodiment I-6. A compound according to Embodiment I-5, wherein Z 1 is O.

[0726] Embodiment I-7. A compound according to Embodiment I-5, wherein Z 1 For S.

[0727] Embodiment I-8. A compound according to any one of Embodiments I-5 to I-7, wherein R 40a For-A 1 -L 1 -A 2 -B, where A 1 and A 2 Does not exist.

[0728] Embodiment I-9. A compound according to any one of Embodiments I-5 to I-7, wherein R 40a For-A 1 -L 1 -A 2 -B, where A 2 Does not exist.

[0729] Embodiment I-10. A compound according to any one of Embodiments I-5 to I-7, wherein R 40a For-A 1 -L 1 -A 2 -B, where A 1 Does not exist.

[0730] Embodiment I-11. A compound according to any one of Embodiments I-5 to I-7, wherein R 40a For-A 1 -L 1 -A 2 -B.

[0731] Embodiment I-12. A compound according to any one of Embodiments I-5 to I-7, wherein R 40a For-A 1 -A 2 -B.

[0732] Embodiment I-13. A compound according to any one of Embodiments I-5 to I-7, wherein R40a For -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2 and A 1 Does not exist.

[0733] Embodiment I-14. A compound according to any one of Embodiments I-5 to I-7, wherein R 40a For -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2 Does not exist.

[0734] Embodiment I-15. A compound according to any one of Embodiments I-5 to I-7, wherein R 40a For -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 3 Does not exist.

[0735] Embodiment I-16. A compound according to any one of Embodiments I-5 to I-7, wherein R 40a -O-(C 1 -C 6 )alkyl or -O-(C 6 -C 10 ) aryl; wherein the aryl is unsubstituted or selected from -NO 2 and 1 to 5 substituents of halogen.

[0736] Embodiment I-17. A compound according to any one of Embodiments I-1 to I-4, wherein the compound is represented by the structure of Formula I-28:

[0737]

[0738] or a pharmaceutically acceptable salt thereof.

[0739] Embodiment I-18. A compound according to embodiment I-17, wherein Z 1 is O.

[0740] Embodiment I-19. A compound according to embodiment I-17, wherein Z 1 For S.

[0741] Embodiment I-20. A compound according to any one of Embodiments I-17 to I-19, wherein R 28a For-A 1 -L 1 -A 2 -B, where A 1 and A 2 Does not exist.

[0742] Embodiment I-21. A compound according to any one of Embodiments I-17 to I-19, wherein R 28a For-A 1 -L 1 -A 2 -B, where A 2 Does not exist.

[0743] Embodiment I-22. A compound according to any one of Embodiments I-17 to I-19, wherein R 28a For-A 1 -L 1 -A 2 -B, where A 1 Does not exist.

[0744] Embodiment I-23. A compound according to any one of Embodiments I-17 to I-19, wherein R 28a For-A 1 -L 1 -A 2 -B.

[0745] Embodiment I-24. A compound according to any one of Embodiments I-17 to I-19, wherein R 28a For-A 1 -A 2 -B.

[0746] Embodiment I-25. A compound according to any one of Embodiments I-17 to I-19, wherein R 28a For -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2 and A 1 Does not exist.

[0747] Embodiment I-26. A compound according to any one of Embodiments I-17 to I-19, wherein R 28a For -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L2 Does not exist.

[0748] Embodiment I-27. A compound according to any one of Embodiments I-17 to I-19, wherein R 28a For -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 3 Does not exist.

[0749] Embodiment I-28. A compound according to any one of Embodiments I-17 to I-19, wherein R 28a -O-(C 1 -C 6 )alkyl or -O-(C 6 -C 10 ) aryl; wherein the aryl is unsubstituted or selected from -NO 2 and 1 to 5 substituents of halogen.

[0750] Embodiment I-29. A compound according to any one of Embodiments I-1 to I-11, I-13 to I-15, I-17 to I-23 and I-25 to I-27, wherein L 1 for

[0751] Embodiment I-30. A compound according to any one of Embodiments I-1 to I-11, I-13 to I-15, I-17 to I-23 and I-25 to I-27, wherein L 1 for

[0752] Embodiment I-31. A compound according to any one of Embodiments I-1 to I-11, I-13 to I-15, I-17 to I-23 and I-25 to I-27, wherein L 1 for

[0753] Embodiment I-32. A compound according to any one of Embodiments I-1 to I-11, I-13 to I-15, I-17 to I-23 and I-25 to I-27, wherein L 1 for

[0754] Embodiment I-33. A compound according to any one of Embodiments I-1 to I-11, I-13 to I-15, I-17 to I-23 and I-25 to I-27, wherein L 1 for

[0755] Embodiment I-34. A compound according to any one of Embodiments I-1 to I-7, I-15, I-17 to I-19 and I-27, wherein L 2 for

[0756] Embodiment I-35. A compound according to any one of Embodiments I-1 to I-7, I-13 to I-14, I-17 to I-19 and I-25 to I-26, wherein L 3 for

[0757] Embodiment I-36. A compound according to any one of Embodiments I-1 to I-8, I-10, I-13, I-17 to I-19, I-20, I-22, I-25 and I-29 to I-35, wherein A 1 Does not exist.

[0758] Embodiment I-37. A compound as in any one of Embodiments I-1 to I-7, I-9, I-11 to I-12, I-14 to I-15, I-17 to I-19, I-21, I-23 to I-24, I-26 to I-27 and I-29 to I-35, wherein A 1 for

[0759] Embodiment I-38. A compound as in any one of Embodiments I-1 to 1-7, I-9, I-11 to I-12, I-14 to I-15, I-17 to I-19, I-21, I-23 to I-24, I-26 to I-27 and I-29 to I-35, wherein A 1 for

[0760] Embodiment I-39. A compound as in any one of Embodiments I-1 to I-7, I-9, I-11 to I-12, I-14 to I-15, I-17 to I-19, I-21, I-23 to I-24, I-26 to I-27 and I-29 to I-35, wherein A 1 for

[0761] Embodiment I-40. A compound as in any one of Embodiments I-1 to I-7, I-9, I-11 to I-12, I-14 to I-15, I-17 to I-19, I-21, I-23 to I-24, I-26 to I-27 and I-29 to I-35, wherein A 1 for

[0762] Embodiment I-41. A compound as in any one of Embodiments I-1 to I-7, I-9, I-11 to I-12, I-14 to I-15, I-17 to I-19, I-21, I-23 to I-24, I-26 to I-27 and I-29 to I-35, wherein A 1 for

[0763] Embodiment I-42. A compound as in any one of Embodiments I-1 to I-7, I-9, I-11 to I-12, I-14 to I-15, I-17 to I-19, I-21, I-23 to I-24, I-26 to I-27 and I-29 to I-35, wherein A 1 for

[0764] Embodiment I-43. A compound as in any one of Embodiments I-1 to I-7, I-9, I-11 to I-12, I-14 to I-15, I-17 to I-19, I-21, I-23 to I-24, I-26 to I-27 and I-29 to I-35, wherein A 1 for

[0765] Embodiment I-44. A compound as in any one of Embodiments I-1 to I-7, I-9, I-11 to I-12, I-14 to I-15, I-17 to I-19, I-21, I-23 to I-24, I-26 to I-27 and I-29 to I-35, wherein A 1 for

[0766] Embodiment I-45. A compound according to any one of Embodiments I-1 to I-9, I-17 to I-21 and I-29 to I-44, wherein A 2 Does not exist.

[0767] Embodiment I-46. A compound as in any one of Embodiments I-1 to I-7, I-10 to I-15, I-17 to I-19, I-22 to I-27 and I-29 to I-44, wherein A 2 for

[0768] Embodiment I-47. A compound according to any one of Embodiments I-1 to I-7, I-10 to I-15, I-17 to I-19, I-22 to I-27 and I-29 to I-44, wherein A 2 for

[0769] Embodiment I-48. A compound according to any one of Embodiments I-1 to I-7, I-10 to I-15, I-17 to I-19, I-22 to I-27 and I-29 to I-44, wherein A 2 for

[0770] Embodiment I-49. A compound as in any one of Embodiments I-1 to I-7, I-10 to I-15, I-17 to I-19, I-22 to I-27 and I-29 to I-44, wherein A 2 for

[0771] Embodiment I-50. A compound according to any one of Embodiments I-1 to I-7, I-10 to I-15, I-17 to I-19, I-22 to I-27 and I-29 to I-44, wherein A 2 for

[0772] Embodiment I-51. A compound as in any one of Embodiments I-1 to I-7, I-10 to I-15, I-17 to I-19, I-22 to I-27 and I-29 to I-44, wherein A 2 for

[0773] Embodiment I-52. A compound as in any one of Embodiments I-1 to I-7, I-10 to I-15, I-17 to I-19, I-22 to I-27 and I-29 to I-44, wherein A 2 for

[0774] Embodiment I-53. A compound as in any one of Embodiments I-1 to I-7, I-10 to I-15, I-17 to I-19, I-22 to I-27 and I-29 to I-44, wherein A 2 for

[0775] Embodiment I-54. A compound according to any one of Embodiments I-1 to I-53, wherein B is

[0776] Embodiment I-55. A compound according to any one of Embodiments I-1 to I-53, wherein B is

[0777] Embodiment I-56. A compound according to any one of Embodiments I-1 to I-53, wherein B1 is NR 3 -(C(R 3 ) 2 )n -.

[0778] Embodiment I-57. A compound according to any one of Embodiments I-1 to I-53, wherein B1 is

[0779] Embodiment I-58. A compound according to any one of Embodiments I-1 to I-57, wherein R 4 is optionally replaced by -N(R 3 ) 2 、-OR 3 , halogen, (C 1 -C 6 )alkyl, -(C 1 -C 6 )alkylene-heteroaryl, -(C 1 -C 6 )alkylene-CN or -C(O)NR 3 -heteroaryl-substituted 5- to 12-membered heteroaryl.

[0780] Embodiment I-59. A compound according to any one of Embodiments I-1 to I-58, or a pharmaceutically acceptable salt or tautomer thereof, wherein the compound has the following formula:

[0781]

[0782] Embodiment 1-60. A compound selected from:

[0783]

[0784]

[0785]

[0786]

[0787]

[0788]

[0789]

[0790]

[0791]

[0792]

[0793]

[0794]

[0795]

[0796]

[0797]

[0798]

[0799] or a pharmaceutically acceptable salt or isomer thereof.

[0800] Embodiment I-61. A pharmaceutical composition comprising a compound according to any one of Embodiments I-1 to I-60 or a pharmaceutically acceptable salt thereof, and at least one of a pharmaceutically acceptable carrier, diluent or excipient.

[0801] Embodiment I-62. A method for treating a disease or condition mediated by mTOR, comprising administering to a subject suffering from or susceptible to a disease or condition mediated by mTOR a therapeutically effective amount of one or more compounds of any one of Embodiments I-1 to I-60 or a pharmaceutically acceptable salt thereof.

[0802] Embodiment I-63. A method for preventing a disease or condition mediated by mTOR, comprising administering to a subject suffering from or susceptible to a disease or condition mediated by mTOR a therapeutically effective amount of one or more compounds of any one of Embodiments I-1 to I-60 or a pharmaceutically acceptable salt thereof.

[0803] Embodiment I-64. A method for reducing the risk of a disease or condition mediated by mTOR, comprising administering to a subject suffering from or susceptible to a disease or condition mediated by mTOR a therapeutically effective amount of one or more compounds of any one of Embodiments I-1 to I-60, or a pharmaceutically acceptable salt thereof.

[0804] Embodiment 1-65. The method of any one of embodiments 1-62 to 1-64, wherein the disease is cancer or an immune-mediated disease.

[0805] Embodiment 1-66. A method as described in embodiment 1-65, wherein the cancer is selected from brain and neurovascular tumors, head and neck cancer, breast cancer, lung cancer, mesothelioma, lymphoma, stomach cancer, kidney cancer, renal cancer, liver cancer, ovarian cancer, ovarian endometriosis, testicular cancer, gastrointestinal cancer, prostate cancer, glioblastoma, skin cancer, melanoma, neural cancer, spleen cancer, pancreatic cancer, blood proliferative disorders, lymphoma, leukemia, endometrial cancer, cervical cancer, vulvar cancer, prostate cancer, penile cancer, bone cancer, muscle cancer, soft tissue cancer, intestinal or rectal cancer, anal cancer, bladder cancer, bile duct cancer, eye cancer, gastrointestinal stromal tumors and neuro-endocrine tumors.

[0806] Embodiment 1-67. A method as described in embodiment 1-65, wherein the immune-mediated disease is selected from resistance to transplanted heart, kidney, liver, bone marrow, skin, cornea, lung, pancreas, small intestine, limbs, muscle, nerve, duodenum, small intestine or pancreatic islet cells; graft-versus-host disease caused by bone marrow transplantation; rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, allergic encephalomyelitis and glomerulonephritis.

[0807] Embodiment I-68. A method of treating cancer, comprising administering to a subject a therapeutically effective amount of one or more compounds according to any one of Embodiments I-1 to I-60 or a pharmaceutically acceptable salt thereof.

[0808] Embodiment 1-69. A method as described in embodiment 1-68, wherein the cancer is selected from brain and neurovascular tumors, head and neck cancer, breast cancer, lung cancer, mesothelioma, lymphoma, stomach cancer, kidney cancer, renal cancer, liver cancer, ovarian cancer, ovarian endometriosis, testicular cancer, gastrointestinal cancer, prostate cancer, glioblastoma, skin cancer, melanoma, neural cancer, spleen cancer, pancreatic cancer, blood proliferative disorders, lymphoma, leukemia, endometrial cancer, cervical cancer, vulvar cancer, prostate cancer, penile cancer, bone cancer, muscle cancer, soft tissue cancer, intestinal or rectal cancer, anal cancer, bladder cancer, bile duct cancer, eye cancer, gastrointestinal stromal tumors and neuro-endocrine tumors.

[0809] Embodiment I-70. A method for treating an immune-mediated disease, comprising administering to a subject a therapeutically effective amount of one or more compounds of any one of Embodiments I-1 to I-60 or a pharmaceutically acceptable salt thereof.

[0810] Embodiment 1-71. A method as described in embodiment 1-70, wherein the immune-mediated disease is selected from resistance to transplanted heart, kidney, liver, bone marrow, skin, cornea, lung, pancreas, small intestine, limbs, muscle, nerve, duodenum, small intestine or pancreatic islet cells; graft-versus-host disease caused by bone marrow transplantation; rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, allergic encephalomyelitis and glomerulonephritis.

[0811] Embodiment I-72. A method of treating an age-related condition, comprising administering to a subject a therapeutically effective amount of one or more compounds of any one of Embodiments I-1 to I-60 or a pharmaceutically acceptable salt thereof.

[0812] Embodiment 1-73. A method as described in embodiment 1-72, wherein the age-related condition is selected from sarcopenia, skin atrophy, muscle wasting, brain atrophy, atherosclerosis, arteriosclerosis, emphysema, osteoporosis, osteoarthritis, hypertension, erectile dysfunction, dementia, Huntington's disease, Alzheimer's disease, cataracts, age-related macular degeneration, prostate cancer, stroke, shortened life expectancy, impaired kidney function, and age-related hearing loss, age-related disability (e.g., frailty), cognitive decline, age-related dementia, memory impairment, tendon stiffness, cardiac dysfunction (such as cardiac hypertrophy and systolic and diastolic dysfunction), immunosenescence, cancer, obesity and diabetes.

[0813] Embodiment I-74. A compound according to any one of Embodiments I-1 to I-60, or a pharmaceutically acceptable salt thereof, for use in treating, preventing or reducing the risk of a disease or condition mediated by mTOR.

[0814] Embodiment I-75. Use of a compound according to any one of Embodiments I-1 to I-60 or a pharmaceutically acceptable salt thereof for preparing a medicament for treating, preventing or reducing the risk of a disease or condition mediated by mTOR.

[0815] Embodiment I-76. A compound according to any one of Embodiments I-1 to I-60 or a pharmaceutically acceptable salt thereof for use in treating cancer.

[0816] Embodiment I-77. Use of a compound according to any one of Embodiments I-1 to I-60 or a pharmaceutically acceptable salt thereof for preparing a medicament for treating cancer.

[0817] Embodiment i-78. A compound according to any one of embodiments I-1 to I-60 or a pharmaceutically acceptable salt thereof for use in treating an immune-mediated disease.

[0818] Embodiment i-79. Use of a compound according to any one of Embodiments I-1 to I-60 or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of an immune-mediated disease.

[0819] Embodiment I-80. A compound according to any one of Embodiments I-1 to I-60 or a pharmaceutically acceptable salt thereof for use in treating an age-related condition.

[0820] Embodiment I-81. Use of a compound according to any one of Embodiments I-1 to I-60 or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating an age-related condition.

[0821] Some embodiments of the present invention are the following Embodiment II:

[0822] Embodiment II-1. A compound of formula Ic:

[0823]

[0824] or a pharmaceutically acceptable salt or tautomer thereof, wherein:

[0825] R 32 -H, =O, -OR 3 、-N 3 or -OC(=Z 1 )-R 32a ;

[0826] R 28 -H, (C 1 -C 6 )alkyl or -C(=Z 1 )-R 28a ;

[0827] R 40 is -H or -C(=Z 1 )-R 40a ;

[0828] When R 28 and R 40 When H, R 32 Not = O;

[0829] Z 1 Each independently is O or S;

[0830] R 28a , R 32a and R 40a Independently -A 1 -L 1 -A 2 -B, -A 1 -A2 -B, -L 2 -A 1 -L 1 -A 2 -L 3 -B、-O-(C 1 -C 6 )alkyl, or -O-(C 6 -C 10 )aryl; wherein -O-(C 6 -C 10 ) the aryl group is unsubstituted or selected from -NO 2 and 1 to 5 substituents of halogen;

[0831] A 1 and A 2 is independently absent or independently selected from

[0832]

[0833] As shown, A 1 The left bond is bound to -C(=Z 1 )- or L 2 ; and among them, as depicted, A 2 The right side of the key is connected to B or L 3 ;

[0834] Q is each independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0835] X is each independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0836] X 1 each independently is a heteroarylene or heterocyclylene ring;

[0837] W is each independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0838] W 1 each independently is a heteroarylene or heterocyclylene ring;

[0839] G is each independently absent or a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0840] G 1 and G 2 each independently is a heteroarylene or heterocyclylene ring;

[0841] L 1 Each independently selected from

[0842]

[0843] L 2 and L 3 is independently absent or independently selected from

[0844]

[0845] B are each independently selected from

[0846]

[0847] B 1 Each independently selected from NR 3 -(C(R 3 ) 2 ) n -、 NR 3 -(C(R 3 ) 2 ) n -(C 6 -C 10 )arylene-(C(R 3 ) 2 ) n -、 NR 3 -(C(R 3 ) 2 ) n -heteroarylene-, NR 3 -(C(R 3 ) 2 ) n -heteroarylene-(C(R 3 ) 2 ) n -、 (C 6 -C 10 ) arylene-, NR 3 -(C(R 3 ) 2 ) n -NR 3 C(O)-, NR 3 -(C(R 3 ) 2 ) n -heteroarylene-heterocyclylene-(C 6 -C 10 ) arylene-, Heteroarylene-heterocyclylene-(C 6 -C 10) arylene-,

[0848]

[0849] NR 3 -(C(R 3 ) 2 ) n -S(O) 2 -Arylene-C(O)- and NR 3 -(C(R 3 ) 2 ) n -S(O) 2 -arylene-(C(R 3 ) 2 ) n -, where as depicted, B 1 Left Bond to A 2 , L 3 or L 1 ; and wherein the heteroarylene, heterocyclylene and arylene are each independently optionally substituted with alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen or hydroxy;

[0850] R 3 Each independently is H or (C 1 -C 6 )alkyl;

[0851] R 4 Each independently is H, (C 1 -C 6 )alkyl, halogen, 5- to 12-membered heteroaryl, 5- to 12-membered heterocyclyl, (C 6 -C 10 ) aryl, wherein the heteroaryl, heterocyclyl and aryl are optionally substituted by -N(R 3 ) 2 、-OR 3 , halogen, (C 1 -C 6 )alkyl, -(C 1 -C 6 )alkylene-heteroaryl, -(C 1 -C 6 )alkylene-CN, -C(O)NR 3 -heteroaryl or -C(O)NR 3 - Heterocyclyl substitution;

[0852] R 5 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR3 or -N(R 3 ) 2 , where (C 1 -C 6 )alkyl, wherein the alkyl group is optionally substituted with -N(R 3 ) 2 OR 3 replace;

[0853] R 6 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 , where (C 1 -C 6 )alkyl, wherein the alkyl group is optionally substituted with -N(R 3 ) 2 OR 3 replace;

[0854] R 7 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 , where (C 1 -C 6 )alkyl, wherein the alkyl group is optionally substituted with -N(R 3 ) 2 OR 3 replace;

[0855] R 8 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 , where (C 1 -C 6 )alkyl, wherein the alkyl group is optionally substituted with -N(R 3 ) 2 OR 3 replace;

[0856] Y is each independently C(R 3 ) 2 or key;

[0857] n is each independently an integer from 1 to 12;

[0858] o are each independently an integer from 0 to 30;

[0859] p is each independently an integer from 0 to 12;

[0860] q is each independently an integer from 0 to 30; and

[0861] r is an integer of 1 to 6 each independently.

[0862] Embodiment II-1A. A compound of formula Ia:

[0863]

[0864] or a pharmaceutically acceptable salt or tautomer thereof, wherein:

[0865] R 32 -H, =O, -OR 3 、-N 3 or -OC(=Z 1 )-R 32a ;

[0866] R 28 -H, (C 1 -C 6 )alkyl or -C(=Z 1 )-R 28a ;

[0867] R 40 is -H or -C(=Z 1 )-R 40a ;

[0868] When R 28 and R 40 When H, R 32 Not = O;

[0869] Z 1 Each independently is O or S;

[0870] R 28a , R 32a and R 40a Independently -A 1 -L 1 -A 2 -B, -A 1 -A 2 -B, -L 2 -A 1 -L 1 -A 2 -L 3 -B、-O-(C 1 -C 6 )alkyl, or -O-(C 6 -C 10 )aryl; wherein -O-(C 6 -C10 ) the aryl group is unsubstituted or selected from -NO 2 and 1 to 5 substituents of halogen;

[0871] A 1 and A 2 is independently absent or independently selected from

[0872]

[0873] As shown, A 1 The left bond is bound to -C(=Z 1 )- or L 2 ; and among them, as depicted, A 2 The right side of the key is connected to B or L 3 ;

[0874] Q is each independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0875] X is each independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0876] X 1 each independently is a heteroarylene or heterocyclylene ring;

[0877] W is each independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0878] W 1 each independently is a heteroarylene or heterocyclylene ring;

[0879] G is each independently absent or a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene;

[0880] G 1 and G 2 each independently is a heteroarylene or heterocyclylene ring;

[0881] L 1 Each independently selected from

[0882]

[0883] L 2 and L 3 is independently absent or independently selected from

[0884]

[0885] B are each independently selected from

[0886]

[0887] B 1 Selected from NR 3 -(C(R 3 ) 2 ) n -、 NR 3 -(C(R 3 ) 2 ) n -(C 6 -C 10 )arylene-(C(R 3 ) 2 ) n -、 NR 3 -(C(R 3 ) 2 ) n -heteroarylene-, (C 6 -C 10 ) arylene-, NR 3 -(C(R 3 ) 2 ) n -NR 3 C(O)-, NR 3 -(C(R 3 ) 2 ) n -heteroarylene-heterocyclylene-(C 6 -C 10 ) arylene-, Heteroarylene-heterocyclylene-(C 6 -C 10 ) arylene-, and NR 3 -(C(R 3 ) 2 ) n -S(O) 2 -arylene-C(O)-, wherein as shown, B 1 Left Bond to A 2 , L 3 or L 1 ; and wherein the heteroarylene, heterocyclylene and arylene are optionally substituted with alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen or hydroxy;

[0890] R 3Each independently is H or (C 1 -C 6 )alkyl;

[0891] R 4 Each independently is H, (C 1 -C 6 )alkyl, halogen, 5- to 12-membered heteroaryl, 5- to 12-membered heterocyclyl, (C 6 -C 10 ) aryl, wherein the heteroaryl, heterocyclyl and aryl are optionally substituted by -N(R 3 ) 2 、-OR 3 , halogen, (C 1 -C 6 )alkyl, -(C 1 -C 6 )alkylene-heteroaryl, -(C 1 -C 6 )alkylene-CN, -C(O)NR 3 -heteroaryl or -C(O)NR 3 - Heterocyclyl substitution;

[0892] R 5 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 , where (C 1 -C 6 )alkyl, wherein the alkyl group is optionally substituted with -N(R 3 ) 2 OR 3 replace;

[0893] R 6 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 , where (C 1 -C 6 )alkyl, wherein the alkyl group is optionally substituted with -N(R 3 ) 2 OR 3 replace;

[0894] R 7 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 )2 , where (C 1 -C 6 )alkyl, wherein the alkyl group is optionally substituted with -N(R 3 ) 2 OR 3 replace;

[0895] R 8 Each independently is H, (C 1 -C 6 )alkyl, -C(O)OR 3 or -N(R 3 ) 2 , where (C 1 -C 6 )alkyl, wherein the alkyl group is optionally substituted with -N(R 3 ) 2 OR 3 replace;

[0896] Y is each independently C(R 3 ) 2 or key;

[0897] n is each independently an integer from 1 to 12;

[0898] o are each independently an integer from 0 to 30;

[0899] p is each independently an integer from 0 to 12;

[0900] q is each independently an integer from 0 to 30; and

[0901] r is an integer of 1 to 6 each independently.

[0902] Embodiment II-2. A compound according to Embodiment II-1, wherein R 32 is =O.

[0903] Embodiment II-3. A compound according to Embodiment II-1, wherein R 32 For-OR 3 .

[0904] Embodiment II-4. A compound according to any one of Embodiments II-1 to II-3, or a pharmaceutically acceptable salt or tautomer thereof, wherein the compound is represented by the structure of formula (I-40b):

[0905]

[0906] Where R 40 =Z 1 )-R 40a .

[0907] Embodiment II-5. A compound according to Embodiment II-4, wherein Z 1 is O.

[0908] Embodiment II-6. A compound according to Embodiment II-4, wherein Z 1 For S.

[0909] Embodiment II-7. A compound according to any one of Embodiments II-4 to II-6, wherein R 40a For-A 1 -L 1 -A 2 -B, where A 1 and A 2 Does not exist.

[0910] Embodiment II-8. A compound according to any one of Embodiments II-4 to II-6, wherein R 40a For-A 1 -L 1 -A 2 -B, where A 2 Does not exist.

[0911] Embodiment II-9. A compound according to any one of Embodiments II-4 to II-6, wherein R 40a For-A 1 -L 1 -A 2 -B, where A 1 Does not exist.

[0912] Embodiment II-10. A compound according to any one of Embodiments II-4 to II-6, wherein R 40a For-A 1 -L 1 -A 2 -B.

[0913] Embodiment II-11. A compound according to any one of Embodiments II-4 to II-6, wherein R 40a For-A 1 -A 2 -B.

[0914] Embodiment II-12. A compound according to any one of Embodiments II-4 to II-6, wherein R 40a For -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2 and A 1 Does not exist.

[0915] Embodiment II-13. A compound according to any one of Embodiments II-4 to II-6, wherein R 40a For -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2 Does not exist.

[0916] Embodiment II-14. A compound according to any one of Embodiments II-4 to II-6, wherein R 40a For -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 3 Does not exist.

[0917] Embodiment II-15. A compound according to any one of Embodiments I1-4 to II-6, wherein R 40a -O-(C 1 -C 6 )alkyl or -O-(C 6 -C 10 )aryl; wherein -O-(C 6 -C 10 ) the aryl group is unsubstituted or selected from -NO 2 and 1 to 5 substituents of halogen.

[0918] Embodiment II-16. A compound according to any one of Embodiments II-1 to II-3, or a pharmaceutically acceptable salt or tautomer thereof, wherein the compound is represented by the structure of formula (I-28b):

[0919]

[0920] Where R 28 =Z 1 )-R 28a .

[0921] Embodiment II-17. A compound according to Embodiment II-16, wherein Z 1 is O.

[0922] Embodiment II-18. A compound according to Embodiment II-16, wherein Z 1 For S.

[0923] Embodiment II-19. A compound according to any one of Embodiments II-16 to II-18, wherein R 28a For-A1 -L 1 -A 2 -B, where A 1 and A 2 Does not exist.

[0924] Embodiment II-20. A compound according to any one of Embodiments II-16 to II-18, wherein R 28a For-A 1 -L 1 -A 2 -B, where A 2 Does not exist.

[0925] Embodiment II-21. A compound according to any one of Embodiments II-16 to II-18, wherein R 28a For-A 1 -L 1 -A 2 -B, where A 1 Does not exist.

[0926] Embodiment II-22. A compound according to any one of Embodiments II-16 to II-18, wherein R 28a For-A 1 -L 1 -A 2 -B.

[0927] Embodiment II-23. A compound according to any one of Embodiments II-16 to II-18, wherein R 28a For-A 1 -A 2 -B.

[0928] Embodiment II-24. A compound according to any one of Embodiments II-16 to II-18, wherein R 28a For -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2 and A 1 Does not exist.

[0929] Embodiment II-25. A compound according to any one of Embodiments II-16 to II-18, wherein R 28a For -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2 Does not exist.

[0930] Embodiment II-26. A compound according to any one of Embodiments II-16 to II-18, wherein R 28a For -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 3 Does not exist.

[0931] Embodiment ii-27. A compound according to any one of embodiments II-16 to II-18, wherein R 28a -O-(C 1 -C 6 )alkyl or -O-(C 6 -C 10 )aryl; wherein -O-(C 6 -C 10 ) the aryl group is unsubstituted or selected from -NO 2 and 1 to 5 substituents of halogen.

[0932] Embodiment II-28. A compound according to Embodiment II-1 or a pharmaceutically acceptable salt or tautomer thereof, wherein the compound is represented by the structure of formula (I-32b):

[0933]

[0934] Where R 32 =-OC(=Z 1 )-R 32a .

[0935] Embodiment ii-29. A compound according to embodiment II-28, wherein Z 1 is O.

[0936] Embodiment II-30. A compound according to Embodiment II-28, wherein Z 1 For S.

[0937] Embodiment II-31. A compound according to any one of Embodiments II-28 to II-30, wherein R 32a For-A 1 -L 1 -A 2 -B, where A 1 and A 2 Does not exist.

[0938] Embodiment II-32. A compound according to any one of Embodiments II-28 to II-30, wherein R 32a For-A 1 -L1 -A 2 -B, where A 2 Does not exist.

[0939] Embodiment II-33. A compound according to any one of Embodiments II-28 to II-30, wherein R 32a For-A 1 -L 1 -A 2 -B, where A 1 Does not exist.

[0940] Embodiment II-34. A compound according to any one of Embodiments II-28 to II-30, wherein R 32a For-A 1 -L 1 -A 2 -B.

[0941] Embodiment II-35. A compound as in any one of Embodiments II-28 to II-30, wherein R 32a For-A 1 -A 2 -B.

[0942] Embodiment II-36. A compound according to any one of Embodiments II-28 to II-30, wherein R 32a For -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2 and A 1 Does not exist.

[0943] Embodiment II-37. A compound according to any one of Embodiments II-28 to II-30, wherein R 32a For -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2 Does not exist.

[0944] Embodiment II-38. A compound according to any one of Embodiments II-28 to II-30, wherein R 32a For -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 3 Does not exist.

[0945] Embodiment II-39. A compound according to any one of Embodiments II-28 to II-30, wherein R 32a -O-(C 1 -C 6 )alkyl or -O-(C 6 -C 10 )aryl; wherein -O-(C 6 -C 10 ) the aryl group is unsubstituted or selected from -NO 2 and 1 to 5 substituents of halogen.

[0946] Embodiment II-40. A compound according to any one of Embodiments II-1 to II-10, II-12 to II-22, II-24 to II-35 and II-36 to II-39, wherein L 1 for

[0947] Embodiment II-41. A compound according to any one of Embodiments II-1 to II-10, II-12 to II-22, II-24 to II-35 and II-36 to II-39, wherein L 1 for

[0948] Embodiment II-42. A compound according to any one of Embodiments II-1 to II-10, II-12 to II-22, 24 to 35 and 36 to 39, wherein L 1 for

[0949] Embodiment II-43. A compound according to any one of Embodiments II-1 to II-10, II-12 to II-22, II-24 to II-35 and II-36 to II-39, wherein L 1 for

[0950] Embodiment II-44. A compound as in any one of Embodiments II-1 to II-10, II-12 to II-22, II-24 to II-35 and II-36 to II-39, wherein L 1 for

[0951] Embodiment II-45. A compound according to any one of Embodiments II-1 to II-10, II-12 to II-22, II-24 to II-35 and II-36 to II-39, wherein L 1 for

[0952] Embodiment II-46. A compound according to any one of Embodiments II-1 to II-6, II-12 to II-18, II-24 to II-30 and II-36 to II-45, wherein L 2 for

[0953] Embodiment II-47. A compound according to any one of Embodiments II-1 to II-6, II-12 to II-18, II-24 to II-30 and II-36 to II-45, wherein L3 is

[0954] Embodiment II-48. A compound as in any one of Embodiments II-1 to II-7, II-9, II-12, II-16 to II-19, II-21, II-24, II-28 to II-31, II-33, II-36 and II-39 to II-45, wherein A 1 Does not exist.

[0955] Embodiment II-49. A compound as in any one of Embodiments II-1 to II-6, II-8, II-10 to II-11, II-13 to II-18, II-20, II-22 to II-23, II-25 to II-30, II-32, II-34 to II-35 and II-37 to II-45, wherein A 1 for

[0956] Embodiment II-50. A compound as in any one of Embodiments II-1 to II-6, II-8, II-10 to II-11, II-13 to II-18, II-20, II-22 to II-23, II-25 to II-30, II-32, II-34 to II-35 and II-37 to II-45, wherein A 1 for

[0957] Embodiment II-51. A compound as in any one of Embodiments II-1 to II-6, II-8, II-10 to II-11, II-13 to II-18, II-20, II-22 to II-23, II-25 to II-30, II-32, II-34 to II-35 and II-37 to II-45, wherein A 1 for

[0958] Embodiment II-52. A compound as in any one of Embodiments II-1 to II-6, II-8, II-10 to II-11, II-13 to II-18, II-20, II-22 to II-23, II-25 to II-30, II-32, II-34 to II-35 and II-37 to II-45, wherein A 1 for

[0959] Embodiment II-53. A compound as in any one of Embodiments II-1 to II-6, II-8, II-10 to II-11, II-13 to II-18, II-20, II-22 to II-23, II-25 to II-30, II-32, II-34 to II-35 and II-37 to II-45, wherein A 1 for

[0960] Embodiment II-54. A compound as in any one of Embodiments II-1 to II-6, II-8, II-10 to II-11, II-13 to II-18, II-20, II-22 to II-23, II-25 to II-30, II-32, II-34 to II-35 and II-37 to II-45, wherein A 1 for

[0961] Embodiment II-55. A compound as in any one of Embodiments II-1 to II-6, II-8, II-10 to II-11, II-13 to II-18, II-20, II-22 to II-23, II-25 to II-30, II-32, II-34 to II-35 and II-37 to II-45, wherein A 1 for

[0962] Embodiment II-56. A compound as in any one of Embodiments II-1 to II-6, II-8, II-10 to II-11, II-13 to II-18, II-20, II-22 to II-23, II-25 to II-30, II-32, II-34 to II-35 and II-37 to II-45, wherein A 1 for

[0963] Embodiment II-57. A compound according to any one of Embodiments II-1 to II-8, II-15 to II-20, II-27 to II-32 and II-39 to II-45, wherein A 2 Does not exist.

[0964] Embodiment II-58. A compound as in any one of Embodiments II-1 to II-6, II-9 to II-18, II-21 to II-30 and II-33 to II-45, wherein A 2 for

[0965] Embodiment II-59. A compound according to any one of Embodiments II-1 to II-6, II-9 to II-18, II-21 to II-30 and II-33 to II-45, wherein A 2 for

[0966] Embodiment II-60. A compound as in any one of Embodiments II-1 to II-6, II-9 to II-18, II-21 to II-30 and II-33 to II-45, wherein A 2 for

[0967] Embodiment II-61. A compound as in any one of Embodiments II-1 to II-6, II-9 to II-18, II-21 to II-30 and II-33 to II-45, wherein A 2 for

[0968] Embodiment II-62. A compound as in any one of Embodiments II-1 to II-6, II-9 to II-18, II-21 to II-30 and II-33 to II-45, wherein A 2 for

[0969] Embodiment II-63. A compound as in any one of Embodiments II-1 to II-6, II-9 to II-18, II-21 to II-30 and II-33 to II-45, wherein A 2 for

[0970] Embodiment II-64. A compound as in any one of Embodiments II-1 to II-6, II-9 to II-18, II-21 to II-30 and II-33 to II-45, wherein A 2 for

[0971] Embodiment II-65. A compound as in any one of Embodiments II-1 to II-6, II-9 to II-18, II-21 to II-30 and II-33 to II-45, wherein A 2 for

[0972] Embodiment II-66. A compound according to any one of Embodiments II-1 to II-65, wherein B is

[0973] Embodiment II-67. A compound according to any one of Embodiments II-1 to II-65, wherein B is

[0974] Embodiment II-68. A compound according to any one of Embodiments II-1 to II-65, wherein B1 is NR 3 -(C(R 3 ) 2 ) n -.

[0975] Embodiment II-69. A compound according to any one of Embodiments II-1 to II-65, wherein B 1 for

[0976] Embodiment II-70. A compound according to any one of Embodiments II-1 to II-69, wherein R 4 is optionally replaced by -N(R 3 ) 2 , OR 3 , halogen, (C 1 -C 6 )alkyl, -(C 1 -C 6 )alkylene-heteroaryl, -(C 1 -C 6 )alkylene-CN or -C(O)NR 3 -heteroaryl-substituted 5- to 12-membered heteroaryl.

[0977] Embodiment II-71. A compound according to any one of Embodiments II-1 to II-70, or a pharmaceutically acceptable salt or tautomer thereof, wherein the compound has the following formula:

[0978]

[0979] Embodiment II-72. A compound selected from:

[0980]

[0981]

[0982]

[0983]

[0984]

[0985]

[0986]

[0987]

[0988]

[0989]

[0990]

[0991]

[0992]

[0993]

[0994]

[0995]

[0996] or a pharmaceutically acceptable salt or tautomer thereof.

[0997] Embodiment II-73. A compound selected from:

[0998]

[0999]

[1000]

[1001]

[1002]

[1003]

[1004]

[1005]

[1006]

[1007]

[1008]

[1009]

[1010]

[1011]

[1012] or a pharmaceutically acceptable salt or tautomer thereof.

[1013] Embodiment II-74. A compound selected from:

[1014]

[1015]

[1016]

[1017]

[1018] or a pharmaceutically acceptable salt or tautomer thereof.

[1019] Embodiment II-75. A pharmaceutical composition comprising a compound according to any one of Embodiments II-1 to II-74 or a pharmaceutically acceptable salt thereof, and at least one of a pharmaceutically acceptable carrier, diluent or excipient.

[1020] Embodiment II-76. A method for treating a disease or condition mediated by mTOR, comprising administering to a subject suffering from or susceptible to a disease or condition mediated by mTOR a therapeutically effective amount of one or more compounds of any one of Embodiments II-1 to II-74, or a pharmaceutically acceptable salt thereof.

[1021] Embodiment I1-77. A method for preventing a disease or condition mediated by mTOR, comprising administering to a subject suffering from or susceptible to a disease or condition mediated by mTOR a therapeutically effective amount of one or more compounds of any one of Embodiments II-1 to II-74 or a pharmaceutically acceptable salt thereof.

[1022] Embodiment II-78. A method for reducing the risk of a disease or condition mediated by mTOR, comprising administering to a subject suffering from or susceptible to a disease or condition mediated by mTOR a therapeutically effective amount of one or more compounds of any one of Embodiments II-1 to II-74, or a pharmaceutically acceptable salt thereof.

[1023] Embodiment II-79. The method of any one of Embodiments II-76 to II-78, wherein the disease is cancer or an immune-mediated disease.

[1024] Embodiment II-80. A method as described in embodiment II-79, wherein the cancer is selected from brain and neurovascular tumors, head and neck cancer, breast cancer, lung cancer, mesothelioma, lymphoma, stomach cancer, kidney cancer, renal cancer, liver cancer, ovarian cancer, ovarian endometriosis, testicular cancer, gastrointestinal cancer, prostate cancer, glioblastoma, skin cancer, melanoma, neural cancer, spleen cancer, pancreatic cancer, blood proliferative disorders, lymphoma, leukemia, endometrial cancer, cervical cancer, vulvar cancer, prostate cancer, penile cancer, bone cancer, muscle cancer, soft tissue cancer, intestinal or rectal cancer, anal cancer, bladder cancer, bile duct cancer, eye cancer, gastrointestinal stromal tumors and neuro-endocrine tumors.

[1025] Embodiment II-81. A method as described in Embodiment II-79, wherein the immune-mediated disease is selected from resistance to transplanted heart, kidney, liver, bone marrow, skin, cornea, lung, pancreas, small intestine, limbs, muscle, nerve, duodenum, small intestine or pancreatic islet cells; graft-versus-host disease caused by bone marrow transplantation; rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, allergic encephalomyelitis and glomerulonephritis.

[1026] Embodiment II-82. A method of treating cancer, comprising administering to a subject a therapeutically effective amount of one or more compounds of any one of Embodiments II-1 to II-74 or a pharmaceutically acceptable salt thereof.

[1027] Embodiment II-83. A method as described in embodiment II-82, wherein the cancer is selected from brain and neurovascular tumors, head and neck cancer, breast cancer, lung cancer, mesothelioma, lymphoma, stomach cancer, kidney cancer, renal cancer, liver cancer, ovarian cancer, ovarian endometriosis, testicular cancer, gastrointestinal cancer, prostate cancer, glioblastoma, skin cancer, melanoma, neural cancer, spleen cancer, pancreatic cancer, blood proliferative disorders, lymphoma, leukemia, endometrial cancer, cervical cancer, vulvar cancer, prostate cancer, penile cancer, bone cancer, muscle cancer, soft tissue cancer, intestinal or rectal cancer, anal cancer, bladder cancer, bile duct cancer, eye cancer, gastrointestinal stromal tumors and neuro-endocrine tumors.

[1028] Embodiment II-84. A method of treating an immune-mediated disease, comprising administering to a subject a therapeutically effective amount of one or more compounds of any one of Embodiments II-1 to II-74 or a pharmaceutically acceptable salt thereof.

[1029] Embodiment II-85. A method as described in embodiment II-84, wherein the immune-mediated disease is selected from resistance to transplanted heart, kidney, liver, bone marrow, skin, cornea, lung, pancreas, small intestine, limbs, muscle, nerve, duodenum, small intestine or pancreatic islet cells; graft-versus-host disease caused by bone marrow transplantation; rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, allergic encephalomyelitis and glomerulonephritis.

[1030] Embodiment II-86. A method of treating an age-related condition, comprising administering to a subject a therapeutically effective amount of one or more compounds of any one of Embodiments II-1 to II-74 or a pharmaceutically acceptable salt thereof.

[1031] Embodiment II-87. A method as described in embodiment II-86, wherein the age-related condition is selected from sarcopenia, skin atrophy, muscle wasting, brain atrophy, atherosclerosis, arteriosclerosis, emphysema, osteoporosis, osteoarthritis, hypertension, erectile dysfunction, dementia, Huntington's disease, Alzheimer's disease, cataracts, age-related macular degeneration, prostate cancer, stroke, shortened life expectancy, impaired kidney function, and age-related hearing loss, age-related disability (e.g., frailty), cognitive decline, age-related dementia, memory impairment, tendon stiffness, cardiac dysfunction (such as cardiac hypertrophy and systolic and diastolic dysfunction), immunosenescence, cancer, obesity and diabetes.

[1032] Embodiment II-88. A compound according to any one of Embodiments II-1 to II-74, or a pharmaceutically acceptable salt thereof, for use in treating, preventing or reducing the risk of a disease or condition mediated by mTOR.

[1033] Embodiment II-89. Use of a compound according to any one of Embodiments II-1 to II-74 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating, preventing or reducing the risk of a disease or condition mediated by mTOR.

[1034] Embodiment II-90. A compound according to any one of claims 1-74 or a pharmaceutically acceptable salt thereof for use in the treatment of cancer.

[1035] Embodiment II-91. Use of a compound according to any one of Embodiments II-1 to II-74 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating cancer.

[1036] Embodiment II-92. A compound according to any one of Embodiments II-1 to II-74 or a pharmaceutically acceptable salt thereof for use in treating an immune-mediated disease.

[1037] Embodiment II-93. Use of a compound according to any one of Embodiments II-1 to II-74 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of an immune-mediated disease.

[1038] Embodiment II-94. A compound according to any one of Embodiments II-1 to II-74, or a pharmaceutically acceptable salt thereof, for use in treating an age-related condition.

[1039] Embodiment II-95. Use of a compound according to any one of Embodiments II-1 to II-74 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating an age-related condition.

[1040] Example

[1041] The present invention is further illustrated by the following examples and synthetic examples, which should not be construed as limiting the present invention to the specific procedures described herein in terms of scope or spirit. It should be understood that these examples are intended to illustrate certain embodiments and do not limit the scope of the present invention. It should be further understood that various other embodiments, modifications and their equivalents can be taken, which can indicate themselves to those skilled in the art without departing from the spirit of the present invention and / or the scope of the appended claims.

[1042] The definitions used in the following examples and elsewhere herein are:

[1043]

[1044]

[1045] Series 1 Bifunctional Rapaxoids

[1046] The general structure of the series 1 bifunctional rapalogs is shown in Scheme 1 below. For these types of bifunctional rapalogs, the linker may include variations where q = 0 to 30, such as q = 1 to 7, and r = 1 to 6. The linker amine may include substituents such as R = H and C1-C6 alkyl. The carbamate moiety (where Z 1 =O or S) can be in R 40 or R 28 (Formula I and II), including the variations found in Table 1 of the Examples section. The mTOR active site inhibitor can be linked to the linker via a primary or secondary amine, and can include the variations found in Table 2 of the Examples section.

[1047] Scheme 1. Series 1 bifunctional rapamycin analogs.

[1048]

[1049] Series 2 Bifunctional Rapa Analogs

[1050] The general structure of a series 2 bifunctional rapalog is shown below in Scheme 2. For these types of bifunctional rapalogs, the linker may include variations where q = 0 to 30, such as q = 1 to 7. The linker amine may include substituents such as R = H and C1-C6 alkyl. The pre-linker amine may include substituents such as R 2 =H, C1-C6 alkyl and cycloalkyl containing 4 to 8 ring members. Carbamate moiety (wherein Z 1 =O or S) can be in R 40 or R 28 (Formula I and II), including the variations found in Table 1 of the Examples section. The mTOR active site inhibitor can be linked to the linker via a primary or secondary amine, and can include the variations found in Table 2 of the Examples section.

[1051] Scheme 2. Series 2 bifunctional rapamycin analogs.

[1052]

[1053] Series 3 Bifunctional Rapa Analogs

[1054] The general structure of a series 3 bifunctional rapalog is shown in Scheme 3 below. For these types of bifunctional rapalogs, the linker may include variations where q = 0 to 30, such as q = 1 to 7. The linker amine may include substituents such as R = H and C1-C6 alkyl. The rear linker amine may include substituents such as R 2 =H, C1-C6 alkyl and cycloalkyl containing 4 to 8 ring members. Carbamate moiety (wherein Z 1 =O or S) can be in R 40 or R 28 (Formula I and II), including the variations found in Table 1 of the Examples section. The mmTOR active site inhibitor can be linked to the linker via a primary or secondary amine, and can include the variations found in Table 2 of the Examples section.

[1055] Scheme 3. Series 3 Bifunctional Rapaxoids

[1056]

[1057] Series 4 Bifunctional Rapa Analogs

[1058] The general structure of a series 4 bifunctional rapalog is shown in Scheme 4 below. For these types of bifunctional rapalogs, the linker may include variations where q = 0 to 30, such as q = 1 to 7. The linker amine may include substituents such as R = H and C1-C6 alkyl. The front linker amine and the rear linker amine may each include substituents such as R 2 =H, C1-C6 alkyl and cycloalkyl containing 4 to 8 ring members. Carbamate moiety (wherein Z 1 =O or S) can be in R 40 or R 28 (Formula I and II), including the variations found in Table 1 of the Examples section. The mmTOR active site inhibitor can be linked to the linker via a primary or secondary amine, and can include the variations found in Table 2 of the Examples section.

[1059] Scheme 4. Series 4 Bifunctional Rapaxone Analogs

[1060]

[1061] Series 5 Bifunctional Rapa Analogues

[1062] The general structure of a series 5 bifunctional rapalog is shown below in Scheme 5. For these types of bifunctional rapalogs, the front linker amine may contain a substituent such as R 2 =H, C1-C6 alkyl and cycloalkyl containing 4 to 8 ring members. Carbamate moiety (wherein Z 1 =O or S) can be in R 40 or R 28 (Formula I and II), including the variations found in Table 1 of the Examples section. The mTOR active site inhibitor can be linked to the linker via a primary or secondary amine, and can include the variations found in Table 2 of the Examples section.

[1063] Scheme 5. Series 5 Bifunctional Rapaxone Analogs

[1064]

[1065] Series 6 Bifunctional Rapa Analogs

[1066] The general structure of a series 6 bifunctional rapalog is shown in Scheme 6 below. For these types of bifunctional rapalogs, the linker may include variations where q = 0 to 30, such as q = 1 to 7. The linker amine may include substituents such as R = H and C1-C6 alkyl. The rear linker amine may include substituents such as R 2 =H, C1-C6 alkyl and cycloalkyl containing 4 to 8 ring members. Carbamate moiety (wherein Z 1 =O or S) can be in R 40 or R28 (Formula I and II), including the variations found in Table 1 of the Examples section. The mTOR active site inhibitor can be linked to the linker via a primary or secondary amine, and can include the variations found in Table 2 of the Examples section.

[1067] Scheme 6. Series 6 Bifunctional Rapa Analogs

[1068]

[1069] Series 7 Bifunctional Rapa Analogs

[1070] The general structure of a series 7 bifunctional rapalog is shown in Scheme 7 below. For these types of bifunctional rapalogs, the linker may include variations where q = 0 to 30, such as q = 1 to 7. The linker amine may include substituents such as R = H and C1-C6 alkyl. The front linker amine and the rear linker amine may each include substituents such as R 2 =H, C1-C6 alkyl and cycloalkyl containing 4 to 8 ring members. Carbamate moiety (wherein Z 1 =O or S) can be in R 40 or R 28 (Formula I and II), including the variations found in Table 1 of the Examples section. The mTOR active site inhibitor can be linked to the linker via a primary or secondary amine, and can include the variations found in Table 2 of the Examples section.

[1071] Scheme 7. Series 7 Bifunctional Rapaxone Analogs

[1072]

[1073] Series 8 Bifunctional Rapa Analogs

[1074] The general structure of a series 8 bifunctional rapalog is shown below in Scheme 8. For these types of bifunctional rapalogs, the linker may include variations where q = 0 to 30, such as q = 1 to 7. The linker amine may include substituents such as R = H and C1-C6 alkyl. The rear linker amine may include substituents such as R 2 =H, C1-C6 alkyl and cycloalkyl containing 4 to 8 ring members. Carbamate moiety (wherein Z 1 =O or S) can be in R 40 or R 28 (Formula I and II), including the variations found in Table 1 of the Examples section. The mTOR active site inhibitor can be linked to the linker via a primary or secondary amine, and can include the variations found in Table 2 of the Examples section.

[1075] Scheme 8. Series 8 Bifunctional Rapaxone Analogs

[1076]

[1077] Table 1. Carbonate- and thiocarbonate-containing rapamycin analog monomers.

[1078]

[1079]

[1080]

[1081] Table 2. Active site inhibitor monomers.

[1082]

[1083]

[1084]

[1085]

[1086]

[1087]

[1088] Table 3. Active site inhibitor monomers

[1089]

[1090]

[1091] Table 4. Amine containing front and back linkers.

[1092]

[1093]

[1094]

[1095]

[1096]

[1097]

[1098] Preparation of active site inhibitor monomers

[1099] Monomer A. 5-(4-amino-1-(4-(aminomethyl)benzyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine trifluoroacetate.

[1100]

[1101] Step 1: Synthesis of tert-butyl 4-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)benzylcarbamate

[1102] To a solution of 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (3.8 g, 14.56 mmol, 1.0 eq) in DMF (20 mL) at 0°C, NaH (582.27 mg, 14.56 mmol, 60 wt%, 1.0 eq) was added and the reaction solution was stirred at this temperature for 30 minutes, then tert-butyl 4-(bromomethyl)benzylcarbamate (4.59 g, 15.29 mmol, 1.05 eq) was added to the reaction at 0°C and the reaction solution was stirred at room temperature for 2 hours. The solution was poured into H 2 O (80 mL) and filter the precipitated solid. 2 O (2 x 10 mL) and then dried under reduced pressure to give tert-butyl 4-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)benzylcarbamate (5 g, 53% yield) as a yellow solid. LCMS (ESI) m / z: [M+Na] for C 18 H 21 IN 6 O 2 Calculated value: 503.07; measured value: 503.2.

[1103] Step 2: Synthesis of tert-butyl 4-((4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)benzylcarbamate

[1104] At room temperature, in N 2 In DME (100 mL) and H 2 tert-Butyl 4-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)benzylcarbamate (5 g, 7.68 mmol, 1.0 equiv), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol-2-amine (2.40 g, 9.22 mmol, 1.2 equiv) and Pd(PPh 3 ) 4 (887.66 mg, 768.16 μmol, 0.1 eq) was added to the biphasic suspension of Na 2 CO 3(1.91 g, 23.04 mmol, 3.0 equiv.). The mixture was stirred at 110 °C for 3 h. The reaction mixture was cooled to room temperature and filtered, and the filtrate was extracted with EtOAc (3 x 50 mL). The organic phases were combined and washed with brine (10 mL) and then purified by Na 2 SO 4 The mixture was dried, filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (0→20% MeOH / EtOAc) to give tert-butyl 4-((4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)benzylcarbamate (4.5 g, 82% yield) as a yellow solid. LCMS (ESI) m / z: [M+H] for C 25 H 26 N 8 O 3 Calculated value: 487.22; measured value: 487.2.

[1105] Step 3: Synthesis of 5-(4-amino-1-(4-(aminomethyl)benzyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine

[1106] To a solution of tert-butyl 4-((4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)benzylcarbamate (4.5 g, 6.29 mmol, 1.0 equiv) in DCM (50 mL) at 0° C. was added TFA (30.80 g, 270.12 mmol, 20 mL, 42.95 equiv). The reaction solution was stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure to give a residue, which was dissolved in 10 mL of MeCN and then poured into MTBE (100 mL). The precipitated solid was then filtered and the solid cake was dried under reduced pressure to give 5-[4-amino-1-[[4-(aminomethyl)phenyl]methyl]pyrazolo[3,4-d]pyrimidin-3-yl]-1,3-benzoxazol-2-amine (2.22 g, 71% yield, TFA) as a yellow solid. LCMS (ESI) m / z: [M+H] for C 20 H 18 N 8 O calculated value: 387.16; found value 387.1.

[1107] Monomer B. 2-(4-Amino-1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-6-ol trifluoroacetate.

[1108]

[1109] Step 1: Synthesis of tert-butyl N-(4-{4-amino-3-[6-(benzyloxy)-1H-indol-2-yl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}butyl)carbamate

[1110] To DMF (2.6 mL), EtOH (525 μL) and H 2 Pd(OAc) was added to a mixture of tert-butyl (4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)benzylcarbamate (300 mg, 694 μmol, 1.0 equiv) and (6-(benzyloxy)-1-(tert-butoxycarbonyl)-1H-indol-2-yl)boronic acid (763 mg, 2.08 mmol, 3.0 equiv) in 1% CO (350 μL). 2 (15.5 mg, 69 μmol, 0.1 eq), triphenylphosphine (36.1 mg, 138 μmol, 0.2 eq) and sodium carbonate (440 mg, 4.16 mmol, 6.0 eq). The reaction was heated at 80 °C for 20 h, cooled to room temperature and washed with H 2 O (10 mL) and EtOAc (10 mL) were quenched. The mixture was transferred to a separatory funnel and the aqueous phase was extracted with EtOAc (3 x 20 mL). The combined organic phases were washed with saturated aqueous NaCl (1 x 20 mL) and washed with Na 2 SO 4 Dry, filter and concentrate under reduced pressure. The crude material was purified by silica gel chromatography (20→85% EtOAc / heptane) to give the product as an orange solid (201 mg, 46% yield). LCMS (ESI) m / z: [M+H] for C 29 H 33 N 7 O 3 Calculated value: 528.27; measured value: 528.2.

[1111] Step 2: Synthesis of tert-butyl (4-(4-amino-3-(6-hydroxy-1H-indol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate

[1112] To a solution of tert-butyl N-(4-{4-amino-3-[6-(benzyloxy)-1H-indol-2-yl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}butyl)carbamate (1.0 equiv) in EtOH was added Pd / C (10 mol%). The reaction was stirred with H 2 purge and allow the reaction to proceed in HO 2Stir under atmosphere until starting material is consumed as determined by LCMS. The reaction is then diluted with EtOAc, filtered through celite, and concentrated under reduced pressure. The resulting residue is purified by silica gel chromatography to give the desired product.

[1113] Step 3: Synthesis of 2-(4-amino-1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-6-ol

[1114] To a solution of tert-butyl (4-(4-amino-3-(6-hydroxy-1H-indol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (1.0 equiv) in anhydrous DCM at 0°C was added TFA (50 equiv) dropwise. The reaction was stirred at 0°C and warmed to room temperature. Once the reaction was complete, as determined by LCMS, the reaction was concentrated under reduced pressure. The residue was triturated with MeCN and then dropped into MTBE over 10 min. The supernatant was removed and concentrated under N 2 The precipitate was collected by filtration at 40 °C to give 2-(4-amino-1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-6-ol.

[1115] Monomer C. 5-(4-amino-1-((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine trifluoroacetate.

[1116]

[1117] Step 1. Synthesis of tert-butyl 6-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[1118] To a suspension of 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (5 g, 19.16 mmol, 1.0 eq) in DMF (50.0 mL) at 4°C was added NaH (766.22 mg, 19.16 mmol, 60 wt%, 1.0 eq). The mixture was stirred at 4°C for 30 min. To the reaction mixture was added tert-butyl 6-(bromomethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (6.87 g, 21.07 mmol, 1.1 eq) in DMF (30 mL) at 4°C. The mixture was stirred at room temperature for 2 h. The mixture was then cooled to 4°C and H 2O (400 mL) and the mixture was stirred for 30 minutes. The resulting precipitate was collected by filtration to give crude tert-butyl 6-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (9.7 g, 76% yield) as a light yellow solid. The crude product was used directly in the next step.

[1119] Step 2: Synthesis of tert-butyl 6-((4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[1120] At room temperature, in N 2 Under DME (120.0 mL) and H 2 tert-Butyl 6-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (9.7 g, 14.63 mmol, 1.0 equiv), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol-2-amine (4.57 g, 17.55 mmol, 1.2 equiv) and NaOH in 4% CO (60 mL). 2 CO 3 Pd(PPh) (7.75 g, 73.14 mmol, 5.0 equiv) was added to the biphasic suspension 3 ) 4 (1.69 g, 1.46 mmol, 0.1 eq.). The mixture was stirred at 110 °C for 3 h. The reaction mixture was then cooled to room temperature and partitioned between EtOAc (100 mL) and H 2 O (100 mL). The aqueous layer was separated and extracted with EtOAc (2 x 60 mL). The organic layers were combined, washed with brine (80 mL) and purified by anhydrous Na 2 SO 4 The mixture was dried, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (1→100% EtOAc / petroleum ether, then 20→50% MeOH / EtOAc) to give tert-butyl 6-((4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (4.5 g, 58% yield) as a light yellow solid.

[1121] Step 3: Synthesis of 5-(4-amino-1-((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine

[1122] To neat TFA (32.5 mL, 438.97 mmol, 50.0 equiv) was added tert-butyl 6-((4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (4.5 g, 8.78 mmol, 1.0 equiv) at room temperature. The mixture was stirred for 30 min and then concentrated under reduced pressure. The oily residue was triturated with MeCN (8 mL) and then dropped into MTBE (350 mL) over 10 min. The supernatant was removed and then concentrated under N 2 The precipitate was collected by filtration at 40 °C to give 5-(4-amino-1-((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine (5.72 g, over 100% yield, TFA) as a light pink solid. LCMS (ESI) m / z: [M+H] for C 22 H 20 N 8 O calculated value: 413.18; found value 413.2.

[1123] Monomer D. 2-(4-amino-1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-7-ol trifluoroacetate.

[1124]

[1125] Step 1. Synthesis of tert-butyl 2-(4-amino-1-(4-((tert-butoxycarbonyl)amino)butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-7-methoxy-1H-indole-1-carboxylate

[1126] To DME and H 2 Pd(PPh) was added to a mixture of tert-butyl (4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (1.0 equiv) and (1-(tert-butyloxycarbonyl)-7-methoxy-1H-indol-2-yl)boronic acid (3.0 equiv) in water. 3 ) 4 (0.1 eq.) and sodium carbonate (6.0 eq.). The reaction was heated at 80 °C until complete, as determined by LCMS and TLC analysis. The reaction was then heated with H 2 The mixture was transferred to a separatory funnel and the aqueous phase was extracted with EtOAc. The organic phase was washed with saturated aqueous NaCl solution and then purified by Na 2 SO 4 Dry, filter and concentrate under reduced pressure.The desired product is isolated after chromatography on silica gel.

[1127] Step 2: Synthesis of tert-butyl 2-(4-amino-1-(4-((tert-butoxycarbonyl)amino)butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-7-hydroxy-1H-indole-1-carboxylate

[1128] To a solution of tert-butyl 2-(4-amino-1-(4-((tert-butoxycarbonyl)amino)butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-7-methoxy-1H-indole-1-carboxylate (1.0 equiv) in DCM at -10 °C was added BBr 3 (2.0 equiv.). The reaction was allowed to stir until the starting material was consumed as determined by LCMS. The reaction was stirred by slow addition of saturated NaHCO 3 The aqueous solution was quenched, transferred to a separatory funnel and the mixture was extracted with DCM. The organic phase was washed with saturated aqueous NaCl solution and then purified by Na 2 SO 4 Dry, filter and concentrate under reduced pressure.The desired product is isolated after chromatography on silica gel.

[1129] Step 3: Synthesis of 2-(4-amino-1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-7-ol

[1130] To a solution of tert-butyl 2-(4-amino-1-(4-((tert-butoxycarbonyl)amino)butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-7-hydroxy-1H-indole-1-carboxylate (1.0 equiv) in DCM at 0°C was added TFA dropwise. The reaction was stirred at 0°C and warmed to room temperature. Once the reaction was complete, as determined by LCMS, the reaction was concentrated under reduced pressure. The residue was triturated with MeCN and then dropped into MTBE over 10 min. The supernatant was removed and concentrated under N 2 The precipitate was collected by filtration at 40 °C to give 2-(4-amino-1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-7-ol.

[1131] Monomer E. 5-(4-amino-1-(piperidin-4-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine trifluoroacetate.

[1132]

[1133] Step 1: Synthesis of tert-butyl 4-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate

[1134] To a solution of 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (3 g, 11.49 mmol, 1.0 equiv) in DMA (30 mL) was added tert-butyl 4-(bromomethyl)piperidine-1-carboxylate (3.36 g, 12.07 mmol, 1.05 equiv) and K 2 CO 3 (4.77 g, 34.48 mmol, 3.0 equiv) and the reaction was then stirred at 80 °C for 3 hours. The reaction mixture was filtered to remove K 2 CO 3 The filtrate was poured into H 2 O (200 mL). The precipitated solid was then filtered to give tert-butyl 4-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate (3 g, 57% yield) as a light yellow solid. LCMS (ESI) m / z: [M+H] for C 16 H 23 IN 6 O 2 Calculated value: 459.10; measured value: 459.1.

[1135] Step 2: Synthesis of tert-butyl 4-((4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate

[1136] At room temperature, in N 2 In DME (60 mL) and H 2 tert-Butyl 4-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate (3 g, 6.55 mmol, 1.0 equiv) and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol-2-amine (2.04 g, 7.86 mmol, 1.2 equiv) and Na 2 CO 3 (3.47 g, 32.73 mmol, 5.0 equiv) was added to the two-phase suspension of Pd(PPh 3 ) 4 (756.43 mg, 654.60 μmol, 0.1 eq.). The mixture was stirred at 110 °C for 3 h and the two batches were combined. The reaction mixture was cooled and partitioned between EtOAc (500 mL) and H 2 O (500 mL). The aqueous layer was separated and extracted with EtOAc (3 x 300 mL). All organic layers were combined, washed with brine (20 mL), and dried over anhydrous Na 2 SO 4The mixture was dried, filtered and the filtrate was concentrated under reduced pressure to give tert-butyl 4-((4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate (4.5 g, 74% yield) as a yellow solid. LCMS (ESI) m / z: [M+H] for C 23 H 28 N 8 O 3 Calculated value: 465.24; measured value: 465.2.

[1137] Step 3: Synthesis of 5-(4-amino-1-(piperidin-4-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine

[1138] A solution of tert-butyl 4-((4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate (2.5 g, 5.38 mmol, 1.0 equiv) in TFA (25 mL) was stirred at room temperature for 30 minutes. The reaction solution was concentrated under reduced pressure to remove TFA. The residue was added to MTBE (400 mL), and the precipitated solid was then filtered to give 5-(4-amino-1-(piperidin-4-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine (2.7 g, over 100% yield, TFA) as a yellow solid. LCMS (ESI) m / z: [M+H] for C 18 H 20 N 8 O calculated value: 365.18; found value 365.1.

[1139] Monomer F. 2-(4-Amino-1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-ol trifluoroacetate.

[1140]

[1141] Step 1: Synthesis of tert-butyl (4-(4-amino-3-(5-((tert-butyldimethylsilyl)oxy)-1H-indol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate

[1142] At room temperature, in N 2 In dioxane (10.5 mL) and H 2To a solution of tert-butyl (4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (1.0 g, 2.31 mmol, 1.0 equiv) in 2% CO (3.5 mL) were added (1-(tert-butoxycarbonyl)-5-((tert-butyldimethylsilyl)oxy)-1H-indol-2-yl)boronic acid (1.54 g, 2.78 mmol, 1.2 equiv), K 3 PO 4 (1.47 g, 6.94 mmol, 3.0 equiv), Pd 2 (dba) 3 (211.84 mg, 231.34 μmol, 0.1 eq) and SPhos (189.95 mg, 462.69 μmol, 0.2 eq). The sealed tube was heated at 150 °C in a microwave for 20 min. This was repeated for 9 additional batches. The 10 batches were combined and the reaction mixture was cooled and partitioned between EtOAc (60 mL) and H 2 O (80 mL). The aqueous layer was separated and extracted with EtOAc (2 x 50 mL). The organic layers were combined, washed with brine (60 mL) and purified by anhydrous Na 2 SO 4 To the 4- (4-amino-3- (5- ((tert-butyldimethylsilyl) oxy) -1H- indol-2-yl) -1H- pyrazolo [3, 4-d] pyrimidin-1-yl) butyl) carbamate (10 g, 60% yield) in a pale yellow solid.

[1143] Step 2: Synthesis of tert-butyl (4-(4-amino-3-(5-hydroxy-1H-indol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate

[1144] At room temperature, in N 2 To a mixture of tert-butyl (4-(4-amino-3-(5-((tert-butyldimethylsilyl)oxy)-1H-indol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (10 g, 18.12 mmol, 1.0 equiv) in THF (100 mL) was added TBAF·3H in one portion. 2 O (1 M, 54.37 mL, 3.0 equiv). The mixture was stirred for 1 h, and then H 2 O (100 mL) was added to the reaction mixture. The layers were separated and the aqueous phase was extracted with EtOAc (2 x 80 mL). The combined organic phases were washed with brine (100 mL) and purified by anhydrous Na2 SO 4 The residue was purified by silica gel chromatography (1→67% EtOAc / petroleum ether) to give tert-butyl (4-(4-amino-3-(5-hydroxy-1H-indol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (7 g, 87% yield) as a light pink solid.

[1145] Step 3: Synthesis of 2-[4-amino-1-(4-aminobutyl)pyrazolo[3,4-d]pyrimidin-3-yl]-1H-indol-5-ol

[1146] To TFA (50.0 mL, 675.26 mmol, 38.9 equiv) at room temperature was added tert-butyl (4-(4-amino-3-(5-hydroxy-1H-indol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (7.6 g, 17.37 mmol, 1.0 equiv). The mixture was stirred for 40 minutes and then concentrated under reduced pressure. The oily residue was triturated with MeCN (20 mL) and then added dropwise to MTBE (300 mL) for 10 minutes. The supernatant was removed and then heated to 40 ℃ for 10 minutes. 2 The precipitate was collected by filtration at 40 °C to give 2-[4-amino-1-(4-aminobutyl)pyrazolo[3,4-d]pyrimidin-3-yl]-1H-indol-5-ol (7.79 g, 91% yield, TFA) as a light yellow solid. LCMS (ESI) m / z: [M+H] for C 17 H 19 N 7 O calculated value: 338.17; found value 338.2.

[1147] Monomer G. 5-(4-Amino-1-(azetidin-3-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine trifluoroacetate.

[1148]

[1149] Step 1: Synthesis of tert-butyl 3-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)azetidine-1-carboxylate

[1150] To a solution of 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (4 g, 15.32 mmol, 1.0 equiv), tert-butyl 3-(hydroxymethyl)azetidine-1-carboxylate (3.01 g, 16.09 mmol, 1.05 equiv) and PPh 3DIAD (4.47 mL, 22.99 mmol, 1.5 eq) was added dropwise to a solution of 1% paraformaldehyde (6.03 g, 22.99 mmol, 1.5 eq). After the addition was complete, the reaction was stirred at room temperature for 14 h. The reaction was poured into H 2 O (200 mL), and then extracted with EtOAc (3 x 50 mL). The organic layers were combined and washed with brine (2 x 50 mL). The organic phase was washed with Na 2 SO 4 The mixture was dried, filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (0→100% EtOAc / petroleum ether) to give tert-butyl 3-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)azetidine-1-carboxylate (4.2 g, 64% yield) as a white solid. LCMS (ESI) m / z: [M+H] for C 14 H 19 IN 6 O 2 Calculated value: 431.07; measured value: 431.0.

[1151] Step 2: Synthesis of tert-butyl 3-((4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)azetidine-1-carboxylate

[1152] At room temperature, in N 2 In DME (100 mL) and H 2 tert-Butyl 3-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)azetidine-1-carboxylate (4 g, 9.30 mmol, 1.0 equiv), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol-2-amine (2.90 g, 11.16 mmol, 1.2 equiv) and NaOH in 4% CO (50 mL). 2 CO 3 (4.93 g, 46.49 mmol, 5.0 equiv) was added to the two-phase suspension of Pd(PPh 3 ) 4 (1.07 g, 929.71 μmol, 0.1 eq.). The mixture was stirred at 110 °C for 3 h. The reaction mixture was then cooled to room temperature and filtered, and the filtrate was extracted with EtOAc (3 x 50 mL). The organic layers were combined and washed with brine (10 mL) and then purified by Na 2 SO 4The mixture was dried, filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (0→20% MeOH / EtOAc) to give tert-butyl 3-((4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)azetidine-1-carboxylate (3.5 g, 80% yield) as a yellow solid. LCMS (ESI) m / z: [M+H] for C 21 H 24 N 8 O 3 Calculated value: 437.20; measured value: 437.2.

[1153] Step 3: Synthesis of 5-(4-amino-1-(azetidin-3-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine

[1154] To a solution of tert-butyl 3-((4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)azetidine-1-carboxylate (3.29 g, 6.87 mmol, 1.0 equiv) in DCM (20 mL) at 0°C was added TFA (7.50 mL, 101.30 mmol, 14.7 equiv). The reaction was warmed to room temperature and stirred for 2 hours. The reaction solution was concentrated under reduced pressure to give a residue. The residue was dissolved in MeCN (6 mL) and then poured into MTBE (80 mL). The precipitated solid was filtered and the solid cake was dried under reduced pressure to give 5-[4-amino-1-(azetidin-3-ylmethyl)pyrazolo[3,4-d]pyrimidin-3-yl]-1,3-benzoxazol-2-amine (4.34 g, over 100% yield, TFA) as a yellow solid. LCMS (ESI) m / z: [M+H] for C 16 H 16 N 8 O calculated value: 337.15; found value 337.1.

[1155] Monomer H. 5-(4-amino-1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]-oxazol-2-amine trifluoroacetate.

[1156]

[1157] This monomer was synthesized following the procedure outlined in Nature 2015, 534, 272-276 (incorporated by reference in its entirety).

[1158] Monomer I. 5-(4-Amino-1-(pyrrolidin-3-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine trifluoroacetate.

[1159]

[1160] Step 1: Synthesis of tert-butyl 3-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidine-1-carboxylate

[1161] 3-Iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (4.5 g, 17.24 mmol, 1.0 equiv), tert-butyl 3-(bromomethyl)pyrrolidine-1-carboxylate (4.78 g, 18.10 mmol, 1.05 equiv) and K 2 CO 3 A suspension of (7.15 g, 51.72 mmol, 3.0 equiv) was heated to 85°C. The reaction was stirred at 85°C for 3 hours, at which time the solution was cooled to room temperature. 2 O (80 mL) was added to the reaction and a solid precipitated out. The mixture was filtered and the solid filter cake was washed with H 2 O (2 x 40 mL), and then dried under reduced pressure to give tert-butyl 3-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidine-1-carboxylate (6 g, 78% yield) as a yellow solid. LCMS (ESI) m / z: [M+H] for C 15 H 21 IN 6 O 2 Calculated value: 445.08; measured value: 445.1.

[1162] Step 2: Synthesis of tert-butyl 3-[[4-amino-3-(2-amino-1,3-benzoxazol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]pyrrolidine-1-carboxylate

[1163] At room temperature, in N 2 In DME (120 mL) and H 2 tert-Butyl 3-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidine-1-carboxylate (4 g, 9.00 mmol, 1.0 equiv), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol-2-amine (2.81 g, 10.80 mmol, 1.2 equiv) and Na 2 CO 3(4.77 g, 45.02 mmol, 5.0 equiv) was added to the two-phase suspension of Pd(PPh 3 ) 4 (1.04 g, 900.35 μmol, 0.1 eq.). The mixture was stirred at 110 °C for 3 h. The reaction mixture was cooled to room temperature and filtered and the filtrate was extracted with EtOAc (3 x 50 mL). The organic phases were combined and washed with brine (50 mL) and then purified by Na 2 SO 4 The mixture was dried, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (0→20% MeOH / EtOAc) to give tert-butyl 3-((4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidine-1-carboxylate (3 g, 64% yield) as a yellow solid. LCMS (ESI) m / z: [M+H] for C 22 H 26 N 8 O 3 Calculated value: 451.21, measured value 451.2.

[1164] Step 3: Synthesis of 5-(4-amino-1-(pyrrolidin-3-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine

[1165] To a solution of tert-butyl 3-((4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidine-1-carboxylate (3 g, 6.66 mmol, 1.0 equiv) in DCM (40 mL) at 0°C was added TFA (20 mL) dropwise. The reaction mixture was warmed to room temperature and stirred for 2 hours. The reaction solution was then concentrated under reduced pressure to give a residue. The residue was dissolved in MeCN (4 mL) and then poured into MTBE (100 mL), and a solid precipitated out. The solid was filtered and the filter cake was dried under reduced pressure to give 5-(4-amino-1-(pyrrolidin-3-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine (4.00 g, over 100% yield, TFA) as a yellow solid. LCMS (ESI) m / z: [M+H] for C 17 H 18 N 8 O calculated value: 351.17; found value 351.2.

[1166] Monomer J. 1-(4-Aminobutyl)-3-(7-methoxy-1H-indol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine trifluoroacetate.

[1167]

[1168] Step 1: Synthesis of tert-butyl 2-(4-amino-1-(4-((tert-butoxycarbonyl)amino)butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-7-methoxy-1H-indole-1-carboxylate

[1169] To DME and H 2 Pd(PPh) was added to a mixture of tert-butyl (4-(4-amino-3-indol-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (1.0 equiv) and (1-(tert-butoxycarbonyl)-7-methoxy-1H-indol-2-yl)boronic acid (3.0 equiv) in water. 3 ) 4 (0.1 eq.) and sodium carbonate (6.0 eq.). The reaction was heated at 80 °C until complete, as determined by LCMS and TLC analysis. The reaction was then heated with H 2 The mixture was transferred to a separatory funnel and the aqueous phase was extracted with EtOAc. The organic phase was washed with saturated aqueous NaCl solution and then purified by Na 2 SO 4 Dry, filter and concentrate under reduced pressure.The desired product is isolated after chromatography on silica gel.

[1170] Step 2: Synthesis of 1-(4-aminobutyl)-3-(7-methoxy-1H-indol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

[1171] To a solution of tert-butyl 2-(4-amino-1-(4-((tert-butoxycarbonyl)amino)butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-7-methoxy-1H-indole-1-carboxylate (1.0 equiv) in DCM at 0°C was added TFA dropwise. The reaction was stirred at 0°C and warmed to room temperature. Once the reaction was complete, as determined by LCMS, the reaction was concentrated under reduced pressure. The residue was triturated with MeCN and then dropped into MTBE over 10 min. The supernatant was removed and concentrated under N 2 The precipitate was collected by filtration at 40 °C to give 1-(4-aminobutyl)-3-(7-methoxy-1H-indol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine.

[1172] Monomer K. Synthesis of 1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine trifluoroacetate.

[1173]

[1174] Step 1: Synthesis of tert-butyl (4-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate

[1175] To a mixture of tert-butyl (4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (300 mg, 694 μmol, 1.0 equiv) in MeOH (14 mL) at 0°C was added zinc powder (226 mg, 3.46 mmol, 5.0 equiv). Saturated NH 4 Aqueous Cl (14 mL) was added to the reaction mixture and the reaction was warmed to room temperature and stirred for 18 h. The reaction was washed with EtOAc (40 mL) and H 2 O (10 mL) and the mixture was transferred to a separatory funnel. The aqueous phase was extracted with EtOAc (3 x 20 mL) and the combined organic phases were washed with saturated NaHCO 3 The mixture was washed with aqueous solution (15 mL) and then with Na 2 SO 4 Dry, filter, and concentrate under reduced pressure to give the product as a light yellow solid (210 mg, 99% yield), which was used without further purification. LCMS (ESI) m / z: [M+H] for C 14 H 22 N 6 O 2 Calculated value: 307.19; measured value: 307.1.

[1176] Step 2: Synthesis of 1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

[1177] To a solution of tert-butyl (4-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (210 mg, 691 μmol) in DCM (3.5 mL) at 0°C was added TFA (3.5 mL) dropwise. After 3 hours, the reaction was warmed to room temperature and concentrated under reduced pressure to give the trifluoroacetate salt of the product as a brown oil (220 mg, 99% yield), which was used without further purification. LCMS (ESI) m / z: [M+H] for C 9 H 14 N 6 Calculated value: 207.13; measured value: 207.1.

[1178] Monomer L. 1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-9-(quinolin-3-yl)-1H,2H-benzo[h]1,6-naphthyridin-2-one

[1179]

[1180] The preparation of this monomer has been previously reported in the literature. See the following references: i) Liu, Qingsong, Chang, Jae Won, Wang, Jinhua, Kang, Seong A., Thoreen, Carson C., Markhard, Andrew, Hur, Wooyoung, Zhang, Jianming, Sim, Taebo, Sabatini, David M. et al. from Journal of Medicinal Chemistry (2010), 53(19), 7146-7155. ii) Gray, Nathanael, Chang, Jae Won, Zhang, Jianming, Thoreen, Carson C., Kang, Seong Woo Anthony, Sabatini, David M., Liu, Qingsong from PCT Int. Appl. (2010), WO 2010044885A2, the entirety of which is incorporated by reference.

[1181] Monomer M. 5-(1-(4-aminobutyl)-4-(dimethylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine trifluoroacetate.

[1182]

[1183] Step 1: Synthesis of 3-iodo-1-trityl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

[1184] A suspension of 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (10.5 g, 40.23 mmol, 1.0 equiv) in DMF (170.0 mL) was treated with Cs 2 CO 3 (19.7 g, 60.34 mmol, 1.5 eq.) and [chloro(diphenyl)methyl]benzene (13.5 g, 48.27 mmol, 1.2 eq.). The reaction mixture was stirred at 70 °C for 4 h under a nitrogen atmosphere. The reaction mixture was added to H 2 O (1200 mL). Filter the precipitate and 2 The residue was purified by silica gel chromatography (0→60% EtOAc / petroleum ether) to give 3-iodo-1-trityl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (15.40 g, 73.5% yield) as a white solid.

[1185] Step 2: Synthesis of 3-iodo-N,N-dimethyl-1-trityl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

[1186] To a suspension of NaH (2.98 g, 74.50 mmol, 60 wt%, 2.5 eq) in DMF (150 mL) at 0°C was added a solution of 3-iodo-1-trityl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (15.0 g, 29.80 mmol, 1.0 eq) in DMF (50 mL). The mixture was stirred at 0°C for 10 minutes. Methyl iodide (16.92 g, 119.20 mmol, 7.42 mL, 4.0 eq) was then added to the reaction mixture at 0°C. The mixture was stirred at room temperature for 2 hours, at which time H was added at 0°C. 2 The mixture was stirred at 0 ° C for another 10 minutes. The resulting precipitate was collected by filtration to give a crude product, which was purified twice by silica gel chromatography (1% → 25% EtOAc / petroleum ether) to give 3-iodo-N, N-dimethyl-1-trityl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (9.0 g, 89% yield) as a white solid.

[1187] Step 3: Synthesis of 3-iodo-N,N-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

[1188] To a cooled solution of TFA (19.1 mL, 258.1 mmol, 15.0 equiv) in DCM (100.0 mL) at 4°C was added 3-iodo-N,N-dimethyl-1-trityl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (9.10 g, 17.12 mmol, 1.0 equiv). The mixture was stirred at room temperature for 1 hour. The residue was poured into H 2 O (100 mL) and the aqueous phase was extracted with DCM (2 x 50 mL). To the aqueous phase was then added saturated NaHCO 3 aqueous solution until the solution was pH 8. The resulting precipitate was collected by filtration to give 3-iodo-N,N-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (3.40 g, 68.7% yield) as a white solid.

[1189] Step 4: Synthesis of tert-butyl (4-(4-(dimethylamino)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate

[1190] To a suspension of 3-iodo-N,N-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.7 g, 5.88 mmol, 1.0 equiv) in DMF (20 mL) at 4°C was added NaH (247 mg, 6.17 mmol, 60 wt%, 1.05 equiv). The mixture was stirred at 4°C for 30 minutes. To the reaction mixture at 4°C was then added tert-butyl N-(4-bromobutyl)carbamate (2.22 g, 8.82 mmol, 1.81 mL, 1.5 equiv) in DMF (10 mL). The mixture was stirred at room temperature for 2 hours. To the mixture at 4°C was then added H 2 The mixture was stirred at 4 °C for another 30 minutes and the resulting precipitate was collected by filtration to give the crude product. The residue was purified by silica gel chromatography (0→75% EtOAc / petroleum ether) to give tert-butyl (4-(4-(dimethylamino)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (2.0 g, 56% yield) as a white solid.

[1191] Step 5: Synthesis of tert-butyl (4-(3-(2-aminobenzo[d]oxazol-5-yl)-4-(dimethylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate

[1192] At room temperature, in N 2 Under DME (80.0 mL) and H 2 tert-Butyl (4-(4-(dimethylamino)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (4.0 g, 8.69 mmol, 1.0 equiv), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol-2-amine (3.4 g, 13.03 mmol, 1.5 equiv) and Na 2 CO 3 Pd(PPh) (4.6 g, 43.45 mmol, 5.0 equiv) was added to the two-phase suspension 3 ) 4 (1.0 g, 868.98 μmol, 0.1 eq.). The mixture was stirred at 110 °C for 3 h. The reaction mixture was then cooled and partitioned between EtOAc (300 mL) and H 2 O (600 mL). The aqueous layer was separated and extracted with EtOAc (2 x 100 mL). The organic layers were combined, washed with brine (2 x 60 mL) and purified by anhydrous Na 2 SO 4The mixture was dried, filtered and concentrated under reduced pressure. The crude material was purified by silica gel chromatography (50% EtOAc / hexanes, followed by 20% MeOH / EtOAc). The desired fractions were combined and concentrated under reduced pressure to give tert-butyl (4-(3-(2-aminobenzo[d]oxazol-5-yl)-4-(dimethylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (3.2 g, 78.9% yield) as a light brown solid.

[1193] Step 6: Synthesis of 5-(1-(4-aminobutyl)-4-(dimethylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine

[1194] To TFA (20.82 mL, 281.27 mmol, 36.5 equiv) at room temperature was added tert-butyl (4-(3-(2-aminobenzo[d]oxazol-5-yl)-4-(dimethylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (3.6 g, 7.72 mmol, 1.0 equiv). The mixture was stirred for 30 min, at which time the mixture was concentrated under reduced pressure. The oily residue was triturated with MeCN (8 mL) and MTBE (60 mL) for 10 min. The supernatant was removed and then heated to 40 °C for 1 hr at RT. 2 The precipitate was collected by filtration at 40 °C to give 5-(1-(4-aminobutyl)-4-(dimethylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine (4.0 g, crude, TFA) as a light brown solid.

[1195] 5-(1-(4-aminobutyl)-4-(dimethylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine (3.5 g, crude, TFA) was added to 1 M NaOH (107.2 mL, 14.7 eq) at room temperature. The mixture was stirred for 10 minutes, and then the aqueous phase was extracted with DCM (3 x 50 mL). The combined organic phases were washed with brine (50 mL) and washed with anhydrous Na 2 SO 4 The mixture was dried, filtered and concentrated under reduced pressure. TFA (539.37 μL, 7.28 mmol, 1.0 equiv) was added and concentrated under reduced pressure. MeCN (10 mL) was then added, followed by MTBE (150 mL). The resulting precipitate was collected by filtration to give 5-(1-(4-aminobutyl)-4-(dimethylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine (1.3 g, 36.6% yield, TFA) as a light brown product. LCMS (ESI) m / z: [M+H] for C 18 H 22 N8 O calculated value: 367.19; found value 367.1.

[1196] Monomer N. 6-(4-amino-1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo-[d]isoxazol-3-amine trifluoroacetate.

[1197]

[1198] Step 1: Synthesis of tert-butyl (6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]isoxazol-3-yl)carbamate

[1199] To a solution of tert-butyl (6-bromobenzo[d]isoxazol-3-yl)carbamate (1.0 equiv) in dioxane was added Pd(PPh3) 4 (0.1 eq.), sodium carbonate (6.0 eq.), and bis(pinacolato)diboron (3.0 eq.). The reaction mixture was stirred and heated until complete as determined by LCMS and TLC analysis. The reaction was cooled to room temperature and heated with saturated NaHCO 3 The aqueous solution was quenched and the mixture was transferred to a separatory funnel. The aqueous phase was extracted with EtOAc and the organic phase was washed with saturated aqueous NaCl solution and then purified by Na 2 SO 4 Dry, filter and concentrate under reduced pressure.The desired product is isolated after purification by silica gel chromatography.

[1200] Step 2: Synthesis of tert-butyl (4-(4-amino-3-(3-((tert-butoxycarbonyl)amino)benzo[d]isoxazol-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate

[1201] To DME and H 2 Pd(PPh) was added to a mixture of tert-butyl (4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (1.0 equiv) and tert-butyl (6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]isoxazol-3-yl)carbamate (3.0 equiv) in water. 3 ) 4 (0.1 eq.) and sodium carbonate (6.0 eq.). The reaction was heated at 80 °C until complete, as determined by LCMS and TLC analysis. The reaction was then heated with H 2 The mixture was transferred to a separatory funnel and the aqueous phase was extracted with EtOAc. The organic phase was washed with saturated aqueous NaCl solution and then purified by Na 2 SO 4Dry, filter and concentrate under reduced pressure.The desired product is isolated after chromatography on silica gel.

[1202] Step 3: Synthesis of 6-(4-amino-1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo-[d]isoxazol-3-amine

[1203] To a solution of tert-butyl (4-(4-amino-3-(3-((tert-butoxycarbonyl)amino)benzo[d]isoxazol-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (1.0 equiv) in DCM at 0°C was added TFA dropwise. The reaction was stirred at 0°C and warmed to room temperature. Once the reaction was complete, as determined by LCMS, the reaction was concentrated under reduced pressure. The residue was triturated with MeCN and then added dropwise to MTBE over 10 min. The supernatant was removed and concentrated under N 2 The precipitate was collected by filtration at 40 °C to give 6-(4-amino-1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo-[d]isoxazol-3-amine.

[1204] Monomer O. 4-(5-(4-morpholino-1-(1-(pyridin-3-ylmethyl)piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-1H-indol-1-yl)butan-1-amine trifluoroacetate.

[1205]

[1206] The synthesis of this monomer was carried out by alkylating WAY-600 (CAS No. 1062159-35-6) with tert-butyl (4-bromobutyl)carbamate under basic conditions, followed by deprotection using TFA to produce a TFA salt.

[1207] References for the preparation of WAY-600: Discovery of Potent and Selective Inhibitors of the Mammalian Target Of Rapamycin (mTOR) Kinase: Nowak, P., Cole, DC, Brooijmans, N., Bursavich, MG, Curran, KJ, Ellingboe, JW, Gibbons, JJ, Hollander, I., Hu, Y., Kaplan, J., Malwitz, DJ, Toral-Barza, L., Verheijen, JC, Zask, A., Zhang, W.-G., Yu, K. 2009; Journal of Medicinal Chemistry Vol. 52, No. 22, 7081-89, the entire text of which is incorporated by reference.

[1208] Monomer P. 2-(4-(8-(6-(Aminomethyl)quinolin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropionitrile trifluoroacetate.

[1209]

[1210] The synthesis of this monomer is first performed by synthesizing the Suzuki reaction coupling partner (3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan)quinolin-6-yl)-N-boc-methylamine starting from methyl 3-bromoquinoline-6-carboxylate. Reduction of the methyl ester with lithium aluminum hydride followed by Mitsunobu reaction with phthalimide and hydrazine cleavage affords the benzylamine. Protection of the benzylamine with di-tert-butyl dicarbonate followed by Miyaura borylation affords (3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan)quinolin-6-yl)-N-boc-methylamine.

[1211] S-Hydrogenation of 2-(4-aminophenyl)-2-methylpropionitrile using 6-bromo-4-chloro-3-nitroquinoline N Ar reaction to give substituted amino-nitro-pyridines. Reduction of the nitro group using Raney nickel under a hydrogen atmosphere followed by cyclization using trichloromethyl chloroformate gives aryl-substituted ureas. Substitution of the free NH of the urea using methyl iodide mediated by tetrabutylammonium bromide and sodium hydroxide followed by Suzuki coupling of (3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan)quinolin-6-yl)-N-boc-methylamine and subsequent deprotection using TFABoc- gives the TFA salt.

[1212] Reference for the preparation of 2-[4-(8-bromo-3-methyl-2-oxo-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)phenyl]-2-methyl-propionitrile: Vannucchi, AM, Bogani, C., Bartalucci, N. 2016. JAK PI3K / mTOR combination therapy. US9358229. Novartis Pharma AG, Incyte Corporation, the entire text of which is incorporated by reference.

[1213] Monomer Q. 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1H,2H,3H-imidazo[4,5-c]quinolin-2-one

[1214]

[1215] This monomer is commercially available as a chemical called BGT226 (CAS No. 1245537-68-1). At the time of preparing this application, it was available as the free amine from several suppliers.

[1216] Monomer R. 3-(4-amino-1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(4,5-dihydrothiazol-2-yl)benzamide trifluoroacetate.

[1217]

[1218] Step 1: Synthesis of tert-butyl (4-(4-amino-3-(3-((4,5-dihydrothiazol-2-yl)carbamoyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate

[1219] To dioxane (19.1 mL), EtOH (3.8 mL) and H 2 Pd(PPh) was added to a solution of (3-((4,5-dihydrothiazol-2-yl)carbamoyl)phenyl)boronic acid (500 mg, 1.15 mmol, 1.0 equiv) and (tert-butyl (4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (575 mg, 2.30 mmol, 2.0 equiv) in 2% CO (2.3 mL). 3 ) 4(265 mg, 230 μmol, 0.2 eq) and sodium carbonate (730 mg, 6.89 mmol, 6.0 eq). The reaction mixture was sonicated until a clear yellow solution was formed, which was then heated at 80 °C for 14 h. The reaction was then diluted with saturated aqueous NaCl (30 mL) and the mixture was transferred to a separatory funnel. The aqueous phase was extracted with DCM (3 x 25 mL). The combined organic phases were washed with Na 2 SO 4 Dry, filter and concentrate under reduced pressure. The desired product is isolated as a yellow solid (324 mg, 53% yield) after silica gel chromatography (0→15% MeOH / DCM). LCMS (ESI) m / z: [M+H] for C 24 H 30 N 8 O 3 S calculated value: 511.22; measured value: 511.2.

[1220] Step 2: Synthesis of 3-(4-amino-1-(4-aminobutyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(4,5-dihydrothiazol-2-yl)benzamide

[1221] To a solution of tert-butyl (4-(4-amino-3-(3-((4,5-dihydrothiazol-2-yl)carbamoyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (324 mg, 614 μmol) in DCM (4.1 mL) at 0°C was added TFA (1.5 mL) dropwise. After 1 hour, the reaction was warmed to room temperature and concentrated under reduced pressure to give the trifluoroacetate salt of the product as a yellow solid (320 mg, 99% yield). It was used without further purification. LCMS (ESI) m / z: [M+H] for C 1 9H 22 N 8 OS calculated value: 411.16; measured value: 411.1

[1222] Monomer S. 2-(5-(4-morpholino-1-(1-(pyridin-3-ylmethyl)piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-1H-indol-3-yl)ethan-1-amine.

[1223]

[1224] The synthesis of this monomer is carried out by condensation of 2,4,6-trichloropyrimidine-5-carboxaldehyde and 3-((4-hydrazinopiperidin-1-yl)methyl)pyridine hydrochloride. The product is reacted with morpholine and then with a boric acid ester Suzuki reaction to obtain a Boc-protected amine. Finally, the protecting group is removed using TFA to obtain the monomer. This synthetic route closely follows the preparation of highly related structures reported in the following references: i) Nowak, Pawel, Cole, Derek C., Brooijmans, Natasja, Curran, Kevin J., Ellingboe, John W., Gibbons, James J., Hollander, Irwin, Hu, Yong Bo, Kaplan, Joshua, Malwitz, David J. et al. from Journal of Medicinal Chemistry (2009), 52(22), 7081-7089. ii) Zask, Arie, Nowak, Pawel Wojciech, Verheij en, Jeroen, Curran, Kevin J., Kaplan, Joshua, Malwitz, David, Bursavich, Matthew Gregory, Cole, Derek Cecil, Ayral-Kaloustian, Semiramis, Yu, Ker et al. from PCT Int. Appl. (2008), WO 2008115974 A220080925, the entirety of which is incorporated by reference.

[1225] Monomer T. 1-(4-Aminobutyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine trifluoroacetate.

[1226]

[1227] To a mixture of tert-butyl (4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)carbamate (496 mg, 1.14 mmol, 1.0 equiv) in DCM (5.7 mL) at 0°C was added TFA (1.5 mL) dropwise. The reaction was allowed to stir at 0°C for 1 hour, at which time the reaction was concentrated under reduced pressure to give a yellow solid (505 mg, 99% yield) which was used without further purification. LCMS (ESI) m / z: [M+H] for C 9 H 13 IN 6 Calculated value: 333.02; measured value: 332.9.

[1228] Monomer U. 5-(4-amino-1-(4-(methylamino)butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine trifluoroacetate.

[1229]

[1230] Step 1: Synthesis of tert-butyl (4-hydroxybutyl)(methyl)carbamate

[1231] To a solution of 4-(methylamino)butan-1-ol (0.5 g, 4.85 mmol, 104.2 mL, 1.0 equiv) in DCM (10 mL) at room temperature was added Boc 2 The mixture was stirred at room temperature for 3 hours, and then the mixture was concentrated under reduced pressure at 30 ° C. The residue was purified by silica gel chromatography (100 / 1 to 3 / 1 petroleum ether / EtOAc) to give tert-butyl (4-hydroxybutyl)(methyl)carbamate (0.9 g, 91.4% yield) as a colorless oil.

[1232] Step 2: Synthesis of tert-butyl (4-bromobutyl)(methyl)carbamate

[1233] To a solution of tert-butyl (4-hydroxybutyl)(methyl)carbamate (0.9 g, 4.43 mmol, 1.0 equiv) in THF (20 mL) at room temperature was added PPh 3 (2.21 g, 8.41 mmol, 1.9 equiv) and CBr 4 (2.79 g, 8.41 mmol, 1.9 equiv). The mixture was stirred for 1 hour, and then the reaction mixture was filtered and concentrated. The residue was purified by silica gel chromatography (1 / 0 to 4 / 1 petroleum ether / EtOAc) to give tert-butyl (4-bromobutyl)(methyl)carbamate (1.1 g, 93.3% yield) as a colorless oil.

[1234] Step 3: Synthesis of tert-butyl (4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)(methyl)carbamate

[1235] To a suspension of 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (0.9 g, 3.45 mmol, 1.0 eq) in DMF (10 mL) at 4° C. was added NaH (137.92 mg, 3.45 mmol, 60 wt %, 1.0 eq). The mixture was stirred at 4° C. for 30 min, and then a solution of tert-butyl (4-bromobutyl)(methyl)carbamate (1.01 g, 3.79 mmol, 25.92 mL, 1.1 eq) in DMF (3 mL) was added. The mixture was stirred at room temperature for 3 h, at which time H 2 The aqueous phase was extracted with EtOAc (3 x 30 mL) and the combined organic phases were washed with brine (20 mL) and dried over anhydrous Na 2 SO 4 The residue was purified by silica gel chromatography (1 / 0 to 0 / 1 petroleum ether / EtOAc) to give tert-butyl (4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)(methyl)carbamate (1.2 g, 78% yield) as a white solid. LCMS (ESI) m / z: [M+H] for C 15 H 23 IN 6 O 2 Calculated value: 447.10; measured value: 447.1.

[1236] Step 4: Synthesis of tert-butyl (4-(4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)(methyl)carbamate

[1237] In N 2 At room temperature, DME (20 mL) and H 2 tert-Butyl (4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)(methyl)carbamate (1.2 g, 2.69 mmol, 1.0 equiv), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol-2-amine (1.19 g, 3.23 mmol, 1.2 equiv) and Na 2 CO 3 (1.42 g, 13.44 mmol, 5.0 equiv) was added to the biphasic suspension of Pd(PPh 3 ) 4 (310.71 mg, 268.89 μmol, 0.1 eq.). The mixture was stirred at 110° C. for 3 h, and then the reaction mixture was cooled and partitioned between EtOAc (20 mL) and H 2O (15 mL). The aqueous layer was separated and extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (2 x 20 mL) and washed with anhydrous Na 2 SO 4 The crude product was purified by silica gel chromatography (1 / 0 to 4 / 1 EtOAc / MeOH) to give tert-butyl (4-(4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)(methyl)carbamate (0.78 g, 62.5% yield) as an orange solid.

[1238] Step 5: Synthesis of 5-(4-amino-1-(4-(methylamino)butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine

[1239] A solution of tert-butyl (4-(4-amino-3-(2-aminobenzo[d]oxazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butyl)(methyl)carbamate (0.78 g, 1.72 mmol, 1.0 equiv) in TFA (5 mL) was stirred at room temperature for 30 min. The solution was concentrated under reduced pressure and the oily residue was triturated with MeCN (1 mL) and then added to MTBE (100 mL). The supernatant was removed and then heated to 40 °C for 1 h under N 2 The precipitate was collected by filtration at 40 °C to give 5-(4-amino-1-(4-(methylamino)butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine bistrifluorosulfonate (0.959 g, 93% yield) as an orange solid. LCMS (ESI) m / z: [M+H] for C 17 H 20 N 8 O calculated value: 353.18; found value 353.1.

[1240] Monomer V. 1-(4-(4-(5-(aminomethyl)pyrimidin-2-yl)piperazin-1-yl)-3-(trifluoromethyl)phenyl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one.

[1241]

[1242] Step 1: Synthesis of tert-butyl N-tert-butoxycarbonyl-N-[(2-chloropyrimidin-5-yl)methyl]carbamate

[1243] To a solution of tert-butyl N-tert-butoxycarbonylcarbamate (7.33 g, 33.74 mmol, 1.0 eq) in DMF (80 mL) at 0°C was added NaH (1.62 g, 40.49 mmol, 60 wt%, 1.2 eq). The mixture was stirred at 0°C for 30 minutes, and then 5-(bromomethyl)-2-chloro-pyrimidine (7 g, 33.74 mmol, 1 eq) was added. The reaction mixture was stirred at room temperature for 1.5 hours, and then the mixture was poured into saturated NH 4 Cl (300 mL) and stirred for 5 minutes. The aqueous phase was extracted with EtOAc (3 x 80 mL) and the combined organic phases were washed with brine (50 mL) and washed with anhydrous Na 2 SO 4 The residue was purified by silica gel chromatography (20:1 to 1:1 petroleum ether / EtOAc) to give tert-butyl N-tert-butoxycarbonyl-N-[(2-chloropyrimidin-5-yl)methyl]carbamate (7.0 g, 60.3% yield) as a white solid. LCMS (ESI) m / z: [M+H] for C 15 H 22 C1N 3 O 4 Calculated value: 344.14; measured value: 344.2.

[1244] Step 2: Synthesis of tert-butyl N-tert-butoxycarbonyl-N-[[2-[4-[4-[8-(6-methoxy-3-pyridinyl)-3-methyl-2-oxo-imidazo[4,5-c]quinolin-1-yl]-2-(trifluoromethyl)phenyl]piperazin-1-yl]pyrimidin-5-yl]methyl]carbamate

[1245] To a solution of 8-(6-methoxy-3-pyridinyl)-3-methyl-1-[4-piperazin-1-yl-3-(trifluoromethyl)phenyl]imidazo[4,5-c]quinolin-2-one (0.4 g, 748.32 μmol, 1.0 equiv) in MeCN (7 mL) at room temperature were added tert-butyl N-tert-butoxycarbonyl-N-[(2-chloropyrimidin-5-yl)methyl]carbamate (514.55 mg, 1.50 mmol, 2.0 equiv) and K 2 CO 3To the mixture of 4-(413.69 mg, 2.99 mmol, 4 equivalents). The reaction mixture was stirred at 80 ° C for 14 hours, and then the mixture was cooled to room temperature, filtered and concentrated under reduced pressure. The residue was purified by washing with MTBE (5 mL) to give tert-butyl N-tert-butoxycarbonyl-N-[[2-[4-[4-[8-(6-methoxy-3-pyridyl)-3-methyl-2-oxo-imidazo[4,5-c]quinolin-1-yl]-2-(trifluoromethyl)phenyl]piperazine-1-yl]pyrimidin-5-yl]methyl]carbamate (0.57 g, 90.5% yield) as a light yellow solid. LCMS (ESI) m / z: [M+H] for C 43 H 46 F 3 N 9 O 6 Calculated value: 842.36; measured value: 842.7.

[1246] Step 3: Synthesis of 1-[4-[4-[5-(aminomethyl)pyrimidin-2-yl]piperazin-1-yl]-3-(trifluoromethyl)phenyl]-8-(6-methoxy-3-pyridinyl)-3-methyl-imidazo[4,5-c]quinolin-2-one

[1247] A solution of tert-butyl N-tert-butoxycarbonyl-N-[[2-[4-[4-[8-(6-methoxy-3-pyridinyl)-3-methyl-2-oxo-imidazo[4,5-c]quinolin-1-yl]-2-(trifluoromethyl)phenyl]piperazin-1-yl]pyrimidin-5-yl]methyl]carbamate (0.95 g, 1.13 mmol, 1 eq) in TFA (10 mL) was stirred at room temperature for 1 hour, at which time the solvent was concentrated. The residue was dissolved in MeCN (10 mL), and the solution was then added dropwise to MTBE (150 mL). The precipitate was collected to give 1-[4-[4-[5-(aminomethyl)pyrimidin-2-yl]piperazin-1-yl]-3-(trifluoromethyl)phenyl]-8-(6-methoxy-3-pyridinyl)-3-methyl-imidazo[4,5-c]quinolin-2-one trifluoromethanesulfonate (0.778 g, 84.8% yield) as a yellow solid. LCMS (ESI) m / z: [M+H] for C 33 H 30 F 3 N 9 O 2 Calculated value: 642.26; measured value: 642.4.

[1248] Monomer W. 1-(4-aminobutyl)-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrazolo[3,4-d]pyrimidin-4-amine.

[1249]

[1250] Step 1: Synthesis of tert-butyl N-[4-[4-amino-3-(1H-indol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]butyl]carbamate

[1251] At room temperature, in N 2 In diethylene glycol dimethyl ether (160 mL) and H 2 tert-Butyl N-[4-(4-amino-3-iodo-pyrazolo[3,4-d]pyrimidin-1-yl)butyl]carbamate (8 g, 18.51 mmol, 1 eq.), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine (5.42 g, 22.21 mmol, 1.2 eq.) and Na 2 CO 3 (9.81 g, 92.54 mmol, 5 equiv) was added to the two-phase suspension of Pd(PPh 3 ) 4 (2.14 g, 1.85 mmol, 0.1 eq.). The mixture was stirred at 110 °C for 3 h. The reaction mixture was cooled to room temperature, filtered and the filtrate was partitioned between EtOAc (500 mL) and H 2 O (500 mL). The aqueous layer was separated and extracted with EtOAc (3 x 300 mL). The organic layers were combined, washed with brine (20 mL) and purified by anhydrous Na 2 SO 4 The mixture was dried, then filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (1 / 0 to 0 / 1 petroleum ether / EtOAc then 4 / 1 EtOAc / MeOH) to give tert-butyl N-[4-[4-amino-3-(1H-indol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]butyl]carbamate (6.6 g, 84.6% yield) as a yellow solid. LCMS (ESI) m / z: [M+H] for C 22 H 27 N 7 O 2 Calculated value: 422.22; measured value: 423.3.

[1252] Step 2: Synthesis of 1-(4-aminobutyl)-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrazolo[3,4-d]pyrimidin-4-amine

[1253] TFA (66 mL) was added to tert-butyl N-[4-[4-amino-3-(1H-indol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]butyl]carbamate (6.6 g, 15.66 mmol, 1 eq) and then stirred at room temperature for 30 minutes. The reaction solution was concentrated under reduced pressure to remove TFA, and then MTBE (400 mL) was added to the residue. The suspension was stirred for 15 minutes, at which time the yellow solid was filtered, and the solid filter cake was dried under reduced pressure to give 1-(4-aminobutyl)-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrazolo[3,4-d]pyrimidin-4-amine (10.2 g, 97.1% yield) as a yellow solid. LCMS (ESI) m / z: [M+H] for C 16 H 18 N 8 Calculated value: 323.17; measured value: 323.1.

[1254] Monomer X. 2-(4-Amino-1-((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-ol 2,2,2-trifluoroacetate.

[1255]

[1256] Step 1: Synthesis of tert-butyl 6-((4-amino-3-(5-((tert-butyldimethylsilyl)oxy)-1H-indol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[1257] At room temperature, in N 2 In dioxane (10.5 mL) and H 2 To a solution of tert-butyl 6-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (1 g, 1.97 mmol, 1.0 equiv) in 1H-DMSO (3.5 mL) were added (1-(tert-butoxycarbonyl)-5-((tert-butyldimethylsilyl)oxy)-1H-indol-2-yl)boronic acid (1.16 g, 2.96 mmol, 1.5 equiv), K 3 PO 4 (1.26 g, 5.92 mmol, 3.0 equiv), Pd 2 (dba) 3(180.85 mg, 197.50 μmol, 0.1 eq) and SPhos (162.16 mg, 394.99 μmol, 0.2 eq). The sealed tube was heated at 150 °C in a microwave for 20 min. The reaction mixture was then cooled and 6 separate batches were combined together. The reaction mixture was partitioned between EtOAc (100 mL) and H 2 O (100 mL). The aqueous layer was separated and extracted with EtOAc (3 x 80 mL). The organic layers were combined, washed with brine (100 mL), and purified by anhydrous Na 2 SO 4 The mixture was dried. The solution was filtered and the filtrate was concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (100 / 1 to 1 / 4 petroleum ether / EtOAc) to give tert-butyl 6-((4-amino-3-(5-((tert-butyldimethylsilyl)oxy)-1H-indol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (6.17 g, 82.9% yield) as a light yellow solid.

[1258] Step 2: Synthesis of tert-butyl 6-((4-amino-3-(5-hydroxy-1H-indol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[1259] At 0°C, N 2 To a mixture of tert-butyl 6-((4-amino-3-(5-((tert-butyldimethylsilyl)oxy)-1H-indol-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (6.17 g, 9.86 mmol, 1.0 equiv) in THF (100 mL) was added tetrabutylammonium fluoride trihydrate (1 M, 10.84 mL...

Claims

1. Compound of formula Ic: or a pharmaceutically acceptable salt, oxepane isomer or tautomer thereof, wherein: R 32 =O; R 28 is -H, (C1-C6) alkyl or -C(=Z 1 )-R 28a ; R 40 =Z 1 )-R 40a ; When R 28 and R 40 When H, R 32 Not = O; Z 1 Each independently is O or S; R 28a , R 32a and R 40a Independently -A 1 -L 1 -A 2 -B; -A 1 -A 2 -B; -L 2 -A 1 -L 1 -A 2 -L 3 -B; -O-(C1-C6)alkyl; or -O-(C6-C 10 )aryl; wherein -O-(C6-C 10 ) the aryl group of aryl is unsubstituted or substituted with 1 to 5 substituents selected from -NO2 and halogen; A 1 and A 2 is independently absent or independently selected from As shown, A 1 The left bond is bound to -C(=Z 1 )- or L 2 ; and among them, as depicted, A 2 The right side of the key is connected to B or L 3 ; Q is each independently 1 to 3 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene; X is each independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene; X 1 each independently is a heteroarylene or heterocyclylene ring; W is each independently absent or is 1 to 2 rings selected from arylene, cycloalkylene, heteroarylene and heterocyclylene; W 1 each independently is a heteroarylene or heterocyclylene ring; G is each independently absent or a ring selected from arylene, cycloalkylene, heteroarylene and heterocyclylene; G 1 and G 2 each independently is a heteroarylene or heterocyclylene ring; L 1 Each independently selected from L 2 and L 3 is independently absent or independently selected from B are each independently selected from B 1 Each independently selected from NR 3 -(C(R 3 )2) n -、 NR 3 -(C(R 3 )2) n -(C6-C 10 )arylene-(C(R 3 )2) n -、 NR 3 -(C(R 3 )2) n -heteroarylene-, NR 3 -(C(R 3 )2) n -heteroarylene-(C(R 3 )2) n -、 (C6-C 10 ) arylene-, NR 3 -(C(R 3 )2) n -NR 3 C(O)-, NR 3 -(C(R 3 )2) n -heteroarylene-heterocyclylene-(C6-C 10 ) arylene-, Heteroarylene-heterocyclylene-(C6-C 10 ) arylene-, NR 3 -(C(R 3 )2) n -S(O)2-arylene-C(O)- and NR 3 -(C(R 3 )2) n -S(O)2-arylene-(C(R 3 )2) n -, where as depicted, B 1 The left side Bond to A 2 , L 3 or L 1 ; and wherein the heteroarylene, heterocyclylene and arylene are each independently optionally substituted with alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen or hydroxy; R 3 Each is independently H or (C1-C6) alkyl; R 4 are each independently H, (C1-C6) alkyl, halogen, 5- to 12-membered heteroaryl, 5- to 12-membered heterocyclyl, (C6-C 10 ) aryl, wherein the heteroaryl, heterocyclyl and aryl are optionally substituted by -N(R 3 )2.-OR 3 , halogen, (C1-C6) alkyl, -(C1-C6) alkylene-heteroaryl, -(C1-C6) alkylene-CN, -C(O)NR 3 -heteroaryl or -C(O)NR 3 - Heterocyclyl substitution; R 5 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group of (C1-C6)alkyl is optionally substituted with -N(R 3 )2OR 3 replace; R 6 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group of (C1-C6)alkyl is optionally substituted with -N(R 3 )2OR 3 replace; R 7 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group of (C1-C6)alkyl is optionally substituted with -N(R 3 )2OR 3 replace; R 8 Each independently represents H, (C1-C6) alkyl, -C(O)OR 3 or -N(R 3 )2, wherein the alkyl group of (C1-C6)alkyl is optionally substituted with -N(R 3 )2OR 3 replace; Y is each independently C(R 3 )2 or key; n is each independently an integer from 1 to 12; o are each independently an integer from 0 to 30; p is each independently an integer from 0 to 12; q is each independently an integer from 0 to 30; and r is an integer of 1 to 6 each independently.

2. The compound according to claim 1, or a pharmaceutically acceptable salt, oxepane isomer or tautomer thereof, wherein the compound is represented by the structure of formula (I-40b): Where R 40 =Z 1 )-R 40a .

3. The compound according to claim 2, or a pharmaceutically acceptable salt, an oxepane isomer or a tautomer thereof, wherein Z 1 is O.

4. The compound according to claim 2, or a pharmaceutically acceptable salt, an oxepane isomer or a tautomer thereof, wherein Z 1 For S.

5. The compound according to any one of claims 2 to 4, or a pharmaceutically acceptable salt, an oxepane isomer or a tautomer thereof, wherein R 40a For-A 1 -L 1 -A 2 -B, where A 1 and A 2 Does not exist.

6. The compound according to any one of claims 2 to 4, or a pharmaceutically acceptable salt, oxepane isomer or tautomer thereof, wherein R 40a For-A 1 -L 1 -A 2 -B, where A 2 Does not exist.

7. The compound according to any one of claims 2 to 4, or a pharmaceutically acceptable salt, an oxepane isomer or a tautomer thereof, wherein R 40a For-A 1 -L 1 -A 2 -B, where A 1 Does not exist.

8. The compound according to any one of claims 2 to 4, or a pharmaceutically acceptable salt, oxepane isomer or tautomer thereof, wherein R 40a For-A 1 -L 1 -A 2 -B.

9. The compound according to any one of claims 2 to 4, or a pharmaceutically acceptable salt, oxepane isomer or tautomer thereof, wherein R 40a For-A 1 -A 2 -B.

10. The compound according to any one of claims 2 to 4, or a pharmaceutically acceptable salt, oxepane isomer or tautomer thereof, wherein R 40a For -L 2 -A 1 -L 1 -A 2 -L 3 -B, where L 2 and A 1 Does not exist.